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ABSTRACT 
The scale-up of antiretroviral therapy (ART) services has been one of the best 
achievements witnessed in the health sector in Ethiopia over the past decade. A total of 
339,043 adults had received treatment for Human Immunodeficiency Virus 
(HIV)/Acquired Immunodeficiency Syndrome (AIDS) in Ethiopia as of 2014, and this 
number is expected to increase over the coming years. Achievement of optimal medication 
adherence is becoming the greatest challenge in the management of HIV/AIDS. Patients 
with suboptimal adherence are at high risk of progression to AIDS, emergence of resistant 
viral strains, limited future treatment options, and higher treatment costs.  
Data on barriers to, and facilitators of, adherence in Ethiopian HIV-positive patients taking 
ART remains inconsistent and incomplete. The available cross-sectional studies are limited 
in that they have only assessed limited variables at a single point in time and qualitative 
studies have not yet explored factors associated with medication adherence at the 
individual level. While one prospective study has investigated adherence to ART in 
Ethiopia, it was only conducted for 3 months and also did not focus on treatment-naïve 
patients.  
The objectives of the body of work contained in this thesis were to fill these gaps using a 
mixed-methods approach that include both prospective quantitative and qualitative studies 
to establish the levels of medication adherence and identify a wide range of factors that 
influence medication adherence. We also assessed the incidence of adverse drug reactions 
(ADRs) and associated risk factors in Ethiopian patients with HIV/AIDS initiated on ART.  
xvii 
The main study was conducted in two hospitals in Northwest Ethiopia: Gondar University 
and Felege-Hiwot Hospitals. It began with a prospective study in which 246 adult HIV-
infected patients initiated on ART were followed from the time of initiation to 12 months of 
therapy. Patients had appointments every month for 6 months and every 3 months 
thereafter in ART clinics; research pharmacists collected data in line with patients’ 
appointment schedules in the ART clinics.  
In a subsequent study, semi-structured interviews were conducted with 24 patients, of 
whom 11 had been lost to follow-up and were non-persistent with ART. In addition, focus 
group discussions were performed with 15 ART nurses and 19 case managers. 
Questionnaires and interview guides were developed through a systematic procedure to 
ensure reliability, validity, and cultural appropriateness.  
Of 172 who completed follow-up in the prospective study, 130 (75.6%) had 95% 
adherence at 12 months. In the multivariate analyses, a higher baseline body mass index 
(BMI) (Odds Ratio (OR), 1.2; 95% CI 1.0, 1.4) and use of reminder devices ( OR, 9.1; 95% CI 
2.0, 41.6) were positively associated with adherence, while a higher HIV symptom and ADR 
distress score was an independent negative predictor of adherence (OR, 0.90; 95% CI 0.9, 
1.0). Clusters of differentiated 4 (CD4) count increase was significantly higher in the 
adherent patients compared to non-adherent patients at 12 months (159 cells/µL 
[interquartile range (IQR), 72-324 cells/µL] vs. 132 cells/µL [IQR, 43-190 cells/µL]; p = 
0.026). Patients who experienced a severe ADR were less likely (OR, 0.4, 95% CI 0.2, 0.9) to 
be adherent to ART. Logistic regression analysis indicated that taking zidovudine-
xviii 
containing regimens (OR, 4.2, 95% CI 2.1, 8.4) or being unemployed (OR, 2.2, 95% CI 1.1, 
4.3) were independent predictors of experiencing severe ADRs. 
All factors that were independent predictors of adherence in our prospective study also 
emerged directly or indirectly as important factors influencing adherence in the qualitative 
study. The qualitative study identified economic constraints, perceived stigma and 
discrimination, fasting, religious belief, medication side effects, and dissatisfaction with 
healthcare services were major reasons for patients being non-adherent and lost to follow-
up. Disclosure of HIV status, social support, use of reminder aids, responsibility for raising 
children, improved health on ART, and receiving education and counseling emerged as 
facilitators of adherence to ART. 
In conclusion, this work rigorously evaluated barriers to, and facilitators of, adherence to 
ART in Ethiopian HIV-positive patients using a mixed-methods approach. It identified 
economic constraints such as food insecurity and severe ADRs as important barriers to 
adherence while use of reminder devices promote adherence. Implementation of measures 
to consistently monitor severe ADRs and economic constraints, and to promote use of 
reminder devices have the potential to improve adherence and treatment outcomes in HIV-
positive patients taking ART. 
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CHAPTER ONE 
1. INTRODUCTION
1.1. HIV/AIDS 
Since Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome 
(AIDS) was detected in the United States in 1981, it has become one of the most dreaded 
scourges faced by humankind in the 21st century [1]. HIV destroys clusters of 
differentiation 4 (CD4)+ T cells that result in a decline in immune function [2]. Clinical 
stages of HIV progress from stage 1 (asymptomatic) to stage 4 (AIDS) [3]. AIDS-defining 
opportunistic diseases that decrease survival in patients with HIV infection include 
Pneumocystis jiroveci pneumonia, Mycobacterium avium complex disease, Cytomegalovirus 
disease, Candida oesophagitis, Kaposi’s sarcoma, and lymphoma [4].  
Around 36.9 million people were living with HIV/AIDS worldwide by the end of 2014. The 
majority of these people (25.8 million) live in sub-Saharan Africa [5]. New HIV infections 
have fallen by 35% worldwide since 2000. Of the total 2 million new HIV infections 
worldwide in 2014, 1.4 million were in sub-Saharan Africa [5]. Despite a reduction in new 
infections,  the number of people living with HIV/AIDS is growing as the result of the 
combined effect of new HIV infections and, more importantly, significant expansion of 
access to antiretroviral therapy (ART), which has helped to reduce AIDS-associated deaths 
[5]. 
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The rollout of ART in sub-Saharan Africa over the past 15 years is one of the world’s largest 
public health interventions. At the end of 2002, about 52,000 people were on ART in sub-
Saharan Africa. Currently, of the total 15 million people accessing ART worldwide as of 
March 2015, 10.7 million persons were from sub-Saharan Africa [5].   
1.2. HIV-1 life cycle and antiretroviral targets  
Sexual or parenteral contact with HIV-containing body fluids is a means to transmit HIV [6]. 
The routes of HIV transmission are different in different regions of the world [7]. 
Heterosexual transmission is the dominant mode of HIV transmission in sub-Saharan 
Africa and overall around the globe [2]. In the USA, Europe and Asia, one-third of HIV 
infection is due to the use of contaminated injection equipment [2].  
Once infection occurs, the HIV-1 virus introduces its genetic material to host cells by direct 
fusion of the viral and host membranes [8]. HIV primarily infects CD4+ T cells, 
macrophages, and monocytes. The envelope glycoproteins of the viral-cell membrane, 
glycoprotein 120 (gp120) and glycoprotein 41 (gp41), are derived from a larger 160-kilo 
dalton precursor glycoprotein (gp160) [9]. Three gp120 surface glycoproteins attach 
through non-covalent binding with three gp41 transmembrane glycoproteins to form viral 
spikes [10, 11] which are necessary to mediate viral particle attachment and fusion to 
target cells [12]. The surface glycoprotein, gp120, triggers viral fusion by interacting with 
CD4 receptors and G-protein coupled transmembrane chemokine co-receptors (CCR5 and 
CXCR4) [13]. Drugs designed as fusion inhibitors have been promising. Enfuviritide (T20) 
was the first Food and Drug Administration (FDA) approved fusion inhibitor, which 
interferes with viral fusion by binding to the viral envelope gp41 [14]. The other is 
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maraviroc, which is an antagonist at the HIV-1 co-receptor CCR5, and is a useful drug for R5 
tropic HIV-1 strain infections [15].  
The HIV-core, which contains reverse transcriptase (RT), integrase (IN), and genomic 
ribonucleic acid (RNA), passes to the cytoplasm of the host cell by leaving its cell 
membrane on the surface. The genomic single-stranded viral RNA transcribes into double-
stranded deoxyribonucleic acid (DNA) with the help of the viral enzyme, RT [16]. The two 
most important classes of antiretroviral drugs, nucleoside/nucleotide reverse transcriptase 
inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), inhibit 
RT DNA polymerization and are the cornerstones of HIV treatment.  
The viral DNA enters into the host nucleus as nucleic acid-protein complex (pre-integration 
complex) [17]. Double-stranded viral DNA integrates into the host cell chromosome with 
the help of the viral enzyme IN [18, 19]. The integrated DNA is now referred to as provirus 
[17]. Integration marks the shift of the HIV-1 life cycle from the early to late stage [20]. 
Hereafter, the transcription of proviral DNA mainly depends on cellular transcription 
factors; however, the viral transcription factor, trans-activator-transcription (Tat), also 
plays a significant role [17]. Three integrase strand transfer inhibitors (INSTs) are 
currently approved for use in antiretroviral-naïve patients [21].     
Viral DNA is transcribed to messenger RNA (mRNA); different species and sizes of viral 
mRNA are synthesised. Short mRNA is exported from the nucleus readily while exporting 
long mRNA, which is unspliced or singly spliced, needs the action of a trans-activating 
protein [20]. The 9-kilobase of HIV-1 genome has nine genes, which gives about 15 
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functional proteins. Some of the most important proteins include Gag polyproteins, Pol 
polyproteins, Env polyproteins, and accessory proteins [22].  
The Gag, Env, and Pol polyproteins undergo proteolytic cleavages to provide functional 
proteins [23]. The accumulation of Gag polyproteins derives the formation of spherical 
non-infectious immature virion beneath the host cell membrane [24]. The cleavage of Gag 
polyprotein by the viral protease (PR), results in a mature infectious viral particle. 
Currently, PR inhibitors (PIs) are one of the most important classes of drugs for the 
treatment of HIV/AIDS.  
 
 Figure 1. HIV life cycle showing the sites of action of the different class of 
antiretroviral agents [25]. 
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Acute HIV infection is often symptomatic. HIV-1 infected patients experience an acute 
retroviral syndrome characterised by clinical signs of immune activation and multi-system 
dysfunction such as fevers, malaise, and rash. However, these symptoms often go 
unrecognised [2, 26]. Individuals engaged in unprotected sexual practices or needle 
sharing at this stage of the infection may transmit HIV [26]. Once these acute symptoms 
resolve, the infected person passes into an asymptomatic phase of the disease. This stage 
may persist for several years or rapidly progress to AIDS [26]. As CD4 cell count 
progressively declines, AIDS-defining opportunistic infections, such as Pneumocystis 
jiroveci pneumonia, Kaposi’s sarcoma, and tuberculosis, become common [26]. Adult HIV-
infected patients are normally initiated on ART when their CD4 cell count is  500 cells/µL, 
or with any symptom indicating a World Health Organisation (WHO) clinical stage 3 or 4, 
regardless of CD4 cell count [27]. Once treatment is initiated, viral replication is reduced 
below the threshold where the virus does not evolve, and drug resistance does not emerge, 
and CD4 cell count increases until it reaches normal levels. The effectiveness of ART 
inspires efforts toward earlier diagnosis, referral to care, and scale-up of ART.  Both CD4 
cell count and viral load testing can be conducted using point-of-care testing in HIV-
positive patients and are useful to monitor immune system changes and viral replication, 
respectively [26].  
1.3. Antiretroviral therapy 
Zidovudine was the first antiretroviral agent shown to provide a survival benefit over 
placebo in patients with advanced AIDS [28]. However, the use of a single antiretroviral 
agent did not provide prolonged viral suppression and often did not reverse the decline in 
immune function [29]. The introduction of PIs into the clinical arena in the mid-1990s and 
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their use in combination with two NRTIs provided sustained viral suppression and 
improved immune function [29]. Ever since, the treatment of HIV/AIDS has involved the 
use of a combination of potent antiretroviral drugs.  
In Figure 1, there are six major classes of antiretroviral drugs: NRTIs, NNRTIs, PIs, fusion 
inhibitors, INSTIs, and CCR4 antagonists [26]. The first three classes of antiretroviral drugs 
are used in combination in resource-limited settings [27]. Only these classes of drugs are 
reviewed in this thesis. Class, recommended dose, elimination, and common ADRs of these 
antiretroviral agents are summarised as shown in Table 1. Initial regimens for treatment-
naïve patients consist of two NRTIs plus a third agent that can be NNRI or ‘boosted’ PI [27]. 
The 2013 WHO ART guideline recommended tenofovir plus lamivudine (or emtricitabine) 
plus efavirenz as a preferred first-line ART regimen for adults, with tenofovir plus 
lamivudine (or emtricitabine) plus nevirapine or zidovudine plus lamivudine plus efavirenz 
(or nevirapine) as alternatives. A boosted PI in combination with two NRTIs is 
recommended as second-line treatment [27].  
1.3.1. Nucleoside/nucleotide reverse transcriptase inhibitors 
NRTIs are an important class of antiretroviral drugs that are effective in improving both 
virologic and immunologic outcomes. They are the cornerstone of ART regimens, often 
referred to as the “backbone” of the regimen [21, 30]. All are prodrugs that need 
phosphorylation by host enzymes to transform into an active NRTI triphosphate, and 
competitively inhibit HIV RT to terminate viral replication.
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Table 1. Antiretroviral drugs used in resource limited settings. 
 
Drug Dosing recommendations  Elimination  Adverse drug reactions  
    
Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs): abacavir, lamivudine, tenofovir, zidovudine, stavudine, didanosine, and emtricitabine.  
Abacavir  300 mg BID, or 600 mg once 
daily  
Take without regard to meals.  
82% abacavir metabolites excreted renally Hypersensitivity reaction: patients with HLA-B5701 gene are at 
high risk.  
Lamivudine  150 mg BID, or 300 mg once 
daily  
Take without regard to meals.  
Renal excretion: 70% Minimal toxicity  
Severe acute exacerbation of hepatitis may occur in HBV-coinfected 
patients who discontinue lamivudine.  
Tenofovir  300 mg once daily 
Take without regard to meals.  
Renal excretion is the primary route of 
elimination.  
Renal insufficiency, Fanconi syndrome, and proximal renal 
tubulopathy.  
Zidovudine  300 mg BID  
Take without regard to meals.  
Metabolised to azidothymidine; which 
undergoes renal excretion 
Bone marrow suppression: macrocytic anaemia or neutropaenia.  
Nausea, vomiting, headache, insomnia, asthaenia, and nail 
pigmentation.   
Non-nucleoside reverse transcriptase inhibitors (NNRTIs): efavirenz, nevirapine, delavirdine, etravirine, and rilpivirine.  
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Drug Dosing recommendations  Elimination  Adverse drug reactions  
    
Efavirenz  600 mg once daily, at or before 
bedtime  
Metabolised by CYPs 2B6 (primary), 3A4, and 
2A6.  
CYP3A4 mixed inducer/inhibitor (more an 
inducer than inhibitor) 
CYP2C9 and 2C19 inhibitor; 2B6 inducer 
Neuropsychiatric symptoms, rash  
Nevirapine  200 mg once daily for 14 days 
(lead-in period); after that, 200 
mg BID.  
CYP450 substrate, inducer of 3A4 and 2B6; 
80% excreted in urine (glucuronidated 
metabolites, <5% unchanged); 10% in faeces) 
Rash, including SJS 
Hypersensitivity reactions, characterised by rash, constitutional 
findings, and sometimes organ dysfunction (including hepatic 
failure) reported.  
Nausea  
Protease inhibitors (PIs): atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir, lopinavir, saquinavir, and tipranavir.  
Atazanavir  Atazanavir 300 mg plus ritonavir 
100 mg once daily; 
Take with food 
CYP3A4 inhibitor and substrate; and weak 
CYP2C8 inhibitor 
Indirect hyperbilirubinaemia (clinical jaundice), hyperglycaemia, 
and fat misdistribution.   
Darunavir  Darunavir 800 mg plus ritonavir 
100 mg once daily 
Take with food 
CYP3A4 inhibitor and substrate  
CYP2C9 inducer  
Skin rash, hepatotoxicity, diarrhoea, and nausea. 
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Drug Dosing recommendations  Elimination  Adverse drug reactions  
    
Lopinavir Lopinavir 400 mg plus ritonavir 
100 mg BID, or Lopinavir 800 mg 
plus ritonavir 200 mg once daily 
Take without regard to meals.  
CYP3A4 inhibitor and substrate  GI intolerance, nausea, vomiting, diarrhoea, and hepatotoxicity.   
 
Integrase strand transfer inhibitor (INSTs): dolutegravir, elvitegravir, and raltegravir.   
Raltegravir  400 mg BID, with rifampin 800 
mg BID 
Take without regard to meals.   
UGT1A1-mediated glucuronidation  Rash, Stevens-Johnson syndrome, rhabdomyolysis, myopathy, and 
myalgia.  
    
 
BID= twice daily; CYP= cytochrome P450; HLA= human leukocyte antigen; HBV= hepatitis B virus (HBV); UGT1A1= 
UDP glucuronosyltransferase 1 family, polypeptide A1. Modified from US Department of Health and Human Services 
(DHHS) Panel on antiretroviral guidelines for adults and adolescents [21].
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Most of the NRTIs are eliminated renally and require dose adjustment in patients with 
renal impairment. Drug interactions are not common in this class of antiretroviral drugs as 
they are not substrates for cytochrome P450 (CYP) enzymes [31, 32].                
1.3.2. Non-nucleoside reverse transcriptase inhibitors  
NNRTIs are among the first-line drugs for HIV-1-infected antiretroviral naïve patients in 
adult ART guidelines [21, 27, 33]. Efavirenz and nevirapine are listed in the recent WHO 
ART guideline, which was developed for resource-limited settings [27].  NNRTIs induce 
allosteric changes in HIV-1 RT and prevent viral replication. NNRTIs do not inhibit HIV-2 
RT and are not useful in the treatment of HIV-2-infected patients. Unlike NRTIs, NNRTIs are 
active drugs that do not require sequential phosphorylation to elicit their antiretroviral 
activity [34].  
NNRTIs enhance or inhibit the CYP metabolism of other concomitantly administered drugs 
[34]. Drugs such as rifampin and rifabutin decrease nevirapine levels and the latter should 
not be coadministered with these drugs [21]. Class specific rash, hepatotoxicity, drug-drug 
interactions, efavirenz-associated central nervous system (CNS) disturbances and a low 
threshold for emergence of resistant mutants are shortcomings of this group of drugs [29].     
NNRTIs have a low genetic barrier to the development of resistance; a single mutation to 
one of the drugs causes high-level resistance to all NNRTIs (except etravirine) [21]. NNRTI-
resistant viral strains are common in ART-naïve patients. Genotypic resistance testing is 
necessary to guide regimen selection before initiation on ART [21].  
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1.3.3. Protease inhibitors 
PIs show their antiretroviral activity by binding to HIV PR and blocking its proteolytic 
activity, resulting in an inability to form mature infectious virions. Indinavir and nelfinavir 
use is decreasing as they are associated with intolerable ADRs and pill burden [29]. 
Similarly, ritonavir is also not used independently as an active antiretroviral agent; instead, 
at a low dose, it is used in combination with other PIs as a pharmacokinetic enhancer or 
booster [29]. CYPs metabolise all PIs. Low dose ritonavir (100-200 mg/day) is a potent 
CYP3A4 inhibitor, and it is used in fixed-dose combination with other PIs to increase their 
plasma concentration and half-life, allowing their use at lower doses. This results in 
decreased ADRs and pill burden [21, 29]. PIs have drug interactions with other 
coadministered drugs that are highly dependent on CYP3A4 metabolism, and caution 
should be exercised when prescribing [29].  
PIs have a high barrier to resistance; they require accumulation of multiple resistance 
mutations for resistant strains to emerge. The high barrier to resistance makes them an 
important class of antiretroviral drugs that are effective not only in treatment-naïve 
patients but also for patients who have experienced treatment failure with other classes of 
antiretroviral drugs [29]. They are also a preferred category of drugs for patients with 
adherence concerns, such as patients with a history of poor adherence, active substance 
users and the homeless [35]. Class-associated ADRs include metabolic abnormalities such 
as dyslipidaemia and insulin resistance [21]. 
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1.4. Benefits of antiretroviral therapy 
ART plays a pivotal role in an AIDS response, reduction in mortality and AIDS-related 
morbidity, and prevention of HIV transmission. The goal of ending the AIDS epidemic rests 
on the commitment to provide ART to all who need it, in a right based approach [36]. HIV-
positive patients with CD4 counts <200cells/µL are at higher risk of progression to AIDS, 
non-AIDS morbidity, and mortality than HIV-positive patients with a higher CD4 count [21]. 
In the early days of recognition of HIV/AIDS, when diagnosis with advanced AIDS was not 
uncommon, rates of AIDS-related deaths were high, and estimated between 2.1 to 2.5 
million people globally as of 2000 [37]. 
The introduction of widespread HIV treatment has resulted in a dramatic decrease in AIDS-
related deaths [5]. In 2014, the number of deaths from AIDS was down to 1.2 million 
worldwide, of which 790,000 were from sub-Saharan Africa [5]. Effective ART suppresses 
the viral replication below the limit of detection of the commercially available assay. 
Durable viral suppression with ART prevents selection of antiretroviral resistance 
mutations and restores and preserves immune function [26], resulting in a steep decline in 
the incidence of opportunistic infections [38] and mortality [39]. Life expectancy has 
increased markedly and returned to the pre-1990s level in high-prevalence countries in 
sub-Saharan Africa. In South Africa, for instance,  life expectancy rose from 52 years in 
2005 to 61 years in 2014 [5]. 
Patients who are initiated on ART at an early stage of HIV infection achieve better 
treatment outcomes compared to those who commence ART later. Severe et al. [40]  
reported that initiation of ART in patients with a CD4 count between 200 and 350 cells/µL 
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improved survival, compared with patients who delayed treatment until CD4 counts were 
<200 cells/µL. Data from a large observational study suggested that initiating ART in 
patients with CD4 counts between 350 and 500 cells/µL decreased progression to AIDS 
[41]. In the early stages of HIV infection, viral replication in untreated patients with high 
CD4 counts was associated with non-AIDS-defining complications such as HIV-associated 
nephropathy, liver disease, cardiovascular disease, neurologic complications, and 
malignancies. Sustained virologic suppression delays, prevents or reverses these non-AIDS-
defining morbidities [21]. Treatment guidelines are currently recommending an increase in 
CD4 count threshold for initiation of ART. The recent WHO treatment guideline 
recommended initiation of ART from 350 to 500 cells/µL [27].  
Antiretroviral drugs are effective in the prevention of HIV transmission. Townsend et al. 
[42] reported that only three babies were infected with HIV out of 2,117 infants born to 
women on ART with viral loads of <50 copies/µL. The HTPN 052 study found that early 
initiation of ART reduced the rate of sexual transmission of HIV-1 [43]. This study enrolled 
1763 couples in which one partner was HIV-1-postive, and the other was HIV-1-negative. A 
total of 39 HIV-1 transmissions were noticed; 28 were virologically associated with the 
HIV-infected partner. Of the 28 related transmissions, only one was reported in the early 
initiated group [43]. 
1.5. Challenges to antiretroviral therapy 
Although there are many benefits of ART, it is also associated with several challenges. 
These include suboptimal adherence and development of antiretroviral drug resistance 
and ADRs.  
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1.5.1. Adverse drug reactions  
Acute and long-term ADRs are common in patients on ART and have a negative impact on 
treatment outcomes, including adherence [44-46]. Common ADRs related to ART include 
gastrointestinal complaints, neuropsychiatric reactions, and skin reactions. Initiation of 
ART in symptomatic patients improves the quality of life [21]. However, ADRs induced on 
initiation of ART in asymptomatic patients who are at low risk of AIDS-defining 
opportunistic diseases may compromise quality of life [21]. For instance, zidovudine-
containing regimens that frequently cause severe ADRs such as gastrointestinal complaints 
and anaemia are still first-line antiretroviral regimens in resource-limited settings [27] and 
thus have the negative impact on adherence and quality of life of patients [45]. Details of 
ADRs are described in section 1.6.  
1.5.2. Suboptimal adherence 
Regardless of CD4 count, patients initiated on ART need to achieve an optimal level of 
adherence to provide sustained virologic suppression and prevent the emergence of 
resistant viral strains [21]. ART coverage in adults living with HIV in sub-Saharan Africa 
has been increasing over the last 15 years; 43% were on ART; 32% were virally suppressed 
[5], and almost one-third of patients on ART had suboptimal adherence [47].  
Adherence is a major predictor of positive treatment outcomes in the management of 
HIV/AIDS, without which rates of illness and death are high. Besides, perinatal or sexual 
HIV transmission is more likely in patients with suboptimal adherence [21]. Adherence is 
discussed in detail in Chapter 2.        
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1.6. Adverse drug reactions to antiretroviral therapy 
ADRs are likely to be detrimental to optimal adherence and successful clinical outcomes 
[48]. Assessment of ADRs in patients taking ART is becoming increasingly important as HIV 
transforms into a manageable chronic disease. Long-term achievement of better clinical 
outcomes needs fine tuning of ART, such as management of ADRs and switching to 
tolerable regimens [44].  
ADRs of antiretroviral drugs are classified based on the organ system affected, as 
gastrointestinal, neuropsychiatric, skin reactions, and haematological. Each class of ADRs is 
reviewed below.  
1.6.1. Gastrointestinal symptoms 
Antiretroviral treatment relates to gastrointestinal complications such as nausea, vomiting, 
diarrhoea, and gastric discomfort [49]. These symptoms are often underreported and 
subjective; it is reliant upon clinician interaction and intervention as well as patient 
awareness and reporting [49]. Gastrointestinal symptoms are among the reasons for 
discontinuation or switching of ART. Boyle et al. [50] reported that of 923 regimens 
changed over 18 months; 452 (49%) were due to ADRs to ART, and of these 64 (14%) were 
because of gastrointestinal disturbances. 
Ritonavir-boosted PIs and NRTIs, such as zidovudine and tenofovir, are among the inducers 
of gastrointestinal intolerance [49]. A higher dose of ritonavir is associated with diarrhoea 
and nausea; currently, only a low dose (100-200 mg/day) of ritonavir is used as a 
pharmacokinetic booster to other PIs [51]. Atazanavir/ritonavir and darunavir/ritonavir 
have shown favourable gastrointestinal effects compared to lopinavir/ritonavir [52-54]. 
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The newer generation non-peptidic PI, tipranavir, boosted with ritonavir has shown 
encouraging gastrointestinal tolerance, similar to darunavir/ritonavir in the POTENT trial 
[55].  
Nausea and vomiting are also associated with NRTI therapy. In the CNA30024 trial, the 
incidence of grade 2-4 gastrointestinal complaints was high in the zidovudine arm relative 
to the abacavir arm; nausea was 11% versus 7%, and vomiting was 9% versus 2% when 
both were taken in combination with lamivudine plus efavirenz [56]. The Gilead 934 study, 
which compared zidovudine plus lamivudine plus efavirenz with tenofovir plus 
emtricitabine plus efavirenz, found a slightly higher incidence of gastrointestinal 
intolerance in the tenofovir arm compared to the zidovudine arm; nausea was 8% versus 
6% and diarrhoea was 7% versus 4% [57]. However, in the COMET study, patients 
switched from zidovudine plus lamivudine plus efavirenz to tenofovir plus emtricitabine 
plus efavirenz reported significantly less gastrointestinal HIV symptoms [58]. 
Gastrointestinal complaints are rarely associated with NNRTI therapy. Grade 3 or 4 
diarrhoea and vomiting occurred in less than 1% of patients in a randomised controlled 
trial comparing efavirenz once daily and nevirapine twice daily [59]. The phase III clinical 
trials, ECHO and THRIVE, reported a higher incidence of diarrhoea in the efavirenz arm 
(6%) compared with rilpivirine (3%) when each drug was administered in combination 
with dual-NRTIs [60].  
1.6.2. Neuropsychiatric reactions 
Neuropsychiatric ADRs are commonly associated with the NNRTIs, especially efavirenz. 
Staszewski et al. [61] reported that more than half of treatment naïve patients initiated on 
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efavirenz-containing regimens experienced neuropsychiatric disturbances. A review by 
Shubber et al. [62] found that patients taking efavirenz-containing regimens were three 
times more likely to experience neuropsychiatric ADRs compared to nevirapine-containing 
regimens. The most common symptoms patients experience within the first weeks include 
nightmares, dizziness, insomnia, light-headedness, and psychotic symptoms [63]. Some of 
the efavirenz-induced neuropsychiatric reactions such as depression with suicidal ideation 
were long lasting, over two years [46, 64].  
Studies have reported that 4-10% of patients who experienced short-term 
neuropsychiatric ADRs of efavirenz discontinued the treatment, mainly within the first 4 
weeks [65]. A treatment switch from efavirenz to nevirapine resolves efavirenz-induced 
neuropsychiatric ADRs [66]. However, adults on nevirapine were twice as likely to 
discontinue treatment due to any ADRs compared to patients on efavirenz and thus 
efavirenz-based therapy is the preferred first-line regimen [62]. 
1.6.3. Skin reactions 
A rash is the most common short-term ADR associated with treatment with NNRTIs. Skin 
reactions commonly related to NNRTIs are erythematous, maculopapular, and extensive 
[67]. The incidence of skin rash associated with nevirapine ranges from 17% to 32%, 
although 13% of these were mild in severity[68]. A similar rate of incidence, 14% to 29%, 
was reported in patients taking efavirenz-containing regimens [69]. Severe rashes such as 
Stevens-Johnson syndrome and toxic epidermal necrolysis reported in around 6.5% of 
patients receiving NVP-containing regimens, but less than 1% in NVP-containing regimens 
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[70].The majority of patients who were taking NNRTIs experienced rash within the first 
three weeks [67].  
A person with preserved immune function has a greater risk of developing the NNRTI-
related rash. Women with a baseline CD4 count  250 cells/µL were more likely to 
experience the nevirapine-induced rash and hepatotoxicity [71, 72]. Similarly, the risk of 
developing a skin rash and hepatotoxicity in men with a baseline CD4 count  400 cells/µL 
was greater compared to men who had CD4 counts < 400 cells/µL [72]. Racial difference is 
also a significant risk factor for developing a rash. Thai adults experience skin rash more 
frequently than white adults [71].  
Treatment of nevirapine-induced rash is based on the severity of symptoms. Mild or 
moderate rashes associated with nevirapine are self-limiting and resolve without 
nevirapine discontinuation. Severe, grade 3 or 4, rashes such as Stevens-Johnson syndrome 
(SJS) and toxic epidermal necrolysis (TEN) require immediate and permanent 
discontinuation of nevirapine [73]. Similarly, treatment discontinuation is essential for any 
patient who develops the rash with constitutional symptoms (fever, rigors, and 
myalgia/arthralgia) involving organ dysfunctions such as hepatitis, eosinophilia, and renal 
dysfunction [73]. Nevirapine is initiated at 200mg/day for two weeks, and the dose should 
not be escalated to 400mg/day if the patient experiences a reaction within 14 days [67]. 
Antihistamines or corticosteroids are useful for the management of skin rash [44].  Topical 
corticosteroids are more important than oral corticosteroids in the treatment of skin 
reactions in patients living with HIV/AIDS [74].   
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1.6.4. Haematological ADRs   
Patients initiated on zidovudine-containing regimens experience haematological changes 
[75]. They can develop bone marrow suppression, the most severe ADR, after three months 
of zidovudine therapy, which results in anaemia and neutropaenia [76]. The stage of HIV 
infection, high doses of zidovudine, long durations of treatment, female gender, and 
background anaemia are important risk factors. The incidences of anaemia and 
neutropaenia are high in patients having CD4 counts <100 cells/mL. The dose of 
zidovudine currently used is low, 600mg/day, which decreases the incidence of bone 
marrow suppression [77, 78].  Firnhaber et al. [79] reported that malnutrition and poor 
economic conditions in Africa and Haiti increased the incidence of anaemia compared to 
Asia and the USA.     
HIV/AIDS patients have been defined as anaemic when their haemoglobin (Hb) level is less 
than 12 g/dL for men and less than 11g/dL for women [80]. The incidence of anaemia in 
AIDS patients varies from 1% to 30%, according to AIDS clinical trial group (ACTG) data 
[77]. Patients in sub-Saharan Africa experience a high incidence of anaemia, for example 
50% in the DART trial [81], as a result of deficiencies of micronutrients (e.g. vitamin B12, 
folic acid, and iron), malaria, and intestinal parasite infections [82, 83]. Zidovudine 
monophosphate induces anaemia by reducing the phosphorylation of thymidine 
monophosphate to thymidine triphosphate [84]. 
Monitoring of HIV/AIDS patients’ Hb and haematocrit levels at baseline and during their 
follow-up helps to avoid development of severe anaemia [77]. Drugs prescribed as 
prophylactic agents or for treatment of opportunistic diseases (trimethoprim-
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sulfamethoxazole, pyrimethamine, and ganciclovir) have synergistic toxicity with 
zidovudine [77]. Substitution of zidovudine with another NRTI such as tenofovir or 
abacavir is a feasible option when patients develop anaemia [77]. Previous studies 
recommended erythropoietin treatment for bone marrow suppression in patients with an 
erythropoietin level less <500IU/mL [77]. However, many clinical trials reported that the 
use of recombinant erythropoietin alpha (rHuEPO) did not improve Hb level and the need 
for blood transfusion compared to placebo, as reviewed by Martí-Carvajal et al. [80]. 
Besides, erythropoietin had shown life-threatening ADRs, such as stroke, and thus its 
current use is not justified [80].   
1.6.5. Other ADRs 
NRTIs disrupt oxidative phosphorylation that causes ADRs such as lactic acidosis, hepatic 
steatosis and hyperlactataemia. Lactic acidosis is a fatal ADR in HIV-infected patients; thus, 
the cognisance of its signs and symptoms such as fatigue, diminished exercise tolerance, 
and tachypnoea are necessary for the management [70].  
Some ART regimens, especially those containing PIs, are associated with HIV-lipodystrophy 
syndromes that include dyslipidaemias and insulin resistance [70]. Clinical features of 
lipodystrophy are fat loss in the face, arms, legs, and buttocks, and fat accumulation in the 
intra-abdominal area, dorsocervical spine, and breasts. Metabolic features include 
hypertriglyceridaemia, hypercholesterolaemia, and insulin resistance [67]. 
I have highlighted the important class of antiretroviral agents and their ADRs that are 
currently available for treatment of HIV/AIDS in resource-limited countries. The next 
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chapter revised literature about adherence to ART in sub-Saharan Africa in general and 
Ethiopia in particular.       
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CHAPTER TWO 
2. ADHERENCE TO ANTIRETROVIRAL THERAPY: LITERATURE REVIEW   
Adherence and compliance are interchangeably used terms in the literature to describe the 
medication taking behaviour of a patient. However, slight differences have been perceived 
[85, 86]. Medication compliance refers to the degree to which patients’ medication taking 
behaviour matches with healthcare providers’ recommendations. The term “compliance” 
fails to describe patients’ involvement to establish a treatment plan and thus its use is 
declining [87]. Cramer et al. [88] defined medication adherence as “the act of conforming to 
the recommendations made by the provider on timing, dosage, and frequency of 
medication taking.” The word “adherence” suggests the patient has active, voluntary, and 
collaborative participation in establishing the treatment plan, and many health providers 
prefer the term “adherence” to “compliance” [85].  
Active suppression of viral replication to prevent the emergence of drug resistance 
requires achievement of more than 95% adherence to ART [89]. Current regimens that 
contain boosted PIs or NNRTIs can achieve good viral suppression at a lower level of 
adherence. Boosted PIs reach a higher plasma concentration compared to unboosted PIs, 
which extends their biological half-life. Thus, boosted PIs are more “forgiving” of non-
adherence than unboosted PIs. Furthermore, PIs have a high barrier to the development of 
drug resistance. These properties make regimens containing boosted PIs a treatment of 
choice for possibly non-adherent patients [35].       
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2.1. Measure of adherence  
Monitoring of patients’ medication-taking behaviour has been practised since the time of 
Hippocrates, when the efficacy of different remedies was documented with notations of 
whether the patients had taken medication or not [87]. Even in the modern era of 
medication therapy, patient self-report is a widely used measure of adherence to medicines 
[90]. Despite the fact that antiretroviral medication adherence is crucial for exploiting their 
full potential, there is no ‘gold standard’ method to measure adherence [87].  
Methods for adherence measurement can be classified as direct and indirect. Direct 
methods such as directly observed therapy (DOT), and measuring the level of drug or its 
metabolite in plasma and other body fluids confirm the intake of the drug. Indirect methods 
such as self-report, pill count, pharmacy records, electronic devices, and biological markers 
do not prove drug ingestion [87, 91]. The advantages and disadvantages of these methods 
are reviewed below. 
2.1.1. Patient self-report 
Self-reported measures of adherence (questionnaires, diaries, interviews or visual 
analogue scales) commonly use a single item query regarding missed doses in a particular 
period. The patient is asked about the number of prescribed doses that have been missed in 
the last 1, 3, 4, 7 or 30 day(s) [92, 93]. Researchers have used different items for assessing 
self-reported adherence; there is no standard tool. Furthermore, in some studies 
investigators included additional items that assess patients’ adherence on the weekend, 
taking the dose with a specified schedule, and to food and fluid restrictions [93]. An 
adherence index which amalgamated time and food adherence with dose adherence had a 
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stronger correlation with viral load than adherence measured using a single item of dose in  
adherence questionnaire [94].  
Advantages of self-reported adherence measures include convenience, simplicity, 
feasibility, inexpensiveness, accuracy for identifying non-adherers, and ability to collect 
evidence regarding dose scheduling as well as food and fluid restrictions [92, 95]. As a 
result of the above merits, they are widely applied in research and clinical settings in both 
resource-rich and resource-limited countries [93].  
Self-reported adherence correlates with pill count, medication event monitoring systems 
(MEMS), pharmacy refills, and biological markers. Simoni et al. [92] reported that viral load 
was associated with self-reported adherence in 88% of recall periods that were greater 
than 3 days and in 64% of those that were 3 days or less, 2 (N=63)=4.16, p=0.04. Similarly, 
CD4 count was correlated with self-reported adherence in 62% (16/26) of studies [92].    
Self-report overestimates adherence 10-20% more than objective methods such as MEMS 
[96]. Social desirability and recall bias are the reasons mentioned behind the 
overestimation [95, 96]. Experts advise on using different techniques to decrease 
adherence overestimation, such as saying that non-adherence is a common phenomenon, 
approaching the client with non-judgmental wording, asking open-ended and forced 
multiple choice items, asking about missed doses, asking about the most recent doses, and 
helping patients to remember [92, 93].  
It is crucial to consider the optimal recall period for assessment of self-reported adherence, 
as the frequency of dosing of antiretrovirals is now once or twice daily. Too few doses can 
be assessed in a very short period (i.e. 1-3 days), and the variability of adherence behaviour 
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may not be sufficiently observed [89]. Lu et al. [97] compared 3, 7, and 30-day self-report 
recall periods with MEMS and found that 30-days showed less overestimation of adherence 
than the 3 or 7-day recall periods [97]. The 7-day recall period is advantageous over 1, 3, 
and 4-day period as this time includes a weekend, during which patients may miss 
medications [92].  
2.1.2. Pill count 
Pill count is an objective method for measurement of adherence. It is one of the most 
common methods next to self-report [98]. Similar to self-report, pill count also 
overestimates adherence and over-adherence (>100%) is not uncommon. Percentage 
adherence is calculated as the total number of pills taken during the study period divided 
by the total number of tablets that should have been taken multiplied by one hundred [99]. 
Over-adherence can be because pills are lost, vomited, given to someone or dumped, while 
considered as ingested [99]. Pill count may promote distrust between the healthcare 
provider and the patient if patients believe counting as distrust in their medication 
adherence [91].  
To avoid patients’ pill dumping some researchers have used an unannounced pill count in 
which patients were not informed about the precise date of counting and counting is 
usually done by pill counters in patients’ homes. Unannounced pill count is more reliable 
than announced pill count, but it lacks feasibility as it costs time and money and some 
patients may consider it as an invasion of privacy [91, 99].  
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2.1.3. Pharmacy records 
Some studies have used pharmacy records to measure adherence to antiretroviral drugs 
[100, 101]. The principal premise of this method is that refilling of medication with time is 
considered as a sign of good adherence [93, 102]. Patients who do not refill medication are 
either missing medication or not taking the medication at all. This method has limitations, 
as medication refill does not indicate actual ingestion of the drugs. Also, if patients have 
access to the drug through other means (i.e. free samples, family members, or friends) or 
from other pharmacies, this method is invalid. Pharmacy records are a convenient method 
when patients receive the antiretroviral drug from the same pharmacy [91, 93, 102]. 
Adherence from the pharmacy refill is determined by equating the real to expected refill 
dates [102]. 
Some of the merits of pharmacy refill compared to self-report include it being immune to 
social desirability and recall bias, and pill dumping. It also allows census analysis of 
adherence as data are easily obtained from pharmacies [102]. Data from pharmacy refill 
have been moderately correlated with clinical outcomes [103]. However, Townsend et al. 
[104] reported no significant association between medication refill and viral load or CD4 
count.  
2.1.4. Electronic drug monitoring  
Electronic drug monitoring (EDM) is the most unconventional means to measure 
adherence to medications [91]. It uses a pill bottle with a cap embedded with an electronic 
chip that records the opening date and time of the cap. The information stored in chips is 
transferred onto a computer [93, 102]. EDM captures patterns of both dose and time 
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adherence; it is considered as a gold standard method to measure adherence [102, 105]. 
Several studies have used EDM to measure adherence in patients with antiretroviral drugs 
and to validate other instruments for adherence measurement [105-107].  
EDM can decrease overestimation of adherence by avoiding pill dumping and the “white 
coat effect” (better adherence before a visit to a physician). Several limitations of this 
method have been identified including taking out several doses in one bottle opening, 
opening a bottle without removing a dose, the lack of a guarantee of dose ingestion, and 
monitoring using EDM on its own is an adherence intervention [102, 105]. One of the most 
common types of EDM is the medication event monitoring system (MEMS); however the 
cap is sizeable, cumbersome and not suitable for patients that use pill boxes and non-oral 
dosage forms [91, 102]. 
Haberer et al. [108] used a wireless pill container (Wisepill®) for monitoring medication 
adherence in patients on antiretroviral drugs in Uganda. Wisepill transmits a cellular signal 
upon opening to remove medication. It has provided a capacity to control adherence 
proactively and can prevent treatment failure and the emergence of viral resistance.  
2.1.5. Therapeutic drug monitoring  
Determining the concentration of a parent drug or its metabolite in plasma, urine and 
saliva can be unequivocal proof of the ingestion of medication. This method only assesses 
adherence of patients over 24 hours; few doses can be determined in this short period. 
Besides, patients may take medication just before their appointment - i.e. display “white 
coat adherence” [109]. Podsadecki et al. [109]  showed that 66% of the patients had perfect 
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adherence 1-3 days before pharmacokinetic sampling based on the plasma concentration 
of lopinavir in patients taking tenofovir plus emtricitabine plus lopinavir/ritonavir [109].  
Individual and racial difference in the pharmacokinetics of the drug may also affect the 
amount of drug available in the plasma [110, 111]. Drug-drug and drug-food interactions 
may similarly result in variations in plasma drug concentration [112]. Therapeutic drug 
monitoring suffers from a lack of quality control of the assay. Methods of specimen 
collection, cross-validation of determination of drug level, and interpretation of test 
readings vary between different settings [102, 112].  
2.1.6. Other measures  
Changes in a surrogate marker when patients are initiated on ART have been mentioned in 
the literature as a useful measure of adherence. The increase in mean corpuscular volume 
is suggested to monitor adherence of patients on zidovudine or stavudine therapy. Levels 
of plasma uric acid and bilirubin can be used to measure adherence in patients taking 
didanosine and indinavir therapy, respectively [93]. 
2.2. Adherence to ART in sub-Saharan Africa   
The concern that sub-Saharan Africa patients, many of whom live in poverty and with a 
lack of formal education, may not achieve an optimal level of adherence to ART has been 
waning over the past decade. A meta-analysis by Mills et al. [113] found that 77% of 
patients (95% Confidence Interval (CI), 68%-85%) met the threshold for optimal 
adherence in African studies (27 studies; 12,116 patients in total) compared to 55% (95% 
CI, 49%-62%) in North American studies (31 studies; 17,573 patients in total). The latest 
meta-analysis by Ortego et al. [47] also reported that 67% (95% CI, 56%-79%) of patients 
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were optimally adherent in sub-Saharan Africa studies,  which was still higher than 59% 
(95% CI, 53%-65%) and 62% (95% CI, 59%-66%) in North American and worldwide 
studies, respectively. 
Access to ART in the sub-Saharan Africa has been improving and has transformed 
HIV/AIDS into a chronic disease. However, only two-thirds of patients achieved optimal 
adherence [47]; hence, there is a growing interest in and recognition of the importance of 
identifying issues associated with long-term adherence to ART to improve adherence and 
treatment outcomes. Adherence to medication is a dynamic behaviour influenced by many 
factors. Overall factors associated with adherence to antiretroviral medication can be 
classified into three subgroups: patient-related factors, healthcare system-related factors, 
and regimen related-factors [114]. The influences of these factors on adherence to ART in 
sub-Saharan Africa patients are elaborated on in the following sections.  
2.2.1. Patient-related factors 
Demographic characteristics such as gender, age, marital status, religion, and ethnicity have 
been inconsistent predictors of adherence across studies. Being male has been significantly 
associated with both optimal [115, 116] and suboptimal adherence [117-120]. Maqutu et 
al. [116] reported that the rate of adherence was significantly higher in males than in 
females at the beginning of follow-up, but this difference disappeared at the end of the 17th 
months (17th follow-up visit). Several other studies [121-127] did not find an association 
between gender and adherence to ART.  
Increasing age was associated with better adherence in all studies that found age as a 
significant predictor of adherence [115, 126, 128-132]. For instance, being aged 18-24, 25-
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34 and 35-44 vs. 44 (OR=2.00, 95% CI=1.05-3.83; OR=2.51, 95% CI=1.50-4.20; OR=2.06, 
95% CI=1.28-3.30, respectively) were independently associated with higher odds of 30-day 
non-adherence [126]. Studies have reported a lack of association between marital status 
[115, 117, 119-122, 126, 131, 133-138], ethnicity [121, 135, 139], and religion [115, 117, 
121, 138-140] with adherence. 
Socioeconomic status, as indicated by education, employment status, income, food 
insecurity and transport costs, has been shown to influence adherence to ART in sub-
Saharan Africa. Most of the studies that evaluated the level of education have not found an 
association with adherence [117-120, 122, 126, 131, 136, 139-145]. Those studies that had 
reported significant association found inconsistent relationships. Eholie et al. [125] 
reported that attaining secondary school education or above was associated with 
suboptimal adherence. No schooling was related to optimal adherence to ART among HIV-
positive patients in South Africa [116]. A study in a Nairobi slum on patients taking on ART 
found a low level of education as an independent predictor of suboptimal adherence. This 
study reported that 62% of patients achieved optimal adherence [135]. 
Six studies reported no significant relationship between employment status and adherence 
to ART [117, 120, 129, 139, 142, 145]. Significant but inconsistent relationships were 
reported for unemployment in two studies; being unemployed was associated with 
suboptimal adherence in a survey of 253 Nigerian HIV-positive patients who had been on 
ART for a minimum of 6 months [115] while unemployment was related to optimal 
adherence in Cameroonian HIV-positive patients [140]. Several studies have assessed the 
relationship between income and adherence, but only one study found a significant 
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association. Low income was predictive of suboptimal adherence in treatment naïve 
Cameroonian HIV-positive patients initiated on ART [118].  
Findings have also been inconsistent in describing the association between adherence and 
food insecurity. Berhe et al. [141] reported that malnutrition was about 10 times more 
frequent in Ethiopian patients with suboptimal adherence. Food insecurity independently 
predicted suboptimal adherence in Congolese patients taking ART [145]. On the contrary, 
Sasaki et al. [119] reported experiencing food insufficiency in the past 30 days was 
associated with optimal adherence. This might be due to the greater social support focusing 
on people living in extreme poverty.   
Psychological problems are related to suboptimal adherence in HIV-positive patients 
taking ART. A high level of depression was related to suboptimal adherence in all studies 
that reported depression as a significant predictor of adherence [124, 143, 146-150]. Do et 
al. [124] found that the presence of depression in Botswanan patients taking ART was 
associated with suboptimal adherence. Nakimuli-Mpungu et al. [142] reported that 
psychological distress (depression and anxiety) and living alone were independent 
predictors of suboptimal adherence in Ugandan HIV-positive patients.  
Thirteen studies [124, 126, 129, 133, 140, 146, 147] reported a negative association 
between adherence to ART and alcohol use or disorders. Jaquet et al. [133]  reported that 
alcohol consumption was significantly associated with lower adherence in HIV-positive 
patients in Western Africa. Etienne et al. [146] reported that alcohol use in the last month 
was predictive of poor adherence in HIV-infected patients from five different sub-Saharan 
Africa countries. 
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Social supports that may involve emotional and material support for patients taking ART 
play a significant role in improving adherence. Consistent significant findings define the 
positive relationship between social support and adherence [128, 149, 151]. Diabate et al. 
[128] reported that absence of social support was related to suboptimal adherence. Peltzer 
et al. [149] found that a higher social support score was associated with achieving optimal 
adherence. Tiyou et al. [152] found that family support was related to better overall 
adherence (dose, time, and food). Encouraging patients to disclose their HIV status to 
family and friends, who can provide social support, facilitates medication taking.  
Disclosure of HIV status relates to adherence to ART. Two studies reported that failure to 
disclose HIV status decreased adherence to ART [124, 135]. Do et al. [124] reported that 
failure to disclose one’s HIV-1 status to a partner was predictive of suboptimal adherence. 
Unge et al. [135] found that not disclosing HIV status (OR=4.7, 95% CI=1.78-12.43) was 
significantly associated with dose adherence of < 95%. Five studies [119, 129, 137, 145, 
153] did not find an association between disclosure of HIV status and adherence. Some 
patients may not disclose their HIV status due to fear of stigma and discrimination. Stigma 
and discrimination were barriers to adherence to ART in sub-Saharan HIV-positive patients 
[147, 154]. Dlamini et al. [154] reported that perceived stigma was significantly associated 
with self-reported missed medications. 
The use of memory aids such as mobile phone text-message reminders and pill boxes 
facilitate adherence to ART [144, 151]. Studies trialling the effect of mobile phone text-
message reminders in sub-Saharan African HIV-positive patients found a significant 
improvement in adherence in the intervention group [155, 156].  
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Patients’ baseline clinical parameters such as WHO or Centers for Disease Control and 
Prevention (CDC) clinical stage of HIV/AIDS, CD4 count, viral load, and weight did not 
predict adherence in several sub-Saharan African studies [116, 118, 121, 125, 127, 136, 
137, 139, 149, 152, 153, 157]. Significant but inconsistent relationships were found 
between adherence and baseline CD4 count in two studies. CD4 count 250 cells/µL was 
associated with lower adherence in Western Africa HIV-positive patients [128] while CD4 
count < 350 cells/µL was related to poor adherence in Ethiopian HIV-infected patients 
[141]. Berhe et al. [141] reported that having a baseline BMI < 18.5 kg/m2 was associated 
with poor adherence to ART.  
2.2.2. Healthcare system-related factors 
Healthcare system-related factors, including quality of care, patient engagement, and 
patient satisfaction, are important determinants of adherence. Etienne and collaborators 
[146] showed that perceived high quality of care was highly correlated with adherence. In 
another study, Watt et al. [131] found that lower perceived quality of patient-provider 
interaction was associated with poor adherence. Munene et al. [138] showed that higher 
patient engagement in HIV care services was correlated with optimal medication 
adherence. However, Ukwe et al. [144] did not find significant correlations between trust in 
HIV care providers and patient satisfaction with the level of care with adherence. 
Structural factors that directly relate to the healthcare system such as transport difficulties 
influence adherence. Taiwo et al. [158] found that HIV-positive patients initiated on ART 
and living <20km from the clinic were significantly more likely to have >95% adherence 
than those living >100km from the hospital. Being resident in the urban area, where 
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patients have better access to HIV care service and thus pay lower transport costs and 
travel shorter distances, was associated with optimal adherence [116, 149]. However, the 
relationship is not consistent; Alakija et al. [115] reported that increasing distance to the 
hospital and transport fare were positively correlated with adherence.  
The structural barriers to clinic attendance scale score, which was developed by Coetzee 
and Kagee [159], was significantly associated with poor adherence to ART [120]. Improving 
healthcare accessibility increased patients’ adherence to ART. Moshabela et al. [160] 
reported that patients referred from hospital-based programmes to primary healthcare 
centres in rural South Africa were more likely to feel respected by healthcare providers, 
less liable to complain of long queues, perceived lower stigma, and showed a better level of 
ART adherence than the hospital-based users. 
2.2.3. Regimen-related factors  
Regimen-related factors such as pill burden, dosing frequency, ADRs, regimen type, and 
dietary and fluid restrictions are important determinants of adherence to ART. Inconsistent 
findings are reported on the impact of pill burden on adherence to ART.  Three studies 
[124, 137, 145] did not find a significant association between pill burden and adherence. 
Falang et al. [129] reported that lower pill burden was associated with higher adherence in 
Nigerian HIV-infected patients taking ART. Diabate et al. [128] showed that the 10 or more 
daily pills was predictive of poor adherence to ART. In earlier studies, frequent dosing was 
not uncommon; Orrell et al. [132] showed that three times daily dosing predicted 
incomplete adherence and virologic failure. 
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Studies have investigated the impact of ADRs on adherence to ART. Some of the studies 
found that ADRs were significant barriers to adherence [122, 126, 150]. Reporting severe 
ADRs in the past 30 days was associated with higher odds of non-adherence [126]. Denison 
et al. [137] reported experiencing more HIV and ADRs symptoms was related to incomplete 
adherence. Three studies did not find an association between ADRs and adherence to ART 
[118, 134, 139].  
Significant but inconsistent relationships were reported for duration of ART and adherence 
across studies; longer duration of ART was associated with higher adherence in Kenyan 
patients taking ART [138] while it was associated with lower adherence in Senegalese 
patients [127]. Eholie et al. [125] also showed that being on ART for equal to or greater 
than 12 months was associated with suboptimal adherence. 
Adherence is significantly different among regimens containing different classes of 
antiretroviral drugs. Patients on a PI-based regimen have been shown to have lower 
adherence compared to patients taking a NNRTI-containing regimen [127]. Patients taking 
different antiretroviral drugs of the same class have also shown different adherence rates. 
Peltzer et al. [149] reported that patients on nevirapine-containing regimens had better 
adherence compared to those taking efavirenz-containing regimens. Denison et al. [137] 
also showed that patients taking non-nevirapine-containing regimens achieved lower 
adherence compared to those on nevirapine-containing regimens. However, other studies 
did not find a significant association between ART regimen and adherence [118, 125, 140, 
146, 157]. Some ART regimens require dietary and fluid restrictions. Regimens that did not 
have such restriction have been associated with optimal adherence [134]. 
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There is a lack of consistency in the sub-Saharan African literature in relation to several of 
the factors identified above. These inconsistencies may correlate with a difference in 
culture, research methodology and quality of healthcare services across countries. Further 
research identifying the broad range of factors that lead to non-adherence in sub-Saharan 
Africa are necessary for developing evidence-based interventions aimed at individuals with 
suboptimal adherence to ART. This recommendation was also shared by Ortego et al. [47] 
in a meta-analysis of 84 observational studies. The efficient use of scarce antiretroviral 
drugs in resource-limited countries requires a comprehensive report on the wider range of 
biological and psychosocial factors involved. The lack of comprehensive studies in the case 
of Ethiopia is described in section 2.3.       
2.3. HIV/AIDS and its management in Ethiopia 
2.3.1. HIV/AIDS and treatment scale-up in Ethiopia  
According to the 2007 census, Ethiopia’s population was estimated at 74 million, the 
second largest population in sub-Saharan Africa nexA to Nigeria, and it grew at an average 
annual rate of 2.6% between 1994 and 2007. Eighty-four percent of the population was 
rural. Around 45% of the Ethiopian population was under the age of 15 [161]. 
Ethiopia is one of the sub-Saharan African countries hardest hit by the HIV epidemic. HIV 
probably began to spread in Ethiopia about three decades ago [162]. HIV was detected for 
the first time in Ethiopia in stored sera collected in 1984 [163] and the first AIDS cases 
were reported in 1986 in Yikatit 12 Hospital, Addis Ababa [164]. HIV prevalence in the 
1980s was very low; however it increased at an alarming rate in the 1990s [162]. It 
reached its peak of about 4.5% between 1998 and 2000. There was significant variation in 
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urban and rural prevalence, 14% and 2.5%, respectively, as shown in Figure 2 . The 
epidemic stabilised in cities between 1996 and 2000, and in rural areas between 1998 and 
2000 [163]. In 2003, the total number of HIV/AIDS patients was estimated to be between 
1.5 and 2.3 million [165]. As in other sub-Saharan Africa countries, new HIV infections have 
been declining in Ethiopia [166]. According to the 2011 Ethiopia Demographic Health 
Survey (EDHS), overall HIV prevalence in adults (15-49 years) was 1.5%.  
 
Figure 2. Trends in HIV prevalence among Ethiopian antenatal care clients in 
urban and rural sites, 2001-2012 [167]. 
 
The scale-up of free ART services has been one of the best achievements that the country 
has witnessed in its health sector. The number of facilities providing the treatment had 
been expanded from three as of 2005/2006, when free treatment launched, to 913 as of 
2012/2013 [167]. AIDS-related deaths decreased substantially following the scale-up of 
ART. The number of people receiving ART in Ethiopia increased from less than 9,000 in 
2005 to more than 439, 000 in 2013 as shown in Figure 3 [168].  The total number of adult 
patients receiving treatment in Ethiopia was 339,043 as 2014 [169]. The overall adult 
treatment coverage of those in need has reached 65%. However, 30% of patients ever 
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initiated on ART are not retained in care and this indicates the challenges in providing ART 
services in Ethiopia [167].  
 
Figure 3. Trends of the number of people receiving ART in Ethiopia, 2007-
2013 [168]. 
 
2.3.2. Factors associated with adherence to ART in Ethiopia 
Given that this research project focused on HIV/AIDS management in Ethiopia, it was 
important to have a comprehensive understanding of the issue in this country.  Seventeen 
studies that evaluated the predictors of adherence in Ethiopian HIV/AIDS adult patients 
were identified in this review. A total of 5,190 participants were involved in the studies. 
Characteristics of the studies are summarised in Table 2.  Among the studies included, 12 
were cross-sectional studies (n=4,288) [147, 150, 152, 170-178], three were qualitative 
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studies (n=154) [179-181], one was a case-control study (n=348) [141], and one a 
prospective study (n=400) [151].  
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Table 2. Characteristics of Ethiopian studies. 
 
Study  Sample Setting  Study design  
Cut-off points 
for adherence  
Number 
adherent 
% 
adherent 
Adherence 
measure  
        
Tsega et al. 2015 
[173] 
351 Gondar Hospitals  
Cross-
sectional  
100% 284 80.9 Pill count  
Ketema et al. 
2015 [175]  
422 
Debrebrihan Hospital and 
Debrebrihan  Health Centre  
Cross-
sectional  
100% 403 95.5 Self-report  
Lifson et al. 2015 
[178]  
22 Arba Minch Hospital  Qualitative          
Mitiku et al. 
2013 [174]  
239 Harari Hospitals  
Cross-
sectional  
 208 87 Self-report  
Berhe et al. 2013 
[138] 
348 
Mekele, Suhul, St. Marry, and Adwa 
Hospitals  
Case-control   174 50 Not reported 
Negash et al. 
2013 [144] 
355 Addis Ababa 
Cross-
sectional  
 261 73.5 Not reported  
Mengistu et al. 
2012 [167] 
420 Addis Ababa Hospitals  
Cross-
sectional  
Not reported  308 73.3 Not reported 
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Study  Sample Setting  Study design  
Cut-off points 
for adherence  
Number 
adherent 
% 
adherent 
Adherence 
measure  
        
Kebede et al. 
2012 [170] 
24 Dawuro Hospital  
Cross-
sectional  
100% 8 33.3 Self-report  
Gusdal et al. 
2011 [176] 
118 
Ethiopian urban hospitals; Ugandan 
urban and rural hospitals  
Qualitative          
Balcha et al. 
2011 [177] 
14 Bishoftu, Mojo, and Sebeta  Qualitative          
Giday A et al. 
2010 [168]  
510 Hawassa Hospital  
Cross-
sectional  
 450 88.2 Self-report  
Tiyou et al. 2010 
[149] 
319 Jimma Hospital  
Cross-
sectional  
 303 95 Self-report  
Tessema et al. 
2010 [171] 
504 Gondar and Felege Hiwot Hospitals  
Cross-
sectional  
100% 231 45.8 Self-report  
Beyene et al. 
2009 [172]   
422 
Yirgalem, Hawassa, and Shashemene 
Hospitals  
Cross-
sectional  
 393 93 
Self-report/Pill 
count  
Amberbir et al. 
2008 [148]  
400 Jimma Hospital  
Prospective 
cross-
 384 96 Self-report  
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Study  Sample Setting  Study design  
Cut-off points 
for adherence  
Number 
adherent 
% 
adherent 
Adherence 
measure  
        
sectional  
Markos et al. 
2008 [172]  
291 Yirgalem Hospital  
Cross-
sectional  
100% 287 98.6 
Self-report /pill 
count  
Tadios Y et al. 
2006 [147]  
431 Addis Ababa 
Cross-
sectional  
 350 81.2 Self-report  
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The studies were published between 2006 and the present. Eight of the studies were 
published before 2012 and the rest in or after 2012 (when this project commenced). 
Most of the studies published in or after 2012 suggest there is an increasing interest in 
issues associated with adherence in Ethiopian patients. 
All except three of the quantitative studies [141, 147, 170] have reported on the 
adherence measure used. Most [141, 147, 150-152, 170-174, 177, 178] evaluated 
adherence using self-report, asking patients about the number of missed doses over a 
particular period. The overall adherence rate using self-report was 80%. Only three 
studies [172, 175, 176] used pill account as the adherence measure, two of them with 
self-report[172, 175]. Beyene et al. [172] reported an adherence level of 88%, while a 
2015 study [176] found a lower rate of adherence of 81%. All qualitative studies [179-
181] involved patients taking ART in addition to caregivers or peer counsellors in 
interview or focus group discussions; the rates of adherence in these groups of patients 
were not reported. Seven quantitative studies [141, 147, 150-152, 170-175, 177, 178] 
used  95% adherence as the cut off point for optimal adherence while five studies 
[173-176, 178] grouped patients as optimally adherent when patients did not miss any 
dose in a specified time. 
Sixteen individual themes relating to barriers to adherence were acknowledged in this 
review. Patient-related barriers include unemployment [171, 172, 176], depression 
[147, 151, 174], low level of education or knowledge [171, 173], stigma and 
discrimination [147, 170], alcohol use [147, 172],  malnutrition [141], failure to disclose 
HIV status [172], lack of social support [172], non-readiness to commence ART [174], 
not having a life project [174], having a dependent [175], and younger age [176]. 
Regimen-related barriers including taking zidovudine/stavudine-containing regimen or 
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experiencing ART-related ADRs [150, 172, 174, 175], frequent dosing [172], and use of 
complementary and alternative medicines [178] were identified. Distance from the 
healthcare facilities [175] was the only healthcare system-related barrier identified.  
Eight themes regarding facilitators of adherence were identified. The two most 
important facilitators identified were an active relationship with the healthcare 
provider [150, 170, 173] and social support [152, 172, 178].  The remaining facilitators 
were identified only in single studies, and included the use of memory aids [151], fitting 
regimens with daily routines [150], diagnosis of late stage HIV/AIDS [152], better family 
income [152], being male [152], and disclosure of HIV status [176].  
Overall, the previous studies conducted in Ethiopia have many weaknesses. Most of the 
studies were cross-sectional and assessed limited variables at one point in time; they 
therefore had limited ability to capture changes in adherence behaviour. Only one 
prospective study of three months’ duration evaluated the levels of adherence and 
factors that hinder or facilitate adherence to ART. More rigorous evaluations of 
associations reported by cross-sectional studies using long-term prospective 
methodologies are required as suggested by Mann et al. [182]. Previous qualitative 
studies mainly focused on exploring factors influencing patient retention at the 
healthcare level and were limited in their ability to examine barriers to, and facilitators 
of, medication adherence at the individual level. 
2.4. Justification for the current study  
As discussed above, studies previously conducted among Ethiopian HIV-positive 
patients taking ART have several limitations. In general, they have lacked the evaluation 
of the level of adherence and its determinants required to provide comprehensive 
information to design effective ART interventions in the Ethiopian setting.  
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This study used mixed methods research methodology including a prospective study 
and exploratory qualitative research to identify barriers to, and facilitators of, 
adherence to ART. It was carried out in two hospitals involving HIV/AIDS patients, 
nurses, and case-managers. The triangulation using the different methodologies 
deepens our understandings of problems associated with HIV/AIDS treatment. ADRs 
are common in patients’ initiated on ART and are important issues in the management 
of ART. However, only a few retrospective studies have attempted to identify ADRs in 
Ethiopian patients’ initiated on ART.  We examined the incidence and nature of ADRs, 
identified the risk factors associated with the development of ADRs, and assessed their 
impact on adherence. Given the evolution of therapy over time and unresolved 
questions regarding what ‘optimal adherence’ actually means, a meta-analysis was 
performed to determine the relationship between the cut-off point for optimal 
adherence to ART and virologic outcomes.  As access to ART is progressively improving, 
the results of this study will aid policy makers and HIV care managers to develop 
efficient strategies to improve treatment outcomes in Ethiopian HIV/AIDS patients. 
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CHAPTER THREE 
3. ADHERENCE TO ANTIRETROVIRAL DRUG THERAPY IN ADULT HIV-POSITIVE 
PATIENTS IN NORTHWEST ETHIOPIA: A STUDY PROTOCOL. 
3.1. Abstract  
Introduction: Achievement of optimal medication adherence and management of 
antiretroviral toxicity pose great challenges among Ethiopian patients with HIV/AIDS. 
There is currently a lack of long-term follow-up studies that identify the barriers to, and 
facilitators of, adherence to antiretroviral therapy (ART) in the Ethiopian setting. 
Therefore, we aim to investigate the level of adherence to ART and a wide range of 
potential influencing factors, including adverse drug reactions (ADRs) occurring with 
ART. 
Methods and analysis: We are conducting a 1-year prospective cohort study involving 
adult patients with HIV/AIDS starting on ART between December 2012 and March 
2013. Data are being collected on patients’ appointment dates in the ART clinics. 
Adherence to ART is being measured using pill count, medication possession ratio, and 
patient’s self-report. The primary outcome of the study will be the proportion of 
patients who are adherent to their ART regimen at 3, 6 and 12 months using pill count. 
Taking 95% or more of the dispensed ART regimen using pill count at given points of 
time will be considered the optimal level of adherence in this study. Data will be 
analysed using descriptive and inferential statistical procedures.  
Ethics and dissemination: 
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Ethics approval was obtained from the Tasmania Health and Medical Human Research 
Ethics Committee and Bahir-Dar University’s Ethics Committee. The results of the study 
will be reported in peer-reviewed scientific journals, conferences, and seminar 
presentations.  
Article summary  
Article focus 
To establish the level of adherence and identify factors that influence adherence to ART 
in Ethiopian HIV/AIDS patients in a cohort study.  
Key messages: 
Factors that affect adherence to ART have not yet been identified in Ethiopian HIV/AIDS 
patients in a long-term follow-up study.  
Data obtained during this prospective cohort study over the period of at least of 12 
months will identify important factors associated with long-term adherence to ART that 
will assist in optimising the outcomes of Ethiopian HIV/AIDS patients.  
Strength and limitations of this study 
This study will identify factors that affect adherence to ART in treatment naïve patients 
who are initiated on ART with long-term follow-up.  
Rates of patient drop out, loss to follow-up and death are high in this setting, which may 
challenge the success of the project. 
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3.2. Introduction 
Ethiopia is home to approximately 800,000 patients with HIV/AIDS and the prevalence 
of HIV/AIDS in the general population is estimated to be 1.5% [183]. The free 
antiretroviral therapy (ART) program in Ethiopia, introduced in 2005, has decreased 
mortality and morbidity, and improved the quality of life of patients [184]. In the past 8 
years, decentralisation and scale-up of the HIV care program has occurred, and by the 
end of 2011, 249,174 adult patients (86% of eligible patients) were on ART [185].  
Achievement of optimal medication adherence, management of antiretroviral drug-
related toxicities, and patient retention [174, 186] are becoming the greatest challenges 
in the management of HIV/ADS in Ethiopia. A cross-sectional study of Ethiopian 
patients reported an adherence rate of 88.1% [172], which is below the near perfect 
adherence (≥95%) required to maintain the effectiveness of ART [187].  
Patient retention in HIV care facilities is low, and averaged 51% to 85% in 55 Ethiopian 
HIV care facilities in a 2-year patient follow-up study [186]. Similarly, a 2011 report 
from the Ethiopian Ministry of Health indicated that patients dropping out from HIV 
care was a serious issue, with up to 40% of patients who started ART dropping out from 
treatment in some regions of the country [188]. Mortality and drop out from treatment 
are most common in the first year of patient follow-up in Ethiopia [189]. 
Adherence to medication is a dynamic behaviour affected by factors related to 
treatment regimen complexity, patient-related variables, patient-health care provider 
relationships, and the quality of health care services [190].Patient adherence to ART is 
also influenced by regimen-related factors such as pill burden, frequency of dosing, 
adverse drug reactions (ADRs), and fluid and dietary restrictions[191]. Similarly, 
patient-related factors such as lack of transport, shortage of food, use of traditional 
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medicine, alcohol abuse, depression, stigma and discrimination, and lack of social 
support undermine adherence [192-195]. Further, a poor patient-health care provider 
relationship and low quality services, such as lack of confidentiality and privacy, and 
drug stock outs can hamper adherence with ART[192]. 
3.3. Justification for this study 
Previous studies were retrospective cross-sectional studies, lacked active surveillance 
and did not focus on treatment naïve HIV/AIDS patients. While one prospective study 
has investigated adherence to ART in Ethiopia [151] it was only conducted for three 
months and also did not focus on treatment naïve patients. A prospective study with a 
longer follow-up focusing on treatment naïve patients is required to assess the level of 
adherence in this patient group and its barriers and facilitators. There is also a need to 
conduct a prospective study in Ethiopian patients with HIV/AIDS to assess the 
emergence of ADRs to ART in clinical practice, and the potential relationship between 
ADRs and non-adherence to ART. 
3.4. Objectives  
The objectives of this study are to establish the level of medication adherence and 
identify factors that influence medication adherence, and assess the incidence of ADRs 
and associated risk factors in Ethiopian patients with HIV/AIDS initiated on ART. 
3.5. Methods and analysis 
3.5.1. Study design 
This study is a prospective cohort study in which adult Ethiopian patients with 
HIV/AIDS initiated on ART are being followed from the time of ART initiation (Month 
(M) =0) to 12 months of therapy (M=12). ART-initiated patients have an appointment 
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every month for six months and every three months thereafter in ART clinics in 
Ethiopia; research pharmacists will collect data on appointment dates. The timeline of 
data collection activities is structured as shown in Table 3. The sequencing and 
repeating of measures is to observe the time pattern of different predictors on 
adherence to ART in treatment naïve patients. Depression, stigma, HIV-treatment 
knowledge, healthcare relationship, and belief about medication, and HIV-symptom 
index may affect adherence in a time-dependent manner and are being measured before 
and after 6 months of patients’ ART using validated scales. Data regarding the 
concomitantly administered medications, comorbidities, ADRs, and laboratory values 
are collected on every appointment date.  
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Table 3. Time line of data collection.  
 
 
3.5.2. Study setting 
The project is being carried out in two hospitals in Northwest Ethiopia: Gondar 
University Hospital and Felege-Hiwot Hospital. Each hospital has 400 beds and serves a 
catchment area of 5 million people. The total number of HIV/AIDS patients attending 
each hospital is approximately 7,000 and 10,000 at Gondar University Hospital and 
Felege-Hiwot Hospital, respectively. Recruitment into the study occurred between 
Data  Time point 
Baseline M1 M2  M3  M4 M5 M6 M9 M12 
Socio-demographics √         
HIV treatment knowledge  √       √  
Social support   √      √ 
Substance abuse  √         
Depression (CES-D)   √     √  
Berger-stigma    √     √  
Self-report adherence     √   √ √ √ 
Pill count   √ √  √ √ √ √ 
Pharmacy record review      √   √ √ √ 
Self-reported HIV symptoms (HSI)     √   √ √ √ 
Beliefs about medication (BMQ)    √     √  
Health care relationship     √     √ 
Patient experience of ADRs for the last 
4 weeks 
 √ √ √ √ √ √ √ √ 
Patient’s medical record review √   √   √ √ √ 
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December 2012 and March 2013. The study will continue to March 2014, which will 
allow a follow-up period of at least 12 months for each patient.   
3.5.3. Inclusion / Exclusion criteria  
All HIV/AIDS patients at least 18 years old and being initiated on ART for the first time, 
are invited to participate. Patients whose follow-up was to be conducted in other 
hospitals, rather than at the hospital where ART was initiated, are not included.   
3.5.4. Sample size  
The sample size for this study was determined based on a previous study, where 76% of 
patients had optimal dose, time, and food adherence to ART [151].Taking a 95% 
confidence level, and precision of 0.07, the sample size was estimated to be 143.  
Based on an average of 43 new patients per month, within four months of recruitment 
in each ART clinics the pool of patients for recruitment will be 344. Allowing for a non-
participation rate of 23%, and loss to follow-up of up to 30% (Mekides B and Desalew K, 
July 2012, personal communication), the sample size is achievable. 
 
3.5.5. Recruitment 
Between December 2012 and March 2013, participants were initially invited by their 
nurses to participate in this study. At the first visit (usually two weeks before ART 
initiation), nurses gave patients information about the study and invited them to 
participate. If patients were interested in participating in the study, the research 
pharmacists contacted them to discuss the research. Informed consent was obtained 
from volunteer participants using a standard information statement and consent form. 
Each participant receives $US 3 to reimburse their time and transport cost. The 
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characteristics of patients who declined participation were collected to determine the 
representativeness of the sample.    
3.5.6. Measures  
The questionnaires have been spread to track changes of the different parameters over 
time as shown in Table 3, while minimising questionnaire fatigue. Assessment of 
adherence is a problematic issue as there is no gold standard method of measurement 
[91]. In this study self-report, pill count and Medication Possession Ratio (MPR) will be 
used to measure adherence at months 3, 6, 9, and 12. Use of multiple measures of 
adherence is recommended in literature as there is no single optimal measure of 
adherence [91]. Adherence to medication found using multiple measures will be 
converted into ‘percentage dose adherence’ and triangulated. For example, self-
reported percentage adherence over 30 days will be triangulated with percentage dose 
adherence obtained using pill count over the same duration, which will be useful to 
estimate patients’ true medication adherence. Percentage adherence to each of the 
medications will be calculated and the lowest dose adherence taken as the adherence 
for a given patient.  
The primary outcome of the study will be the proportion of patients who are adherent 
to their ART regimen at 3, 6 and 12 months using pill count. The optimal level of 
adherence in this study will be considered as taking 95% or more of the dispensed ART 
regimen using pill count at a point in time. Adherence from pill counts will be calculated 
by dividing the difference between current and previous pill counts by the number of 
pills that have to be taken during the same period [172]. Pill counts have been found to 
be an economic and reliable measure of adherence in resource-limited settings [196].    
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A modified AIDS Clinical Trial Group (ACTG) self-reported adherence questionnaire that 
asks patients how many doses they missed in the last 7 days has been used to measure 
patients’ dose adherence to ART. In addition, two four-item modified questionnaires 
from the ACTG have been used to measure time and food adherence in the last 7 days 
[90]. Assessing multiple dimensions of adherence by using all items of the ACTG self-
reported adherence questionnaires has provided a strong measure of adherence [94]. 
Self-reported adherence is well correlated with viral load suppression and is 
particularly suitable for resource-limited settings because of its low cost [92]. 
Patients stating they have missed medication will be asked to indicate reasons for 
nonadherence from a list of 16 reasons (e.g. away from home, busy with other things, 
simply forgot). Fourteen of the reasons for non-adherence are taken from the ACTG [90] 
and two reasons associated with traditional medicine and religious treatment, 
respectively, were obtained from literature review [193].   
Pharmacy refill records have been reviewed and the MPR will be calculated by dividing 
the total number of days covered with the medication dispensed by the number of days 
between the first fill and the last refill plus the days’ supply of the last refill [197]. This 
method is suitable in our study as HIV-medication is refilled only from the nearby 
governmental hospital/health centre pharmacy in Ethiopia [185]. Pill count and MPR 
are superior to self-reported adherence measures and well correlated with virological 
failure and clinical outcomes [198]. Biological surrogate markers such as viral load and 
CD4 count correlate with medication adherence [199]. The CD4 count is measured 
every 6 months in ART clinics; the measures at months 6 and 12 will be used as a 
biological surrogate marker of adherence. Viral load is not routinely measured in 
Ethiopian clinical practice, and so has not been included in the trial protocol. 
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Depression in patients is being evaluated using the seven-item questionnaire of the 
Center for Epidemiological Studies Depression (CES-D) scale. This scale has been 
extensively applied in different settings, including in HIV/AIDS patients [90]. The 
Revised Berger HIV stigma scale has been used for measurement of stigma. The 10 
items of the Berger stigma scale have been validated in HIV-positive youth [200]. The 
Berger stigma scale was also used in Kenyan patients with HIV/AIDS [201]. A higher 
score indicates the existence of greater stigma [202]. 
Previous studies have suggested that a lack of social support predisposes patients with 
HIV/AIDS to medication non-adherence [203]. Patients’ satisfaction with the social 
support they get from family members and friends and the help of the support for 
remembering their medication has been measured using two four-point scale social 
support questionnaires [90]. 
The HIV treatment knowledge scale has been used to measure patients’ knowledge on 
adherence, ADRs and drug resistance. This instrument has been developed and 
validated by Balfour et al. [204] in HIV/AIDS patients taking ART.  
The BMQ has been used to measure patients’ beliefs about ART. The BMQ consists of 
two five-item scales probing patients’ beliefs about the necessity of the given 
medication and their concerns about possible ADRs [205, 206].  
The trust between the patients and health care providers has been measured using the 
13-item HCR trust scale. Items are rated from 0 to 4; the total score ranges from 0 to 52 
and a higher score indicates a greater level of trust [207].  
A Self-completed HIV Symptom Index (HSI) is used to measure patients’ concern about 
20 possible symptoms associated with ART ADRs. The research pharmacists are 
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interviewing patients, their caregivers and physicians, and referring to patients’ medical 
records and documenting detailed information regarding the adverse effects that 
patients experience. The severity of ADRs has been rated using the WHO ADR severity 
scale [208]. Similarly, a physician and a pharmacist have been determining the causality 
of each ADR using Naranjo’s probability scale [209]. The reliability between raters and 
within raters has improved significantly (p<0.001) with the use of Naranjo’s probability 
scale [209].This scale has been widely used in various settings [210]. In addition, the 
Schumock and Thornton scale has been used to rate the preventability of adverse drug 
events [211].  
Socio-demographic and economic variables such as age, gender, marital status, religion, 
level of education, number of children, employment status, disclosure of HIV status, 
average number of meals per day, monthly income, transportation costs to the clinic, 
and waiting time in the hospital are collected at the baseline.  
Laboratory data such as weight, height, history of ADRs, hepatitis B virus (HBV) and 
hepatitis C virus (HCV) infection status, WHO stage of HIV/AIDS, CD4 count, 
haematocrit, white blood cell (WBC) count, absolute neutrophil count, platelet count, 
liver function tests [alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
alkaline phosphatase (ALP), and bilirubin direct and total], renal function tests [such as 
blood urea nitrogen (BUN), serum creatinine, and urea], and ART regimen, date of 
initiation, dose and frequency of treatment, other concomitant medications and 
comorbidities have been recorded from patients on each appointment date from their 
medical records using a clinical and laboratory data collection sheet. 
‘Non-persistance’ from ART program is defined as patients not presenting for refilling of 
their ART for the last 3 months. Patients’ record will be used to calculate the number of 
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days covered by the last dispensed HIV medication and 90 days will be added to 
determine the date when patients are categorised as ‘non-persistances’. The 
characteristics of study subjects who do not make at least 6 months follow-up (non-
persistent patients) will be examined separately and compared with those who are 
persistent. It helps to determine the potential impact of attrition bias on the validity of 
our findings.  Patients lost the follow-up are being tracked by peer counsellors working 
in the ART clinics of both hospitals using the registered address and phone number of 
them or their family member or close friend in their medical record.  The reason for 
being lost to follow-up has been recorded. Socio-demographic and clinical prognostic 
characteristics of those lost from the treatment, and those continuing ART will be 
compared. 
The percentage of missing items for each scale will be calculated for each participant. If 
more than 10% of the items of the scale are missed, the patient’s total score on that 
scale will be excluded from data analysis at that time point. The proportion of missing 
participants for each variable of interest will be calculated.   
3.5.7. Statistical analysis  
Descriptive univariate analysis will be conducted for socio-demographic and economic 
variables. Adherers will be compared with non-adherers with the Pearson chi-squared 
test for categorical variables and independent samples t-tests for normally distributed 
continuous data. Similarly, the characteristics of patients who developed ADRs and did 
not develop ADRs will be compared using Pearson chi-squared tests for categorical 
variables and independent samples t-test for continuous variables. Risk factors for 
adherence will be determined by investigating the influence of socio-demographic, 
socio-economic variables, and psychosocial variables, healthcare provider relationship, 
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beliefs about medications and ADRs. Risk factors for ADRs will be determined by 
investigating the effects of gender, age, body mass index (BMI), CD4 count, history of 
drug allergy, comorbidities, concomitant medications, and type of regimen. Multiple 
variable binary logistic regression will be used to evaluate the independent influence of 
these risk factors on adherence. The exposure and the potential confounders will be 
modelled in relation with the outcome variable for adjustment using a multiple-
predicative regression model. The final model will be determined after checking 
multicollinearity. All statistical calculations will be performed using SPSS Version 21.0 
(IBM Corp., New York, USA). A p-value of <0.05 will be considered as statistically 
significant. 
3.6. Quality control   
The English-speaking native researcher made the forward translation of the validated 
questionnaires into Amharic. Two physicians working in the ART clinics of the 
Ethiopian hospitals reviewed the developed Amharic versions. A professional translator 
made the backward translation to check the difference between the Amharic versions 
and the original English versions. The differences between the source version and target 
version were settled by a meeting of the forward translator, a physician and the back-
translator, and final Amharic versions were developed. The Amharic version was 
pretested with 40 adult patients receiving ART who would not be included in the main 
study to check for reliability and validity of the questionnaires. Items found to be 
problematic by patients were modified.  
3.7. Data management 
The investigators have been checking the collected data for completeness, accuracy and 
clarity. These checks have been performed daily after data collection and amendments 
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have been made before the next data collection point. Data clean up and crosschecking 
have also been done prior to data analysis. The research pharmacists have been 
assessing the severity [208], causality [209], and preventability [211] of adverse events 
separately using validated algorithms.  
The data have been entered from the two study sites in Ethiopia into a custom-built 
website housed on a secure server at the University of Tasmania. Stored data have been 
backed up on a daily basis. Access to the information has been only granted to 
authenticated investigators from anywhere using the Internet.  
The custom-built website generates data collection forms for printing. After completion 
these forms have been scanned and then uploaded to the website. The data from the 
forms have been entered onto the website by the research pharmacists. A random 
sample of the scanned forms has been checked against the website data to ensure 
accuracy. Additionally, the website has a sophisticated series of checks to ensure that 
fields are entered and that all fields are within expected values. Researchers at each 
site have been informed of any incomplete or inconsistent data. 
3.8. Strengths of the study  
Several features in the design and planning of the project contribute to the strengths of 
the study. First, the study is intended to examine predictors of adherence from different 
perspectives including patient characteristics, medication regimens, and the health care 
system. Patients’ socio-economic status, level of education, belief and knowledge of HIV 
medication, social support and psychosocial variables are mentioned as predictors of 
adherence elsewhere [212, 213].  
Second, the study uses multiple measures of adherence, which is recommended in the 
literature as there is no gold standard method of adherence measurement [91]. 
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Although patients in sub-Saharan Africa have been reported to have a comparable rate 
of adherence with those in the developed countries [113], there is a plausible 
explanation in the literature that studies in sub-Saharan Africa measure adherence 
mainly using self-report, which overestimates adherence by as much as 20% [96]. 
Patients refill their HIV-medication in a specific government ART clinic pharmacy; this 
allows us to use pill count and pharmacy records for adherence measurement [91, 93, 
102].  
3.9. Limitations of the study   
Rates of patient drop out, loss to follow up and death are high in this setting [189], 
which may challenge the success of the project. The multiple measures of adherence 
used in the study may alter patients’ behaviour and overestimate medication adherence 
[214] (i.e. Hawthorne effect).  
The study period may not be sufficient to document long-term ADRs, such as endocrine 
and metabolic adverse events, which may need more than one year to become apparent. 
Patients may not show up in ART clinics for treatment of ADRs or may be treated in 
other nearby clinics, which may underestimate the incidence of ADRs.  
3.10. Ethics and dissemination   
Ethics approval was obtained from the Tasmania Health and Medical Human Research 
Ethics committee (Approval Number: H0012722); and Bahir Dar University’s Ethics 
Committee (RCS/567/2004). Nurses working in the ART clinics familiarised patients 
with the study; research pharmacists delivered further information to interested 
participants. Participants were given the chance to read and understand the 
information sheet and to ask any questions before providing written consent. Copies of 
the information sheet and consent form were handed on to study participants who 
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consented. All personally identifying information has been removed from the 
questionnaires and study documents. Study participants have been identified only using 
a unique study number. The hardcopy data will be stored in a locked filing cabinet in the 
Bahir Dar University premises for 5 years; afterwards the data will be shredded and 
disposed of in secure bins. Access to the filing cabinet and custom-built website will 
only be granted to authenticated investigators. We will disseminate our findings via a 
public presentation to stakeholders working on HIV/AIDS treatment in Ethiopia. The 
results of the study will be reported in peer-reviewed scientific journals, conferences, 
and seminar presentations. 
3.11. Conclusion  
The study is expected to provide extensive information about adherence, including the 
barriers to and facilitators of adherence, and the ADR profile among a cohort of 
Ethiopian patients commencing on ART. This will establish an important foundation for 
a subsequent intervention study focussing on improving adherence in ART naïve 
patients with HIV/AIDS.  
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CHAPTER FOUR 
4. ANTIRETROVIRAL ADHERENCE AND TREATMENT OUTCOMES AMONG 
ADULT ETHIOPIAN PATIENTS  
4.1. Abstract 
Developing appropriate strategies to sustain optimal medication adherence among the 
increasing number of HIV-positive patients taking antiretroviral therapy (ART) in sub-
Saharan Africa is a major challenge. The objective of this study was to determine 
patient, regimen, disease, patient-provider, and healthcare-related factors associated 
with adherence with ART over a one-year period, and assess the impact of adherence on 
treatment outcomes. We performed a prospective, observational study among 246 
patients who were initiated on ART in Ethiopia. Of 172 who completed follow-up, 130 
(75.6 %) had  95 % self-reported adherence. In multivariate analyses, lower BMI (OR 
1.2; 95 % CI 1.0, 1.4) and HIV symptoms distress scores (OR 0.9; 95 % CI 0.9, 1.0) and 
the use of medication reminder devices (OR, 9.1; 95 % CI 2.0, 41.6) were associated 
with higher adherence. CD4 count increase was significantly higher in the adherent 
patients compared to non-adherent patients at 12 months (159 cells/µL [Interquartile 
range (IQR), 72-324 cells/µL] vs. 132 cells/µL [IQR, 43-190 cells/µL]; p = 0.026, Mann-
Whitney U test). Our findings indicate that interventions aimed at improving adherence 
and thereby treatment outcomes in patients initiated on ART should promote the use of 
reminder devices, and monitor HIV symptoms and adverse reaction distress and 
nutritional status. 
Keywords Antiretroviral therapy, highly active; Medication adherence; HIV; Treatment 
outcomes; Ethiopia 
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4.2. Introduction 
At the end of 2013, 12.9 million people were on antiretroviral therapy (ART) 
worldwide. Of these 11.7 million (90.7 %) were living in low-and middle-income 
countries [215]. Since 2005, when a free ART programme was launched in Ethiopia 
[184, 188], decentralisation and scale-up of the programme has occurred and a total of 
270,460 adult patients were receiving ART by 2012 [167]. ART has resulted in a 
dramatic decrease in mortality and morbidity in patients with HIV/AIDS [216]. 
Although studies have reported that less-than-perfect adherence (< 95 %) to non-
nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens can lead to 
viral suppression [217, 218], near perfect adherence (≥ 95 %) to ART achieves better 
virological and treatment outcomes [219]. Furthermore, it is recognised that non-
adherence to treatment can lead to insufficient viral suppression and promote the 
emergence of drug-resistant viral strains, resulting in regimen failure, clinical 
progression to AIDS, and death [220, 221].  
Medication adherence to ART changes over time [222]. Previous studies have identified 
regimen and disease-related factors, healthcare-related factors, psychological factors, 
and knowledge and belief about treatments as being associated with non-adherence 
[223, 224]. Only a few studies (three cross-sectional studies and a three-month follow-
up study) that assessed limited variables at a single time point have been performed in 
Ethiopia [150-152, 172]. There was a need for a multicentre longitudinal study to assess 
a wide range of factors potentially associated with long-term adherence among adult 
HIV-positive patients initiated on ART. The objective of this study was therefore to 
identify key determinants of adherence with ART over a one-year period, and to 
compare treatment outcomes between adherent and non-adherent patients.  
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4.3. Methods 
This was a prospective cohort study of treatment-naïve adult ( 18 years) HIV/AIDS 
patients recruited from Felege-Hiwot and Gondar University Hospitals, Northwest 
Ethiopia, from December 2012 through March 2013. Details of the study setting have 
been described elsewhere [225]. Nurses and research pharmacists recruited 
participants from hospitals. Written informed consent was obtained from each 
participant for their participation. Patients were followed for 12 months after initiation 
of ART. All patients who attended 12 months’ follow-up and had complete self-reported 
adherence data were included in this analysis.  
4.3.1. Measures 
Details of the questionnaires and the time-line of administration have previously been 
described [225]. Patients’ sociodemographic (e.g., gender, age) and socioeconomic (e.g., 
level of education, employment status) information was self-reported at the study 
baseline. Clinical data (e.g., CD4 count, weight) were obtained from patients’ medical 
charts every month for the first six months and every three months thereafter. The 
chart schedule switched to fit with patients appointment in the ART clinics.   
Dose and time adherence was measured using the modified AIDS Clinical Trial Group 
(ACTG) self-reported adherence questionnaire [90]. The questionnaire was 
administered every three months.  Dose adherence was assessed by asking patients 
how many doses they had missed in the last 7 days, and calculated as the percentage of 
prescribed doses actually taken over that period. Similarly, time adherence was 
assessed by asking participants how closely they followed their specific medication time 
in the past 7 days, using a 5-point Likert scale, ranging from “never” to “all the time”; the 
score was converted to percentage time adherence. Means of dose and time adherence 
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were taken as a combined indicator of ACTG self-reported adherence. Clinic-based pill 
count, 30 day visual analogue scale (VAS), and medication possession ratio (MPR) 
measures were also carried out at the same time for comparison. Details of adherence 
measures have previously been described [225]. Adherence in this study was the 
combined self-reported dose and time ACTG measured adherence at 12 months. 
Optimal adherence in this study was defined as achieving 95 % or more in combined 
self-reported dose and time adherence at 12 months.  
4.3.1.1. Healthcare relationship   
The trust between the patients and healthcare providers was measured using the 13-
item Healthcare Relationship (HCR) scale. Items were rated from 0 to 4; the total score 
ranged from 0 to 52 and a higher score indicated a greater level of trust [207, 226]. 
Reliability for the HCR scale in this sample was 0.94 using Cronbach’s alpha.  
4.3.1.2. HIV treatment knowledge 
The HIV treatment knowledge scale was used to measure patients’ knowledge on 
adherence, adverse drug reactions, and drug resistance. This instrument was developed 
and validated by Balfour et al. [204] in patients with HIV/AIDS. Cronbach’s alpha in this 
study was 0.50.  
4.3.1.3. Beliefs about medicines   
The Beliefs about Medicines Questionnaire (BMQ) was used to assess patients’ beliefs 
about ART [206]. The BMQ measures perceived necessity of ART (8 items) and 
perceived concern about potential adverse drug reactions (11 items). Necessity-
Concern Differential (NCD) was calculated by subtracting concern scores from necessity 
scores, and used as a numerical indicator for rating patients’ perceived need of 
treatment to concern about taking medication [205, 206]. Reliability was good for BMQ 
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necessity and concern subscales (0.71-0.78) in the sample. Cronbach’s alpha for the 
whole BMQ scale in this sample was 0.68.  
4.3.1.4. HIV Symptoms and ADR distress 
The HIV-Symptom Index (HSI) [227] was used to measure distress associated with HIV 
symptoms and ADRs. It included a 20-item scale where participants were asked if they 
had experienced each of the listed symptoms (e.g., nausea, headache) during the past 
four weeks. Participants rated on a 5-point Likert-type scale (0 = I do not have this 
symptom, 4 = It bothers me terribly) the extent to which the symptoms bothered them. 
The HSI had good internal consistency in this sample (Cronbach’s alpha 0.85).  
4.3.1.5. Depression 
The Centre for Epidemiological Studies Depression scale (CES-D) [228] assessed 
frequency of seven depressive symptoms over the past week. It employs a 4-point 
Likert-type scale ranging from 0 = never/rarely to 3 = mostly or always. It has been 
extensively applied in different settings, including in patients with HIV/AIDS [90]. CES-
D had good internal consistency in this sample; with Cronbach’s alpha of 0.81.  
4.3.1.6. Stigma  
Stigma was assessed using the revised 10-item version Berger Stigma Scale [200], which 
consist of four subscales: Personalized Stigma, Disclosure Concerns, Negative Self-Image 
and Public Attitudes. Participants could answer on a 4-point Likert-type scale ranging 
from 1 = strongly disagree to 4 = strongly agree. For each subscale, item scores were 
added to provide a personalized stigma score ranging from 0 to 12, a disclosure concern 
score ranging from 0 to 8, a negative self-image score ranging from 0 to 12, and public 
attitudes score ranging from 0 to 8. The whole Berger Stigma scale had good internal 
consistency (Cronbach’s alpha 0.90).  
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4.3.1.7. Substance use  
The Alcohol Use Disorder Identification Test (AUDIT-C) has two questions about alcohol 
use; the number of days on which the patients had alcohol-containing drinks in last 30 
days and the amount of alcohol drinks consumed on the days when they did drink 
alcohol [229]. Cronbach’s alpha for AUDIT-C in this sample was 0.65. Questions about 
the use of khat, a shrub whose fresh leaves and shoots are chewed for psychostimulant 
effects [230], in the past 6 months were also collected.  
4.3.2. Statistical analysis  
Characteristics of adherent (adherence at 12 months  95 %) versus non-adherent ( 
95 %) patients were compared using independent sample t-tests for normally 
distributed continuous variables; Mann-Whitney U tests for ordinal (Likert-type scales) 
and non-normally distributed continuous variables; and chi-square or Fisher’s exact 
tests (cell size less than 5) for nominal variables. Variables with a p value of  0.2 on 
univariate analysis were included in the logistic regression model. Two-sided 
assumptions and tests were adopted for all statistical readings. P < 0.05 was used as the 
threshold of statistical significance. Analyses were performed using SPSS, version 22 
(IBM Corp., New York, USA).  
4.4. Results  
4.4.1. Study participants  
From December 2012 to March 2013, 347 HIV-positive individuals were screened; 337 
adults (18 years; 191 females and 146 males) initiated on ART at the two sites and 246 
(72.9 %) patients (143 females and 103 males) were enrolled in this study. There were 
no significant differences in the WHO clinical stage of HIV/AIDS, gender, age, CD4 count, 
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and weight between subjects who did and did not participate in the study. One hundred 
and seventy-two (69.9 %) participants who completed 12 months’ follow-up were 
included in this analysis. Seventy-four (30.1 %) were excluded from analysis: 15 were 
lost to follow-up, 17 withdrew from the study, 15 died, 12 transferred to other ART 
clinics, and 15 did not complete 12 months’ follow-up. There were no significant 
differences in gender, age, CD4 count and weight at baseline between those who did and 
did not complete 12 months’ follow-up. Patients who had WHO clinical stage III/IV 
HIV/AIDS at baseline were twice more likely to not complete 12 months’ follow-up.    
One hundred and four (60.5 %) patients were female, and the median age of patients 
included in the analysis was 32 years [Interquartile Range (IQR), 27-40]. The median 
CD4 count at treatment initiation was 185 cells/µL [IQR, 95-253] and 85 (51.5%) 
participants were diagnosed with stage III or IV HIV/AIDS based on WHO clinical 
staging criteria. The median income per month was 400 Ethiopian Birr (20 USD), and 
the median travel time to the clinic was 30 minutes. At enrolment visit, 136 (79%) 
patients had their own mobile phone among them 87 (64%) patients could be able to 
send and receive a text-message.  
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Table 4. Participant characteristics. 
 
Characteristic 
Total (%) Adherent patients 
Non-adherent 
patients 
Odds Ratio (95 % 
CI) 
P value  
(n=172) (n=130) (n=42) 
Demographics            
Gender (female) 104 (60.5) 81 (62.3) 23 (54.8) 1.37 (0.68-2.76) 0.491 
Age, median years 
(IQR) 
32 (27-40) 32 (28-40) 30 (25-40) - 0.228 
 Married 99 (57.6) 73 (56.2) 26 (61.9) 0.79 (0.39-1.61) 0.634 
Completed secondary 
school or above 
83 (48.3) 69 (53.1) 14 (33.3) 2.26 (1.09-4.67) 0.041 
HIV treatment 
knowledge score, 
median (IQR) 
19 (17-20) 19 (17-20) 18 (17-19) - 0.035 
Parents living with 
children 
113 (65.7) 84 (64.6) 29 (69.0) 0.82 (0.39-1.73) 0.735 
Ethiopian Orthodox 
Christian  
157 (91.3) 118 (90.8) 39 (92.9) 0.76 (0.20-2.82) 0.478 
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Characteristic 
Total (%) Adherent patients 
Non-adherent 
patients 
Odds Ratio (95 % 
CI) 
P value  
(n=172) (n=130) (n=42) 
Disclosure of HIV 
status to: 
          
Spouse 87 (50.6) 69 (51.5) 20 (47.6) 1.17 (0.58-2.35) 0.792 
Offspring 49 (28.5) 40 (30.8) 9 (21.4) 1.63 (0.71-3.72) 0.332 
Parents 34 (19.8) 23 (17.7) 11 (26.2) 0.61 (0.27-1.4) 0.327 
Siblings 23 (13.4) 13 (10.0) 10 (23.8) 0.36 (0.14-0.89) 0.043 
Relatives 27 (15.7) 19 (14.6) 8 (19.0) 0.73 (0.29-1.81) 0.658 
Friends 24 (14) 17 (13.1) 7 (16.7) 0.75 (0.29-1.96) 0.743 
Socioeconomic 
characteristics 
          
Employed  79 (45.9) 65 (50) 14 (33.3) 2.0 (0.97-4.14) 0.088 
 meals per day 138 (82.1) 107 (84.3) 31 (75.6) 1.73 (0.73-4.07) 0.307 
Monthly income, 
median ETB* (IQR) 
400 (100-1000) 400 (100-1000) 400 (100-1000) - 0.682 
Transport cost, median 
ETB* (IQR) 
5 (3-20) 4.5 (3-20) 7.5 (2-20) - 
0.928 
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Characteristic 
Total (%) Adherent patients 
Non-adherent 
patients 
Odds Ratio (95 % 
CI) 
P value  
(n=172) (n=130) (n=42) 
 
 
Travel time to clinic, 
median min (IQR) 
30 (20-60) 30 (20-60) 30 (15-67.5) - 0.714 
Disease and 
medication-related 
variables 
          
Body-mass index, 
median kg/m2 (IQR) 
19.5 (18.0-22.1) 19.7 (18.1-22.6) 19.0 (17.7-20.7) - 0.117 
Weight, median kg 
(IQR) 
52 (47-57) 53 (47-57.8) 50 (45-56) - 0.051 
CD4, median cells/µL 
(IQR) 
185 (95-253) 188 (94.5-260.5) 162.5 (95.5-248) - 0.387 
WHO HIV/AIDS clinical 
stage III & IV 
85 (51.5) 61 (49.6) 24 (57.1) 0.74 (0.36-1.5) 0.505 
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Characteristic 
Total (%) Adherent patients 
Non-adherent 
patients 
Odds Ratio (95 % 
CI) 
P value  
(n=172) (n=130) (n=42) 
HIV symptom index 
score, median (IQR) 
3 (0-6) 1 (0-4) 5 (2.3-15.5) - <0.001 
Zidovudine-based 
regimen 
86 (50) 68 (52.3) 18 (42.9) 1.46 (0.73-2.95) 0.375 
Nevirapine-based  
regimen 
71 (41.3) 60 (46.2) 11 (26.2) 2.4 (1.12-5.21) 0.035 
Dosing once daily 79 (45.9) 57 (43.8) 22 (52.4) 0.71 (0.35-1.43) 0.431 
 
* ETB – Ethiopian birr 
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Table 5. Psychosocial and healthcare system-related factors associated with ACTG adherence.  
 
Variables  Total (%) 
(n=172) 
Adherent 
patients 
(n=130) 
Non-adherent 
patients (n=42) 
Univariate analysis  Multivariable analysis 
Odds Ratio (95 % 
CI) 
P value Odds Ratio 
(95 % CI) 
P value 
        
Depression score  3  18 (10.5) 10 (7.7) 8 (19.0) 0.35 (0.13-0.97) 0.046 0.9 (0.2-4.9) 0.906 
Berger stigma score, median (IQR) 2.2 (1.4-2.4) 2.1 (1.3-2.3) 2.3 (2.2-2.5) - <0.001 0.9 (0.3-3.0) 0.896 
Personalized stigma score, median (IQR) 2 (1-2) 2 (1-2) 2 (2-2) - <0.001 - - 
Disclosure concerns stigma score, median 
(IQR) 
2.5 (2.5-3) 2.5 (2.5-3) 2.5 (2.5-3) - 0.277 - - 
Negative self-image stigma score, median 
(IQR) 
2 (1-2) 2 (1-2) 2 (2-2.8) - <0.001 - - 
Public attitudes stigma score, median 
(IQR) 
2 (1-2.5) 2 (1-2.5) 2.5 (2.4-3) - 0.001 - - 
Substance use         
AUDIT-C score  4 21 (12.2) 15 (11.5) 6 (14.3) 0.78 (0.28-2.17) 0.840 - - 
Khat use in past 6 months 9 (5.2) 5 (3.8) 4 (9.5) 0.38 (0.1-1.48) 0.299 - - 
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Variables  Total (%) 
(n=172) 
Adherent 
patients 
(n=130) 
Non-adherent 
patients (n=42) 
Univariate analysis  Multivariable analysis 
Odds Ratio (95 % 
CI) 
P value Odds Ratio 
(95 % CI) 
P value 
Belief about medicines         
Necessity-concern differential score, 
median (IQR) 
2.0 (1.4-2.8) 2.2 (1.4-2.8) 1.6 (1.2-2.1) - 0.001 1.1 (0.5-2.3) 0.869 
Necessity score, median (IQR) 2.27 (1.7-2.6) 2.2 (1.7-2.5) 2.4 (2.2-2.8) - 0.001 - - 
Concern score, median (IQR) 4.38 (3.9-4.5) 4.5 (4-4.5) 4.1 (3.8-4.5) - 0.014 - - 
Social support         
Satisfaction with the support, median 
(IQR) 
3 (2-4) 4 (3-4) 2.5 (2-4) - 0.005 1.2 (0.7-1.8) 0.525 
Extent of support from friends and family, 
median (IQR) 
4 (2-4) 4 (3-4) 2.5 (2-4) - 0.023 - - 
 Using reminder devices 76 (44.2) 73 (56.2) 3 (7.1) 16.65 (4.89-56.64) <0.001 9.1 (2.0-41.6) 0.004 
Healthcare relationship trust score, 
median (IQR) 
3.4 (2.7-3.7) 3.6 (2.8-3.7) 3 (2.5-3.4) - <0.001 1.5 (0.8-3.0) 0.231 
Waiting time in clinic, median min (IQR) 60 (30-180) 60 (30-120) 180 (120-305) - <0.001 - - 
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All participants were taking a regimen containing three drugs, composed of two 
nucleoside reverse transcriptase inhibitors (NRTIs) (zidovudine or tenovofir plus 
lamivudine) and a NNRTI (nevirapine or efavirenz). Ninety-five (45.9 %) participants 
took their antiretroviral medication once a day and the remaining took it twice daily. 
The baseline characteristics of study participants who completed the study are as 
shown (Table 4 and Table 5).  
4.4.2. Patterns of adherence over time 
The proportion of non-adherent patients increased over the study period by 4.1 % and 
18.4 % from month 3 to 12 for ACTG self-reported and VAS assessments, respectively 
(Figure 4). One hundred and thirty patients (75.6 %) reported optimal ACTG self-
reported medication adherence at 12 months and the remaining 42 (24.4 %) patients 
were considered non-adherent. Identifying the predictors of long-term adherence is 
important to improve the treatment outcomes of chronic diseases, including HIV/AIDS. 
Hence, the twelve-month adherence measurements were used in the analysis. The 
closest measured value of the variables to the 12-month time period was used in the 
analysis. For instance, stigma was measured at month 2 and month 9 throughout the 
study period; in this study the 9 month stigma value was used.  The decline in mean VAS 
adherence was statistically significantly over the study period (p  0.05). It was 
significantly different between months 3 and 9 (p= 0.006), months 3 and 12 (p < 0.001), 
and months 9 and 12 (p= 0.034). Correlations between self-reported ACTG and VAS 
adherence varied from 0.26 to 0.59 (P  0.001) at different points in time.  
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Figure 4. Percentage of non-adherent patients over time by multiple measures. 
 
4.4.3. Treatment outcomes 
The median increases in CD4 count, BMI, and weight among adherent and non-adherent 
patients using multiple adherence measures are shown in Table 6. Among all patients, 
CD4 count increased from baseline by a median of 146 cells/µL at month 12. The CD4 
count increase was significantly higher in the adherent patients compared to non-
adherent patients using ACTG self-reported adherence at 12 months (159 cells/µL [IQR, 
72-324 cells/µL] vs. 132 cells/µL [IQR, 43-190 cells/µL]; p = 0.026, determined by 
Mann-Whitney U test). Adherent patients using VAS had a trend towards greater CD4 
count gain at 12 months (p=0.056). However, there were no statistically significant 
differences in CD4 count gain between adherent and non-adherent patients at 12 
months using pharmacy record and pill count measures. Stock-outs of a particular 
regimen which was common in the setting decreased the accuracy of pharmacy record 
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and pill count adherence measures. Thus, it was decided to focus on the determinants of 
ACTG self-reported adherence. 
Among all participants, weight and BMI increased from the baseline by a median of 3kg 
and 1.1kg/m2 at month 12. No significant differences in weight and BMI gain were 
detected between adherent and non-adherent patients using the multiple adherence 
measures.  
4.4.4. Predictors of adherence: univariate analyses 
Gender, age, marital status, religion, and living with a child, being alcoholic and chewing 
khat were not associated with adherence. Factors positively associated with ACTG self-
reported adherence were higher educational attainment (secondary school and above), 
higher scores in HIV treatment knowledge, use of reminders devices (e.g., mobile phone 
or clock alarms), social support, higher necessity-concerns differential (NCD) scores, 
higher trust in their HIV care provider, shorter waiting time in the hospitals, and lower 
depressive symptoms. Factors negatively associated with adherence were higher scores 
in overall Berger stigma and its subscales, personalized stigma, negative self-image, and 
public attitudes, and higher HIV symptoms and ADRs (Table 4 and Table 5).  
4.4.5. Factors associated with adherence: multivariate analysis 
In the multivariate analyses, a higher baseline BMI (OR, 1.2; 95 % CI 1.0, 1.4), and use of 
reminder devices (OR, 9.1; 95 % CI 2.0, 41.6) remained positively associated with 
adherence (Table 7), while a higher HIV symptom and ADR distress score was an 
independent negative predictor of adherence (OR, 0.90; 95% CI 0.9, 1.0).  
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Table 6. Adherence to ART and clinical outcome. 
 
 
 
 
 
 
Endpoint-median (IQR) Total 
(n=172) 
ACTG self-reported P 
value Adherent 
(n=130) 
Non-
adherent 
(n=42) 
Change in CD4 count ( cells/µL))  146 (62, 
279) 
159 (72, 324) 132 (43, 190) 0.026 
Change in BMI (kg/m2)  1.1 (0.0, 2.4) 1.1 (0.0, 2.4) 1.4 (-0.3, 2.5) 0.948 
Change in body weight (kg)  3.0 (0.0, 6.0) 3 (0.0, 6.0) 4 (-0.8, 6.0) 0.973 
  VAS   
  Adherent 
(n=130)  
Non-
adherent 
(n=41) 
 
Change in CD4 count (cells/µL)  146 (62, 
279) 
159 (69, 288) 103 (61, 172) 0.056 
Change in BMI (kg/m2)  1.1 (0.0, 2.4) 1.1 (0.0, 2.4) 1.2 (0.0, 2.5) 0.772 
Change in body weight (kg) 3.0 (0.0, 6.0) 3.0 (0.0, 6.0) 3.0 (0.0, 6.0) 0.824 
  MPR   
  Adherent 
(n=153) 
Non-
adherent  
(n=19) 
 
Change in CD4 count (cells/µL)  146 (62, 
279) 
140 (65, 274) 156 (81, 250) 0.749 
Change in BMI (kg/m2)  1.1 (0.0, 2.4) 1.1 (0.0, 2.4) 2.0 (-1.5, 2.5) 0.898 
Change in body weight (kg)  3.0 (0.0, 6.0) 3.0 (0.0, 6.0) 5.0 (-4.0, 9.0) 0.927 
  Pill count   
  Adherent 
(n=161)  
Non-
adherent 
(n=9)  
 
Change in CD4 count (cells/µL)  146 (62, 
279) 
140 (62, 274) 207 (136, 
280) 
0.485 
Change in BMI (kg/m2)  1.1 (0.0, 2.4) 1.1 (0.0, 2.4) 2.5 (0.5, 3.0) 0.432 
Change in body weight (kg)  3.0 (0.0, 6.0) 3.0 (0.0, 6.0) 5.0 (-1.0, 9.0) 0.532 
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Table 7. Factors included in final logistic regression model. 
Variable  Multivariable analysis  
Odds Ratio (95 % 
CI) 
P value  
Education level (Literate) 2.3 (0.8-6.5) 0.127 
Full time or par-time employed  0.9 (0.3-2.5) 0.884 
Baseline body-mass index, kg/m2 1.2 (1.0-1.4) 0.048 
Nevirapine based  1.4 (0.5-3.7) 0.536 
HIV treatment knowledge score (0 to 21) 1.0 (0.8-1.3) 0.927 
Depression score  3 0.9 (0.2-4.9) 0.906 
Berger Stigma score  0.9 (0.3-3.0) 0.896 
Necessity-concern differential score 1.1 (0.5-2.3) 0.869 
HIV symptoms and ADRs distress score 0.9  (0.9-1.0) 0.045 
Healthcare relationship trust score 1.5 (0.8-3.0) 0.231 
Satisfaction with the support  1.2 (0.7-1.8) 0.525 
Using reminder devices 9.1 (2.0-41.6) 0.004 
 
4.5. Discussion 
This is the first prospective study to assess the association between a range of variables, 
including socio-economic, psychological, and disease/regimen-related factors, and self-
reported ACTG adherence in adult patients who were initiated on ART in Ethiopia. This 
long-term study permitted us to reaffirm the dynamic nature of adherence behaviour. 
The proportions of non-adherent patients increased over time as reported previously 
by Lazo et al. [231], and at the end of the study period almost one quarter of patients 
(24.4 %) were found to be non-adherent. VAS adherence measure better identified non-
adherent patients in this study; thus clinicians and researchers in resource-limited 
settings might choice VAS over other measures for this advantage.    ACTG self-reported 
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adherence predicted CD4 count gain and was independently associated with higher 
BMI, lower HIV symptom and ADR distress, and use of reminder devices in this study.  
We believe that these findings have important implications for improving services and 
interventions for patients taking ART in Ethiopia following the remarkable scale-up 
over the past decade.  
Findings from previous studies are inconsistent on the association between socio-
demographic characteristics and adherence [223, 232-234]. Most of the socio-
demographic characteristics evaluated in this study did not predict optimal adherence. 
The lack of associations between socio-demographic characteristics and adherence in 
this study sample is not surprising given that treatment is provided free of charge and 
physical access to healthcare has been improving in Ethiopia.  
In this study, we also demonstrated that lower HIV symptom and ADR distress scores 
were independently associated with adherence to ART. To our knowledge, this is the 
first study to demonstrate this relationship. Symptoms attributed to HIV infection 
and/or ADRs of ART are an important source of distress [235]. Reynolds et al. [236] 
reported that HIV symptom distress correlated with non-adherence to non-
antiretrovirals in patients naïve to ART. Previous studies have mainly focused on non-
specific perceived distress in HIV patients and reported inconsistent findings on the role 
of distress on treatment outcomes [90, 237]. Some studies have demonstrated that 
distress predicted non-adherence to ART [237, 238], CD4 count decline [239], and 
virologic failure [240].  Distress precipitates negative health behaviour (e.g., forgetting 
to take pills, drinking alcohol more than usual, etc.) [239] that may impair patients from 
achieving optimal adherence to ART.  
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All patients in this study were ART naïve; HIV symptoms and ADRs are more frequent in 
this patient group compared to ART experienced patients [241]. It is therefore not 
unexpected that distress associated with HIV symptoms and medication ADRs predicted 
non-adherence in this study. Given our findings regarding the association between 
adherence and increase in CD4 count, distress associated with HIV symptoms and ADRs 
has important implications for treatment outcomes. Thus routine monitoring for HIV 
symptoms and ADRs are needed in Ethiopian patients initiated on ART to improve 
adherence and thereby patient outcomes.  
Use of medication reminder devices was positively associated with adherence to ART in 
this study. Mobile phone ownership has grown dramatically in sub-Saharan Africa, 
including Ethiopia [242]. In our study, almost four out of five patients possessed a 
mobile phone of whom more than 64% were able to send and receive a text-message 
reminder.  A randomised control trial in Kenya [155, 156] reported short message 
services improved adherence to ART. Other reminder devices such as clock and watch 
alarms could also be a tool to help patients taking long term medication such as ART in 
resource-limited settings.  Clinics should propose programmes that teach patients how 
to use mobile and other reminder devices to promote adherence to ART and thereby 
treatment outcomes.  
Strengths of this study include the prospective design with previously validated 
questionnaires that enabled us to determine factors associated with long-term non-
adherence to ART, and the fact that a wide range of factors were evaluated. Its 
prospective nature also allowed assessment of changing adherence levels over time. 
These data do have several limitations, however. Firstly, we used self-reported 
adherence measures for our data analyses although objective measures, such as pill 
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count and dispensing records, are believed to be more precise in comparative studies 
[243-245]. Self-reported measures are subject to social desirability and recall biases 
and thus may overestimate adherence. The ACTG self-reported adherence method is 
convenient and inexpensive and has been the most commonly used method in both 
resource-poor and resource-rich clinical settings [93, 95, 231, 246]. This method was 
better in predicting an increase in CD4 count within 12 months than other measures in 
this study. The precision of self-reported adherence in this study may have improved 
over other studies as the result of the amalgamation of time and dose adherence, and 
the relatively short time frame (in the last 7 days) to reduce the potential recall bias. 
The wording in the instrument was non-judgmental and research pharmacists who 
were not directly involved in patient care administered the instrument. Secondly, the 
impact of adherence on treatment outcome in this study was monitored using change in 
CD4 count, which tends to occur later and is, consequently, less visible than the impact 
on HIV viral load [247]. However, the Home-Based AIDS Care Project (HBAC) [248] in 
Uganda reported that clinical monitoring with quarterly CD4 count was more cost-
effective, with no significant difference in rates of new AIDS-defining events or deaths, 
compared with clinical monitoring with quarterly CD4 count and HIV viral load 
monitoring. Clinical monitoring with biannual CD4 counts is used to routinely monitor 
treatment response for patients taking ART in Ethiopia.  
4.6. Conclusion 
Improvement of treatment and care access for patients with HIV/AIDS has been the key 
clinical achievement in Ethiopia over the past decade. This study found that higher BMI, 
lower HIV symptom and ADRs distress scores, and use of reminder devices were 
independent predictors of self-reported adherence. Implementation of measures to 
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consistently monitor HIV symptoms and ADRs distress and malnutrition, and to 
promote the use of reminder devices may improve adherence and treatment outcomes 
in patients initiated on ART.  
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CHAPTER FIVE 
5. ADVERSE DRUG REACTIONS AND CLINICAL OUTCOMES IN PATIENTS 
INITIATED ON ANTIRETROVIRAL THERAPY: A PROSPECTIVE COHORT 
STUDY FROM ETHIOPIA 
5.1. Abstract  
Background The use of antiretroviral therapy (ART) has been scaled-up for HIV/AIDS 
in Ethiopia over the past decade. Adverse drug reactions (ADRs) associated with ART 
pose a unique challenge in the treatment of the infection in this resource-limited setting.   
Objectives The aim of this study was to examine the incidence and nature of ADRs, 
identify the risk factors associated with the development of ADRs, and assess their 
impact on treatment outcomes.  
Methods A prospective cohort study was conducted in adult patients (18 years) with 
HIV/AIDS commenced on ART. All ADRs in the first 12 months of therapy were 
recorded, and the severity, causality, and preventability assessed. The impact of severe 
ADRs on self-reported adherence, immunological, and body mass index (BMI) outcomes 
were assessed.    
Results Of the 211 patients included in the analysis, 181 (85.7%) experienced at least 
one ADR and 66 (31.3%) experienced at least one severe ADR within 12 months of 
commencing ART (incidence rates for any ADR and severe ADR of 14.8 and 3.2 per 100 
person-months, respectively). Logistic regression analysis indicated that taking 
zidovudine-containing regimens [Odds Ratio (OR)=4.2, 95% CI (2.1-8.4)] or being 
unemployed [OR=2.2, 95% CI (1.1-4.3)] were independent predictors of experiencing 
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severe ADRs. Patients who experienced a severe ADR were less likely [OR=0.4, 95% CI 
(0.2-0.9)] to be ≥90% adherent to ART. The mean gain in BMI was significantly lower in 
patients with severe ADRs after 3 months or 12 months of therapy.  
 Conclusions ADRs were common within the first three months in patients initiated on 
ART. Severe ADRs were negatively associated with self-reported adherence and gain in 
BMI. Measures need to be implemented to routinely monitor for severe ADRs to 
improve ART adherence and treatment outcomes. 
Key Points 
 One-third of patients initiated on ART experienced severe ADRs over a one-year 
period. 
 Most severe ADRs were reported within the first three months and found to have 
negative impact on treatment outcomes in patients initiated on ART. 
 Almost half of the severe ADRs related with ART were found to be preventable, 
highlighting the importance of improving antiretroviral prescribing and 
monitoring practices. 
5.2. Introduction 
At the end of 2012, 35.3 million people were living with Human Immunodeficiency 
Virus (HIV) and 9.7 million people (61% of eligible patients) were on Antiretroviral 
Therapy (ART) worldwide [249]. ART has decreased mortality and morbidity, and 
improved the quality of life of patients with HIV [216]. However, ART can also cause 
undesirable adverse drug reactions (ADRs) that are among the most important reasons 
for medication non-adherence, treatment switch or discontinuation, and virologic 
failure [62, 250-252].  
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A free ART programme was introduced in Ethiopia in 2005 [184, 188]. Over the past 10 
years, decentralisation and scale-up of the programme has occurred [249] and 743 free 
ART centres have been established across the country. A total of 249,174 adult patients 
(86% of eligible patients) were on ART as of 2011 [183, 249].  
Detection of ADRs in Ethiopian ART clinics provides an important assessment of the 
burden of antiretroviral-associated morbidity in the HIV care programme. To our 
knowledge, only a few retrospective studies have attempted to identify the type and 
frequency of ADRs in Ethiopian adult patients receiving ART [253, 254], and given the 
poor documentation of ADRs in patients’ medical charts, ADRs are underreported. In 
addition, the impact of ADRs on treatment outcomes (body mass index (BMI), and CD4 
count) has not been evaluated. In resource-limited settings, BMI and CD4 count are 
useful surrogate markers of treatment outcomes [255].       
The aim of this study was to prospectively examine the incidence and nature of ADRs, 
identify the risk factors associated with the development of ADRs, and assess their 
impact on treatment outcomes in Ethiopian patients with HIV/Acquired Immune 
Deficiency Syndrome (AIDS) who commenced ART.   
5.3. Methods 
This was a prospective cohort study, in which adult patients (18 years) with HIV/AIDS 
who commenced on ART were followed from the time of ART commencement (month 
(M)=00) to 12 months (M=12) of therapy. The study was conducted from 18 December 
2012 to 18 May 2014 at Felege-Hiwot and Gondar University Hospitals. Nurses and 
research pharmacists recruited patients from the ART clinics. All participants provided 
written informed consent for their involvement in the study. Details of the study setting 
have previously been described [225].  
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Adult HIV-infected patients were eligible to start ART when their CD4 count was less 
than or equal to 350 cells/µL regardless of the clinical symptoms, or with any symptoms 
indicating a World Health Organization (WHO) clinical stage of 3 or 4, irrespective of 
CD4 count. ART initiation was informed by the Ethiopian ‘Guidelines for management of 
opportunistic infections and antiretroviral treatment in adolescents and adults in Ethiopia 
2008’ and the WHO ‘Antiretroviral therapy for HIV infection in adults and adolescents: 
recommendations for a public health approach 2010 revision’ [256, 257]. ART-initiated 
patients had an appointment every month for the first 6 months and every 3 months 
thereafter in ART clinics. A research pharmacist was assigned to each hospital’s ART 
clinic to assess ADRs throughout the study period. Patients were also asked to report 
any potential ADRs. ADRs that continued for subsequent appointments without 
recovery were reported once. The research pharmacists, who were experienced in 
clinical care in public health facilities, interviewed patients, caregivers and physicians, 
reviewed patients’ medical records and documented detailed information for each of 
the potential ADRs that patients experienced. An ADR was defined according to the 
WHO definition as “a response to a drug that is noxious and unintended and which 
occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of 
disease, or for modification of physiological function” [258]. ADRs were evaluated based 
on the clinical signs and symptoms, and laboratory tests. The severity, causality, and 
preventability of ADRs were assessed using the Division of AIDS Adverse Events (DAIDS 
AE) grading table [259], Naranjo’s probability scale [209], and the Schumock and 
Thornton criteria [211], respectively. The management and outcomes of ADRs were also 
recorded. These data were independently reviewed by a second research pharmacist, 
blinded to the first pharmacist’s assessment, to ensure their accuracy and validity. 
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When there was a disagreement in the assessment of an ADR, the pharmacists resolved 
their disagreement through discussion until consensus was reached.  
Socio-demographic and clinical information, such as age, gender, level of education, 
employment status, comorbidities, WHO stage of HIV/AIDS, weight and height, and 
laboratory test results performed in the hospitals, including CD4 count, haematocrit, 
white blood cell (WBC) count, absolute neutrophil count, platelet count, liver function 
and renal function, were recorded from each patient’s medical record. Similarly, details 
of the ART regimen and other concomitant medications were also recorded. An increase 
in CD4 counts of more than 50cells/µL from the baseline was defined as immunological 
response [260].   
Dose adherence to ART was measured using a modified AIDS Clinical Trial Group 
(ACTG) self-reported adherence questionnaire that asks patients how many doses they 
missed in last 7 days. Similarly, time adherence was measured using the four-item 
Likert-type modified ACTG questionnaire [90]. Details of multiple medication adherence 
measures have previously been reported [225]. Responses to the two questions were 
translated into dose and time adherence scores ranging from 0 to 100% over the 7-day 
period, and the average of the two measures was taken as a combined indicator of dose 
and time adherence.  
The frequency of ADRs was described using descriptive statistics. Characteristics of 
patients who experienced ADRs and those who did not were compared using Pearson’s 
2 tests for gender, age, level of education, employment status,  immunological response 
(CD4 count), WHO HIV stage, history of drug allergy, type of ART regimen, 
comorbidities, concomitant medications, and self-reported adherence. Logistic 
regression analysis was undertaken to determine the independent predictors of severe 
 89 
 
ADRs (grades 3 and 4 using the DAIDS AE grading table), cutaneous reactions, 
gastrointestinal complaints, and neuropsychiatric reactions where univariate analyses 
suggested association with multiple risk factors. Factors with a p value of 0.2 in 
univariate analysis were entered into the logistic regression model after checking 
multicollinearity. Results are presented in terms of odds ratio (OR) for each risk factor 
followed by a 95% confidence interval (CI). Mean changes in body mass index after 3 
months and 12 months of ART were compared between patient groups with 
independent samples t tests. Data were analysed using SPSS version 21 (IBM Corp., New 
York, USA). A value of p <0.05 was considered statistically significant.  
Ethical approvals were received from the Tasmanian Health and Medical Human 
Research Ethics Committee (H0012722) and Bahir-Dar University’s ethics committee 
(RCS/567/2004).  
5.4. Results 
During the 4-month recruitment period (18 December 2012 to 17 March 2013), 337 
adults (18 years; 191 females and 146 males) commenced ART at the two sites. Of 
these, 246 patients (143 females and 103 males) enrolled in this study. The ninety-one 
patients did not take apart in this study because of our exclusion criteria (patients who 
were initiated on ART in the study clinics but whose follow-up was in outlying areas 
were excluded) and not consenting to participate in this study. There were no 
significant differences in the WHO stage of HIV/AIDS, gender, age, CD4 count and 
weight between subjects who did and did not participate in the study. Thirty-five 
patients who did not complete at least 3 months’ follow-up (9 lost to follow-up, 11 
withdrawn, 10 died, and 5 transferred to other clinics) were excluded from this 
analysis. As shown in Table 8, of the 211 patients included in study, 60% were female. 
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Their median baseline CD4 count and BMI were 183 cells/µL and 19.4 kg/m2, 
respectively. 
All patients were receiving an ART regimen containing three drugs - two nucleoside 
reverse transcriptase inhibitors (NRTIs) (zidovudine plus lamivudine, or tenofovir plus 
lamivudine) plus one non-nucleoside reverse transcriptase inhibitor (NNRTI) (efavirenz 
or nevirapine) at baseline. One hundred and twelve (53%) patients were taking a 
zidovudine plus lamivudine-containing regimen, and 109 (52%) patients were taking an 
efavirenz-containing regimen. Self-reported dose adherence in the study sample was 
97.7% at 3 months. The rate of adherence considering the combined (dose and time) 
indicator was 93.8% at 3 months. 
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Table 8. Baseline patient characteristics (n=211). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IQR = interquartile range, BMI = body mass index, ART = antiretroviral therapy  
*Total does not add up to 211 due to missing data. 
**1 missing value. 
 
 
 
 
 
 
 
Characteristic Number (%) Median IQR 
Women 127 (60.2)   
Age  32 27-38 
Education level    
Illiterate 115 (54.5)   
Literate 96 (45.5)   
Employment    
Unemployed 116 (55)   
Employed 95 (45)   
BMI (kg/m2)  19.4 18.0-21.9 
History of drug allergy 16 (7.6)   
Baseline WHO staging*    
Stage I&II 97 (46.0)   
Stage III&IV 105 (49.8)   
ART regimen    
Zidovudine based 112 (53.1)   
Tenofovir based 97 (46.0)   
Stavudine based 2 (0.9)   
Efavirenz based 109 (51.7)   
Nevirapine based 102 (48.3)   
Baseline CD4 
(cells/µL) 
 183 94-252 
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Table 9. Frequency of potential adverse drug reactions of antiretroviral therapy. 
 
 
Specific ADR by organ 
Number of 
cases (%) 
(n=211) 
TDF+3TC+EFV 
(n=87) 
TDF+3TC
+NVP 
(n=10) 
ZDV+3TC+EFV 
(n=22) 
ZDV+3TC+NVP 
(n=90) 
      
Gastrointestinal 115 (54.5) 28 (32.1) 6 (60.0) 12 (54.5) 66 (73.3) 
Nausea 60 (28.4) 11 (12.6) 3 (30) 8 (36.4) 38 (42.2) 
Vomiting 30 (14.2) 8 (9.2) 3 (30) 2 (9.1) 16 (17.7) 
Anorexia 4 (1.9) 1 (1.1) - 1 (4.5) 3 (3.3) 
Diarrhoea 3 (1.4) 1 (1.1) - - 2 (2.2) 
Gastric discomfort 12 (5.7) 4 (4.6) - 1 (4.5) 5 (5.5) 
Gastritis 6 (2.8) 3 (3.4) - - 2 (2.2) 
Neuropsychiatric 113 (53.5) 76 (87.3) 2 (20) 20 (90.9) 14 (15.5) 
Headache 37 (17.5) 19 (21.8) 2 (20) 4 (18.2) 10 (11.1) 
Nightmare 17 (8.0) 14 (16.1) - 3 (13.6) - 
Confusion 9 (4.2) 7 (8.0) - 2 (9.1) - 
Somnolence 1 (0.5) - - - 1 (1.1) 
Insomnia 10 (4.7) 7 (8.0) - 1 (4.5) 2 (2.2) 
Vertigo 23 (10.9) 16 (18.4) - 7 (31.8) - 
Anxiety 1 (0.5) - - 1 (4.5) - 
Tingling 1 (0.5) 1 (1.1) - - - 
Dizziness 5 (2.4) 4 (4.6) - - 1 (1.1) 
Numbness 1 (0.5) 1 (1.1) - - - 
Hearing loss 1 (0.5) - - 1 (4.5) - 
Psychosis 1 (0.5) 1 (1.1) - - - 
Hallucination 2 (0.9) 1 (1.1) - 1 (4.5) - 
Depression 2 (0.9) 2 (2.3) - - - 
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Specific ADR by organ 
Number of 
cases (%) 
(n=211) 
TDF+3TC+EFV 
(n=87) 
TDF+3TC
+NVP 
(n=10) 
ZDV+3TC+EFV 
(n=22) 
ZDV+3TC+NVP 
(n=90) 
      
Lethargy 1 (0.5) 1 (1.1) - - - 
Trouble remembering 1 (0.5) 1 (1.1) - - - 
Agitation 1 (0.5) 1 (1.1) - - - 
Cutaneous reaction 66 (31.3) 24 (27.6) 4 (40) 9 (40.9) 28 (31.1) 
Skin rash 39 (18.5) 17 (19.5) 2 (20) 6 (27.3) 14 (15.5) 
Allergic dermatitis 5 (2.4) - - 1 (4.5) 4 (4.4) 
Nail pigmentation 3 (1.4) - - - 3 (3.3) 
Pruritus 15 (7.1) 7 (8.0) 2 (20) 3 (13.6) 3 (3.3) 
Erythema multiforme 1 (0.5) - - - 1 (1.1) 
Erythema 1 (0.5) - - - 1 (1.1) 
Hepatotoxicity 2 (0.9) 1 (1.1) 1 (10) - - 
Nephrotoxicity 2 (0.9) 2 (2.3) - - - 
Systemic 
signs/symptoms 
23 (10.9) 4 (4.6) - 3 (13.6) 15 (16.6) 
Fever 10 (4.7) 3 (3.4) - 1 (4.5) 6 (6.6) 
Fatigue 13 (6.2) 1 (1.1) - 2 (9) 9 (10) 
Musculoskeletal 12 (5.7) 3 (3.4) 1 (10) 2 (4.5) 6 (6.6) 
Arthralgia 7 (3.3) 2 (2.3) - 2 (4.5) 3 (3.3) 
Muscle pain 5 (2.4) 1 (1.1) 1 (10) - 3 (3.3) 
Haematological 16 (7.6) 4 (4.7) - 5 (22.7) 7 (7.7) 
Anaemia 13 (6.2) 1 (1.1) - 5 (22.7) 7 (7.7) 
Thrombocytopaenia 3 (1.4) 3 (3.4) - - - 
      
TDF=tenofovir, 3TC=lamivudine, ZDV=zidovudine, EFV=efavirenz, NVP=nevirapine. 
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Throughout the study period 370 ADRs were identified Table 9. Twenty-one ADRs were 
excluded from analysis as their causal relationship with ART regimens was rated as 
doubtful according to Naranjo’s scale; 66.5% and 31.8% of ADRs had a possible and 
probable causal relationship with the ART regimen, respectively, as shown in Table 10. 
Most ADRs were rated as grade 1 (52.7%) and grade 2 (25.2%) using the DAIDS AE 
grading table; 22.1% were graded as severe (grades 3 and 4).  
ADRs were common - 181 (85.7%) patients experienced at least one ADR, and 66 
(31.3%) experienced severe (grade 3 or 4) ADRs. The prevalence of ADRs was similar in 
females (86.6%) and males (84.5%). Ninety-seven (45%) patients reported more than 
one ADR; 78 (37%) patients had two or three ADRs, and 19 (9%) patients had four or 
five ADRs.  
The onset and distribution of ADRs within the study period are shown in Figure 5. 
Ninety percent of ADRs (314) were reported within the first three months of ART. 
Seventy-seven severe ADRs were reported throughout the study period and 69 (89.6%) 
of them occurred within the first three months. The total duration of follow-up time was 
2362 person-months, yielding an incidence rate of patients experiencing ADRs as 14.7 
per 100 person-months. The corresponding incidence rate for severe ADRs was 3.2 per 
100 person-months. 
Using univariate analyses, unemployment (p=0.05), zidovudine-based regimens 
(p<0.001) and nevirapine-based regimens (p<0.001) were associated with the 
occurrence of severe ADRs. Logistic regression analysis indicated that taking 
zidovudine-containing regimens [OR=4.2, 95% CI (2.1-8.4)] or being unemployed 
[OR=2.2, 95% CI (1.1-4.3)] were independent predictors of experiencing severe ADRs 
Table 11. The most common classes of ADRs were gastrointestinal complaints (54.5%) 
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followed by neuropsychiatric disorders (32.4%) and skin reactions (31.3%). Nausea 
(28.4%) followed by skin rash (18.5%) and headache (17.5%) were the most frequently 
reported specific ADRs.  Regimens containing zidovudine were significantly associated 
with development of gastrointestinal ADRs (p=0.001) and anaemia (P<0.05). There was 
a significant association between regimens containing efavirenz or zidovudine and 
neuropsychiatric reactions (p<0.001). Female gender (p<0.05) and a previous history of 
allergy to any medications (p<0.05) were risk factors for cutaneous reactions. History of 
allergy (OR=5.3, 95% CI (1.7-16.3)] was more strongly associated with the occurrence 
of skin reactions in a logistic regression model than was female gender [OR=2.0, 95% CI 
(1.1-3.9)]. 
 
Figure 5. Distribution and time of onset of adverse drug reactions.  
 
Fifty-seven (16.3%), and 38 (47.5%) ADRs and severe ADRs, respectively, were 
preventable based on the Schumock and Thornton criteria. Symptomatic treatments 
and substitution of the offending antiretroviral agents were reported for 41 (11.7%) 
and 22 (6.3%) ADRs, respectively. Alteration of the ART regimen occurred in 28 
(13.3%) patients throughout the study period and, of these, 22 (78%) were due to the 
development of severe ADRs. Twenty (35%) preventable severe ADRs were 
gastrointestinal complaints associated with zidovudine-containing regimens. Of them 
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only three patients received symptomatic treatment. Nineteen (33%) preventable ADRs 
were due to inadequate laboratory monitoring of drug toxicities. Of them, 12 (63%) 
ADRs were anaemia associated with zidovudine-containing regimens. Skin reactions 
were third important class of preventable ADRs, behind gastrointestinal complaints and 
anaemia in this study. Among thirty-four female patients who had a baseline CD4 count 
more than 250 cells/µL, twenty-one (60%) were inappropriately taking a nevirapine-
based regimen according to Ethiopian guidelines [256]. Of these, seven patients 
developed skin reactions, three of which were severe. 
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Table 10. Assessment and management of adverse drug reactions. 
 Intervention data for 5 ADRs were not available 
 Adverse drug reactions 
 Gastrointe
stinal 
Neuropsychi
atric 
Cutaneou
s reaction 
Hepatotox
icity 
Nephrotoxi
city 
Systemic 
signs/sympt
oms 
Musculoskel
etal 
Haematol
ogical 
Total  
          
Number cases  115 113 66 2 2 23 12 16 349 
C
au
sa
li
t
y 
Definite  - - - - 2 (100) - - 4 (25) 6 (1.7) 
Probable  32 (27.8) 4 (3.5) 52 (78.7) 2 (100) - 3 (13) 6 (50) 12 (75) 111 (31.8) 
Possible  83 (72.2) 109 (96.5) 14 (21.2) - - 20 (86.9) 6 (50) - 232 (66.5) 
Se
v
er
it
y 
 Grade 1  46 (40) 83 (73.4) 32 (48.5) - - 12 (52.2) 5 (4.2) 6 (37.5) 184 (52.7) 
Grade 2 21 (18.3) 25 (22.1) 
5 (4.4) 
25 (37.8) 1 (50) - 7 (30.4) 6 (50) 3 (18.7) 88 (25.2) 
Grade 3 45 (39.1) 6 (9.1) - - 4 (17.4) - 2 (12.5) 62 (17.7) 
Grade 4 3 (2.6) - 3 (4.5) 1 (50) 2 (100) - 1 (8.3) 5 (31.3) 15 (4.3) 
P
re
ve
n
ta
b
il
it
y 
Yes 24 (20.9) 2 (1.7) 8 (12.1) 2 (100) 2 (100) 3 (13.0) 2 (16.7) 16 (100) 57 (16.3) 
No 91 (79.1) 111 (98.3) 58 (87.9) - - 20 (87) 10 (83.3) - 292 (83.7) 
In
te
rv
en
ti
o
n

 
Y
es
 
Drug 
withdrawal  
3 (2.6) 1 (0.9) 6 (9.1) 1 (50) 2 (100) 1 (4.3) - 8 (50) 22 (6.3) 
Symptomatic 
treatment  
12 (10.4) 6 (5.3) 12 (18.2) - - 5 (21.7) 4 (33.3) 2 (12.5) 41 (11.7) 
N
o
 
 
100 (86.9) 106 (93.8) 48 (72.7) 1 (50) - 17 (73.9) 8 (66.6) 1 (6.25) 281 (80.5) 
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The potential influence of severe ADRs on treatment outcomes was evaluated with 
consideration of the combined self-reported 7-day recall dose and time adherence to 
ART and increased absolute CD4 count and BMI. Patients who experienced a severe 
ADR within the first three months were significantly less likely [OR=0.4, 95% CI (0.2-
0.9), p<0.05] to be adherent when using combined dose and time (>=90%) adherence to 
ART within the first three months of treatment. However, after 3 months of ART, there 
was no significant association between severe ADRs and adherence. 
The mean BMI at baseline was 20.03.1 kg/m2 in those who experienced severe ADRs, 
and 20.03.4 kg/m2 in those who did not experience severe ADRs. There were 
significant differences between these patient groups in terms of mean change in BMI at 
3 and 12 months of therapy (p0.05). Among those who experienced severe ADRs, the 
mean BMI increased by 0.62.7 kg/m2 over 12 months, while the mean BMI rose by 
1.52.2 kg/m2 in patients who did not experience severe ADRs over the same period.  
However, there were no significant differences in immunological response (CD4 count) 
in these patient groups at different time points Table 12. 
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Table 11. Risk factors for adverse drug reactions. 
Adverse drug 
reactions 
Variables  
associated with  
2 test Logistic regression 
OR (95% CI) P value OR (95% CI) P value 
 ADR     
Severe ADR Zidovudine based 
regimens 
3.5 (2.0-6.9) <0.001 4.2 (2.1-8.4) <0.001 
 Nevirapine based 
regimens 
3.5 (1.9-6.4) <0.001 - - 
 Unemployed 1.9 (1.0-3.5) 0.050 2.2 (1.1-4.3) 0.024 
 WHO stage III &IV 0.6 (0.3-1.1) 0.123 0.6 (0.3-1.2) 0.163 
 Eating once per 
day 
1.6 (0.8-3.3) 0.194 1.6 (0.7-3.5) 0.266 
Gastrointestinal Zidovudine based 
regimens 
2.6 (1.5-4.6) 0.001 2.5 (1.4-4.5) 0.002 
 Education-no  0.7 (0.4-1.1) 0.153 0.7 (0.4-1.3) 0.316 
Neuropsychiatric Efavirenz based 
regimens 
7.24 (3.8-
13.7) 
<0.001 8.0 (4.0-15.9) <0.001 
 Tenofovir based 
regimens 
3.7 (2-5) <0.001 - - 
 Female gender  1.5 (0.9-2.7) 0.190 0.7 (0.4-1.5) 0.394 
 BMI 19.5 kg/m2 1.5 (0.8-2.5) 0.220 1.3 (0.6-2.5) 0.535 
 Age  30 years  1.6 (0.9-2.7) 0.124 1.5 (0.8-3.0) 0.237 
 Eating once a day 1.70 (0.8-3.5) 0.200 1.8 (0.8-4.1) 0.165 
Skin reactions Female gender 2.0 (1.1-3.8)  0.0413 2.0 (1.1-3.9) 0.034 
 History of drug 
allergy 
 5.3 (1.7-16.2) 0.003 5.3 (1.7-16.3) 0.004 
Haematological Zidovudine based 
regimens 
4.0 (1.1-14.5) 0.050 - - 
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Table 12. Clinical outcomes and adverse drug reactions. 
 
5.5. Discussion  
This is the first prospective cohort study assessing the incidence, type, severity, 
causality, preventability, predictors, and treatment outcomes of ADRs in patients who 
were initiated on ART in Ethiopia. The study revealed that the incidence rate of severe 
ADRs over one year was 3.2 per 100 person-months, with 89.6% of severe ADRs 
reported within the first three months of ART. Most of the severe ADRs were 
gastrointestinal complaints, haematological, and skin reactions. Taking zidovudine-
based regimens and being unemployed were shown to be independent risk factors for 
severe ADRs. The findings of this study regarding patient groups at risk of ADRs are 
especially important in that they suggest a number of practical interventions that could 
be readily implemented in clinical practice to minimise patients’ risk of developing 
Adherence or Gain in BMI or CD4 cells Severe ADR No Severe ADR 2 test 
 OR (95%CI) P value  
     
     
Adherent (>=90%) patients at month 3 43 (27.2) 115 (72.8) 0.4 (0.2-0.9) 0.046 
Adherent (>=90%) patients at month 6 49 (31.6) 106 (80.9) 1.1 (0.5-2.6) 0.882 
Adherent (>=90%) patients at month 9 45 (28.8) 111 (84.8) 0.7 (0.3-1.5) 0.448 
Adherent (>=90%) patients at month 
12 
39 (27.9) 101 (72.1) 0.7 (0.3-1.4) 0.385 
Gain CD4 +50 cells/µL within 6 
months  
38 (31.4) 83 (68.6) 1.0 (0.4-2.4) 1.000 
Gain CD4 +50 cells/µL within 12 
months  
41 (31.8) 88 (68.2) 1.2 (0.5-3.0) 0.826 
   t test 
    P value 
BMI  (kg/m2) change  within 3 months +0.291.52 +0.881.59  0.017 
BMI (kg/m2) change within 12 months  +0.61  2.73 +1.50  2.22  0.027 
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ADRs. This would represent a significant advance in HIV/AIDS management in Ethiopia 
as our study demonstrated that severe ADRs were associated with not only self-
reported non-adherence with therapy (the importance of optimal adherence to ART in 
optimising patient outcomes is well-recognised [261, 262]) but also a poorer patient 
outcome in terms of gain in BMI. 
In the study period, 86% of patients reported at least one ADR and more than one-third 
experienced a severe ADR. The high prevalence of ADRs in this study might be 
associated with intensive prospective data collection, which assisted to identify mild 
ADRs that might be unreported in other studies. Studies that followed a similar 
methodology in Iranian and Indian patients who commenced ART had also reported a 
high prevalence of ADRs - 88% and 90%, respectively, over two-year study periods 
[241, 263]. 
Zidovudine-containing regimens were a risk factor for gastrointestinal, haematological, 
and severe ADRs. Other studies had also reported NRTIs as a risk factor for the 
occurrence of gastrointestinal problems [264]. The overall prevalence of 
gastrointestinal complaints (54.5%) was lower than reported in a cohort of Iranian 
patients (67.3%), where 81% of patients were taking a zidovudine-based regimen 
[241].  However, the prevalence in this sample was higher than reported in Nigerian 
patients (34%) of whom 57.7% were taking zidovudine-containing regimens [265]. 
Although most of the gastrointestinal problems were mild and self-limiting, they were 
typically observed in the first 8 weeks of therapy and therefore had potential to strongly 
influence patients’ perceptions of their treatment. Perhaps because of this, 
gastrointestinal ADRs are one of the documented reasons for medication non-adherence 
[266].  
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The prevalence of anaemia in this study was low (6.2%) and similar to that in studies 
reported in Nigeria (4%), India (3.1%), and Haiti (4.7%) [267-269]. Given that many 
patients with HIV/AIDS in Ethiopia have coexisting malnutrition and chronic diseases, 
and 60% of study participants were female, the relatively low prevalence of anaemia 
was unexpected. Prospective cohort studies in Iranian and Indian patients reported 
higher incidences of anaemia (22% and 10.3%, respectively), although more than 94% 
of patients who developed anaemia in these studies were receiving zidovudine-based 
ART regimens [241, 263]. One possible explanation for the relatively lower prevalence 
of anaemia in the current study is the lower rate of use of zidovudine-based regimens 
compared to these previous studies.  
Neuropsychiatric ADRs generally appeared within first few days of treatment and 
resolved after 4-8 weeks of therapy. However, this short-term ADR may be intolerable 
and the cause of patient drop out, as reported in our previous study [270], thus patient 
education and regimen switch may improve adherence to ART and retention in care.  
The prevalence of cutaneous reactions reported in this study, 31.3%, was similar to that 
reported in Nigeria (26.2%) [265], and higher than reported in Côte d’Ivoire  (14%) 
[271] and India  (9.2%) [272]. There was no significant difference in rates of skin 
reactions between nevirapine and efavirenz-containing regimens in this sample, unlike 
studies reported elsewhere [62, 273]. Female gender and previous history of allergy 
were implicated as risk factors for experiencing cutaneous reactions in our logistic 
regression analysis. Hormonal and metabolic factors may play a role in the observed 
gender disparity in the development of NNRTI-associated rash [274-276]. Our data 
suggest the need for close monitoring when nevirapine or efavirenz is initiated in 
patients with these risk factors. 
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Most severe ADRs were reported within the first three months. Patients who 
experienced severe ADRs were non-adherent, as reported in other studies [48, 263], 
and experienced a smaller increase in BMI. Early non-adherence to first-line regimens is 
associated with emergence of early and late regimen failure [261, 277] and increasing 
treatment costs [278]. To our knowledge, there have been no previous studies that 
reported that severe ADRs were associated with a smaller gain in BMI. ADRs such as 
nausea reduce food intake and subsequently a gain in BMI. In addition, patients who 
took zidovudine-containing regimens, as reported elsewhere [264], and the 
unemployed were more likely to develop severe ADRs in this sample. Studies in sub-
Saharan patients [279], including our previous study [270], reported that eating 
insufficient food, which is more likely related with unemployment, exacerbated ADRs 
with ART. The relationship between severe ADRs and unemployment may be mediated 
by diagnosis of advanced HIV/AIDS. A previous study has reported that diagnosis of 
advanced HIV/AIDS, which decreases labour productivity and the chance of 
employment [280], increased the severity of ADRs with ART [281]. Complexities of ART 
regimens (e.g. number of doses per day, number of pills per dose) are related with poor 
adherence in other studies [282]. We found no association between dosing frequency 
and adherence in our unpublished data. 
In this study we found that severe ADRs were more likely to be preventable than less 
severe ADRs as reported elsewhere [283]. Almost half of the severe ADRs in patients 
initiated on ART were preventable, which is considerably less than a preventability rate 
(82.7%) reported in a similar study in India [269]. Medication errors related to 
preventable ADRs occurred more frequently at the prescribing and monitoring stages of 
therapy than at the dispensing in this study. Nevirapine was prescribed in more than 
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60% of female patients who had baseline CD4 count >250 cells/µL, although treatment 
guidelines recommend the use of abacavir or efavirenz in these patients [256]; this 
increased these patients’ risk for developing skin reactions. Interventions (e.g. dietary 
modification, patient reassurance) to manage gastrointestinal complaints associated 
with zidovudine-containing regimens were rarely implemented, which potentially 
increased the severity of these ADRs. Similarly, inadequate laboratory monitoring for 
zidovudine-related toxicities may have increased the risk of developing severe anaemia 
in this study.   
 Immunologic outcomes throughout the study period were not different in patients with 
and without severe ADRs. Non-adherence associated with short-term ADRs may not 
prevent patients making gains in CD4 count. Messou et al. [284] reported that patients 
who had detectable viral-load achieved comparable CD4 counts at 6 months to those 
with undetectable viral load. Outcomes of ART in patients who experience short-term 
severe ADRs may be better monitored using viral-load measurement.    
The strengths of our study include the prospective nature, which permitted more 
precise recording of symptoms and assessment of severity, causality, and preventability 
of ADRs. To minimise the occurrence of a Hawthorne effect, data were collected through 
research pharmacists working for our study project only. Staff members working in the 
ART clinics were neither involved in data collection nor received feedback about the 
results of the study before its completion.  
This study has several limitations. Laboratory ADRs were under-reported in our 
findings due to a limited number of laboratory tests being performed for monitoring 
ADRs in these resource-limited hospitals. In addition, there was a lack of continuity with 
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healthcare providers in ordering the recommended laboratory tests according to 
treatment guidelines. 
The majority of severe ADRs were associated with errors in prescribing and monitoring 
of regimens that contain zidovudine and/or nevirapine. This study highlights the 
significance of improving prescribing and monitoring practices in Ethiopian ART clinics 
to decrease the risk of severe ADRs. Changing the paper based prescribing practice in 
the ART clinics to a computer based prescribing practice has the potential to decrease 
errors by providing feedback and suggestions to providers to select the recommended 
antiretrovirals, and to order laboratory tests for monitoring ADRs in time. Future 
implementation of the WHO 2013 ART guideline [27], which downgrades zidovudine 
from a preferred first-line agent, may improve the success of the ART scale-up 
programme in Ethiopia by reducing the incidence of anaemia and severe ADRs. 
5.6. Conclusion 
We found that the majority of severe ADRs were reported within the first three months 
of ART. Taking zidovudine-based regimens and being unemployed were significant risk 
factors for development of severe ADRs. We observed that severe ADRs were negatively 
associated with self-reported adherence, and gain in BMI within the first three months. 
Future studies should focus on prescribing and monitoring of ART, particularly in 
treatment naïve patients who are vulnerable to severe ADRs, to improve ART adherence 
and treatment outcomes.  
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CHAPTER SIX  
6. BARRIERS TO AND FACILITATORS OF ADHERENCE TO ANTIRETROVIRAL 
DRUG THERAPY AND RETENTION IN CARE AMONG ADULT HIV-POSITIVE 
PATIENTS: A QUALITATIVE STUDY FROM ETHIOPIA 
6.1. Abstract 
Background: Antiretroviral therapy (ART) has been life saving for hundreds of 
thousands of Ethiopians. With increased availability of ART in recent years, 
achievement of optimal adherence and patient retention are becoming the greatest 
challenges in the management of HIV/AIDS in Ethiopia.  However, few studies have 
explored factors influencing medication adherence to ART and retention in follow-up 
care among adult Ethiopian HIV-positive patients, especially in the Amhara region of the 
country, where almost one-third of the country’s ART is prescribed. The aim of this 
qualitative study was to collect such data from patients and healthcare providers in the 
Amhara region of Ethiopia. 
Methods: Semi-structured interviews were conducted with 24 patients, of whom 11 had 
been lost to follow-up and were non-persistent with ART. In addition, focus group 
discussions were performed with 15 ART nurses and 19 case managers. All interviews 
and focus groups were audio-recorded, transcribed, and coded for themes and patterns 
in Amharic using a grounded theory approach. The emergent concepts and categories 
were translated into English. 
Results: Economic constraints, perceived stigma and discrimination, fasting, religious 
beliefs, medication side effects, and dissatisfaction with healthcare services were major 
reasons for patients being non-adherent and lost to follow-up. Disclosure of HIV status, 
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social support, use of reminder aids, responsibility for raising children, improved health 
on ART, and receiving education and counseling emerged as facilitators of adherence to 
ART.  
Conclusions: Improving adherence and retention requires integration of enhanced 
treatment access with improved job and food security. Healthcare providers need to be 
supported to better equip patients to cope with the issues associated with ART. 
Development of social policies and cooperation between various agencies are required 
to facilitate optimal adherence to ART, patient retention, and improved patient 
outcomes.  
6.2. Introduction 
Antiretroviral therapy (ART) decreases progression to Acquired Immune Deficiency 
Syndrome (AIDS) and prolongs, and improves the quality of, life. Over 800,000 patients 
are living with Human Immunodeficiency Virus (HIV)/AIDS in Ethiopia and the 
prevalence of  HIV/AIDS in the general population is estimated to be 1.5% [183]. In the 
past 8 years, decentralization and scale-up of the HIV care program have occurred and 
by the end of 2011, 249,174 adult patients (86% of eligible patients) had been 
prescribed ART.  
Adherence to a medication regimen is defined by Cramer et al as “the act of conforming 
to the recommendations made by the provider with respect to timing, dosage, and 
frequency of medication taking” [88]. To optimize ART, at least 95% adherence is 
required in order to prevent the development of resistant viral strains, although 
regimens with boosted protease inhibitors (PIs) or non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) can achieve good viral suppression even below this 
level of adherence [35]. Non-adherence to ART may result in regimen failure, immune 
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suppression, emergence of resistant viral strains, limited future treatment options, and 
higher treatment costs [89]. 
Adherence to a medication is a dynamic behaviour influenced by many factors. The 
findings of several studies conducted in resource-limited settings have shown that 
major facilitators of ART adherence encompass social support, positive treatment 
outcomes, and life-long projects [285-287]. Factors such as cost of medications, access 
to health facilities, transport costs, and fear of stigma and discrimination are recognized 
barriers to adherence with ART [225, 288, 289].  
Achievement of optimal adherence and patient retention[290] are becoming the 
greatest challenges in the management of HIV/AIDS in Ethiopia.  A five-year 
retrospective medical record review of 3012 adult patients who were enrolled in 
therapy at Gondar University Hospital ART clinic demonstrated that 31.4% had been 
lost to follow-up [189].  
To our knowledge, only three qualitative studies have attempted to identify factors that 
influence adherence to ART in adult patients with HIV/AIDS in the Ethiopian setting. 
Financial constraints, distance to ART clinics, patient load, patients’ beliefs, and alcohol 
and drug use were identified as barriers to retention in the Ethiopian healthcare setting 
[180, 181, 291]. Previous studies have mainly focused on exploring factors influencing 
patient retention at the healthcare level and were limited in their ability to identify 
barriers to, and facilitators of, medication adherence at the individual level. Moreover, 
none of these studies were performed in the Amhara region of Ethiopia, where 31.7% of 
the country’s ART usage occurs [292]. The region is home to 20 million people, of whom 
more than 91% are Amhara and about 80% are Orthodox Christians [293]. This study 
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sought to examine the enablers and barriers to medication adherence to ART, including 
reasons for patients being lost to follow-up, in the Amhara region of Ethiopia. 
6.3. Methods 
6.3.1. Study Setting 
This study was carried out at Felege-Hiwot Hospital and Gondar University Hospital, 
Northwest Ethiopia. Each hospital serves a catchment area of 5 million people. In 2005, 
when free ART was launched in the country, both hospitals began to offer ART. The 
numbers of patients receiving ART were 4,378 and 6,265, in Gondar University Hospital 
and Felege-Hiwot Hospital, respectively, at the time of data collection.   
Adult patients with HIV-infection and CD4 count less than or equal to 350 cells/mm3 
regardless of the clinical symptoms, or with any symptoms indicating a WHO clinical 
stage of 3 or 4, irrespective of CD4 count, are eligible to start ART. At both hospitals, 
specific ART nurses provide counseling to patients diagnosed as HIV-positive before 
and after ART initiation, while the physicians working in the ART clinics initiate ART 
medication based on patients’ clinical and laboratory findings. Nurses are also 
responsible for assessing patients’ progress at regular appointments in ART clinics, 
every month for the initial six months and every three months thereafter. If patients 
have any complaints, such as opportunistic infections (OIs) and drug side effects, the 
nurses refer patients to the physician to receive treatment. Furthermore, the study 
clinics have a peer support program staffed with case managers who themselves take 
ART. ART nurses refer patients to case managers for adherence counseling and 
management of ART risk factors. Case managers are certified care providers responsible 
for managing ART risk factors and locating patients lost to follow-up. They carry out a 
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programmed outreach service to track patients who have been lost to follow-up and are 
not reachable by phone, and to provide onsite community support.  
6.3.2. Inclusion/Exclusion criteria  
Adult patients (≥18 years old) who had been receiving ART in the study clinics for at 
least a month and could provide informed consent in Amharic were eligible for the 
interviews. All ART nurses and case managers who had been working in the ART clinics 
for at least 6 months were invited to participate in the focus group discussions.  
6.3.3. Recruitment and Sampling  
 ART nurses and case managers aware of patients’ treatment histories, supplemented by 
checking of patients’ medical records, helped to identify and recruit possible 
participants into the study. The recruitment of patients continued until information 
saturation was achieved. Research pharmacists working across the two sites invited all 
ART nurses and case managers to participate.  
6.3.4. Ethics Statement  
The Tasmanian Social Sciences Human Research Ethics Committee, University of 
Tasmania, Australia, and College of Medicine and Health Science Ethics committee, 
Bahir-Dar University, Ethiopia, approved this study. Patient interviews were conducted 
in private rooms where patients felt safe and stress-free. Focus group discussions were 
conducted in hospital auditoriums. Focus group participants were required to maintain 
the confidentiality of the identities of other participants and the content of the 
discussion. Participants were told either to remove themselves from the room or ask 
the interviewer to move the interview in another direction if they felt distress during 
the interview.  The purpose of the study was explained to all participants using standard 
information statements, and written informed consent was obtained before 
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participation. At the end of the session, the participants received 150 birr (~ $ 7 USD) as 
compensation for their time and transportation costs. Patients who disclosed non-
adherence during interview were referred to case managers in ART clinics for possible 
intervention. Personal or identifying information was not retained within the 
transcripts.  
6.3.5. Data Collection  
Data were collected from 22 February 2013 to 12 July 2013 using semi-structured 
interview and focus group discussion guides with patients and healthcare providers. 
The guides were designed to elicit information from the patients’ and healthcare 
providers’ points of view based on their experience with HIV medication, including 
factors that facilitate or constrain adherence to HIV medication and reasons for loss to 
follow-up. Consistent with an inductive approach, guides were updated continuously 
based on the results of the ongoing data analysis before the next interview or focus 
group discussion. A trained research pharmacist conducted the interviews and focus 
groups in the local language, Amharic. Comprehensive notes were taken throughout and 
after interviews and focus groups, and all sessions were audio-recorded. Participants 
decided on the times and the locations of the individual interviews. Data were stored in 
a locked cabinet in locked facilities in the College of Medicine and Health Sciences at the 
Bahir-Dar University. All electronic records were stored on a secure, password-
protected, server at the University of Tasmania. Researchers were able access the data 
whenever required. Data will be destroyed 5 years following publication. Paper data 
will be securely shredded and electronic data will be erased at this time.   
6.3.6. Data Preparation 
Upon completion of each focus group and interview, the research pharmacist produced 
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a complete transcript in Amharic. The transcribed data were read and reviewed to 
ensure understanding and then compared with the original audio-records for accuracy. 
The study data were established from the transcripts.    
6.4. Data Analysis  
Analysis of data aimed to describe the barriers to, and facilitators of, adherence to ART 
including the possible reasons of patients for missing appointments and/or being lost to 
follow-up at ART clinics. A grounded theory approach was used for analysing the data 
[294]. The process of data analysis was as shown in Figure 6. The documents in Amharic 
were uploaded into NVivo (QSR, Cambridge, MA) and textual data were coded into 
themes inductively. Two coders (the research pharmacist and a general practitioner) 
performed the coding separately and differences were resolved with discussion. Focus 
groups and interviews were coded and analysed separately, and matched for common 
themes. The key findings were illustrated by selecting representative quotes. 
Two bilingual translators translated emerging concepts and categories into English. The 
two translators discussed their differences and developed a single English version. A 
third person translated the final English version back into Amharic. A committee, 
consisting of an expert in English, a pharmacologist, an expert qualitative researcher 
and the research pharmacist, settled issues of conceptual equivalence and use of words 
between concepts and categories in Amharic and the final English version.  
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6.5. Results  
6.5.1. Study Participants  
Twenty-four patients, 15 nurses, and 19 case managers participated in this study. Forty-
four face-to-face interviews and 6 focus group discussion sessions were conducted 
across the two sites. 
Characteristics of Study Participants 
Patients. The mean age of the patients was 36 years. Half of those who participated 
were women. Less than half (41%) were married or living with a partner, and 58% had 
primary school or no education. Approximately half (46%) had been lost to follow-up 
and returned to the ART clinics either through tracking or on their own. The remaining 
patients were on follow-up; of these, 69% never missed appointments and 31% missed 
appointments frequently. 
Healthcare Providers. Approximately two-thirds (65%) of healthcare providers were 
women. The mean age of the healthcare providers was 32 years.  Forty-four percent 
were nurses and the rest were case managers. 
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Figure 6. Data analysis in generating grounded theory. 
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Table 13. List of emergent themes that influence adherence to ART and retention 
in follow-up care. 
 
Themes  Adherence 
facilitators 
Adherence 
barriers  
Factors influencing 
loss to follow-up 
    
  Theme I: Patient-Related    
 Economic constraints  ✓ ✓ 
 Disclosure and social support ✓   
 Reminders  ✓   
 Stigma and discrimination  ✓ ✓ 
 Responsibility for raising children  ✓   
 Religious rituals     
 Fasting   ✓  
 Being baptized with holy water   ✓ 
 Belief of being cured from 
HIV/AIDS 
  ✓ 
Theme II: Healthcare Service-Related     
 Counselling and education  ✓   
 Fatigue of healthcare providers   ✓  
 Poor medical record handling   ✓  
 Unavailability of office   ✓  
 No service at weekends   ✓  
Theme III: Medication-Related     
 Experiencing improved health on 
ART 
✓   
 Adverse effects  ✓ ✓ 
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6.5.2. Themes and Categories 
The themes that emerged were classified as patient-related, healthcare service-related, 
and medication-related. Each theme was classified into categories as presented below 
and shown in Table 13.  
6.5.2.1. Theme I: Patient-Related Factors 
Patient-related factors such as economic constraints, disclosure of HIV status, social 
support, use of reminder tools, stigma and discrimination, responsibility to raise 
children, and religious rituals were the most significant determinants of adherence and 
loss to follow-up.  
Category I: Economic Constraints  
Individual interviews and focus groups indicated that movement for seeking 
employment and food insecurity impaired adherence to ART amongst patients with 
HIV/AIDS who had started ART. Almost all patients (11 of 12) who had been lost to 
follow-up were unemployed, daily laborers or waiters working at a low wage rate. They 
moved from one part of the country to another part of the country searching for a job. 
Lack of money for transport, unavailability of nearby ART clinic services, and language 
and communication barriers prevented such patients from remaining in care.  
 I went to Humera to find a job. I got one time a refill from Humera Hospital. After a while, 
I crossed the Sudan border with friends. I worked in the farm in a jungle for 2 months. I do 
not speak the Arabic language (so) I was not able to refill my medicine. On the way back to 
Ethiopia with friends, looters took all (my) money including (my) ART user identification 
card. Because of this, I missed my medication for about three months. (26 years, male, 
patient, casual worker, 008)  
 117 
 
To get a job, patients usually move to remote areas where they cannot get access to ART. 
For instance, those who went to Sudan did not get the treatment there and were lost to 
follow-up for long period of time. (28 years, female, nurse, FG5)  
Patients with HIV/AIDS reported reduced physical strength, especially in the initial 
phase of ART, and were only able to tolerate reduced work hours. Some patients 
generated a minimal monthly income not sufficient to cover the costs of their basic 
needs, including food. Thus, unavailability of food hindered patients from taking their 
HIV medications. Some of the patients, being dependent on the food supply from ART 
clinics, left their pill bottles with the nurses when they did not receive their food ration 
from the clinic. Some others patients believed that they had to consume costly food 
items to take their HIV medications.  
Previously, I was getting (an) additional nutrition supply, plumpy nut, for free from the 
ART clinic. But the other day, the nurse told me that she would not give it to me anymore. 
When I heard this, I felt angry and left the medication bottle on the nurse’s desk and went 
away from the clinic. Due to this I did not take pills for five days. (33 years, male, patient, 
jobless, 007) 
When Non-Governmental Organizations (NGOs) stopped food donations, patients 
complain about continuing ART. Some of them are even lost to follow-up because of the 
unavailability of food. (32 years, female, case manager, FG3) 
Most people do not have an idea that the medication can be taken eating any food 
available. They do not know that they can prepare the available food in the house with 
proper hygiene. They think the medicine will be harmful if they do not eat an expensive 
diet such as meat and eggs. (30 years, female, case manager, FG3) 
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Category II: Disclosure of HIV Status and Social Support  
Both interview and focus group participants most frequently cited that disclosure of 
their HIV status to friends, family and neighbors was a facilitator of adherence. Patients 
who disclosed their HIV status to relatives and close friends did not fear stigma and 
discrimination to obtain and take drugs.  
I have no problem of disclosing my (HIV) status to my family, friends, and others. When I 
usually introduce myself, I often tell them that I am living with HIV… this helped me to take 
the pills regularly, without any anxiety, and to recover from my illness as well. (35 years, 
female, patient, librarian, 015) 
Many patients told me that disclosure of their status to neighbours and community helped 
them to take pills properly. (26 years, female, nurse, FG4) 
Disclosing one’s HIV status was found to be essential for receiving social support. 
Reminders to take pills, cover for transportation and food costs, and emotional backing 
were commonly reported. The most important way that patients received support was 
in reminders regarding the time they took pills. Patients received support usually from 
their partner, who himself/herself was also on ART, and/or children who were living 
with them. Experienced ART nurses and case managers noticed that transport and food 
support from NGOs had improved patients’ attendance at ART clinics.  
Sometimes when I feel fatigued, am busy with work or sleep at dose time my children 
remind me to take the pills. They bring me a glass of water and the medication bottle. (36 
years, female, patient, casual worker, 004) 
Aids from NGOs such as getting cooking oil, wheat, and soap until HIV patients recover 
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from their illness and support themselves is one facilitator for adherence to ART. (46 years, 
male, case manager, FG1)  
Category III: Stigma and Discrimination 
Patients and healthcare providers frequently mentioned that stigma and discrimination 
caused patients trouble in taking, obtaining, and keeping medications. Patients 
described how they would avoid taking pills in front of others, including family 
members who did not know their HIV status.  
I used to miss pills many times… because people were with me. The guy with me did not 
know my HIV status. I worry what people think about me if they know about my status 
while I am taking pills in front of them. (25 years, female, patient, waitress, 020) 
Only my mother knows about my HIV status… I fear stigma and discrimination if other 
family members noticed me taking the pills. (20 years, female, patient, waitress, 006) 
Patients also preferred to attend treatment in clinics far away from home to avoid 
disclosure of their HIV status to their community members.  
Fearing disclosure in their residential area…. patients attend ART from Gondar when they 
have access to it in Bahir-Dar and vice versa. That creates a challenge for patients in 
picking up their medicine later. (23 years, male, nurse, FG1) 
Lack of privacy was a particular challenge for patients working in a private home or 
organization. Half of the patients were part-time workers, daily labourers or waiters. 
These patients were forced to work at a low wage rate for long hours to cover their 
living costs in places where their privacy could not be maintained. They had problems 
with finding a place to keep and take their medications; they thought that they had to 
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hide their pills from employers and colleagues. Patients felt that they might be 
dismissed from their job if employers learned of their status.  
 If the employer learns that I am living with HIV… I fear to be sacked from my job. (26 
years, female, patient, casual worker, 019) 
When I asked my patient, how she was taking her pills? Whether she kept her time or not… 
she told me that she is a daily laborer baking injera and abshilo in other people’s houses. If 
employers learn that she is living with HIV and taking the pills they would stop her 
working with them. She used to take pills only when they went away from her and she was 
alone. As the result she does not take her pills on time. (45 years, female, nurse, FG5) 
I was working as a cooker in a cement factory compound for Indian employees. For some 
time, I was taking the pills hiding myself (so as) not to be noticed by anyone. But, later, I 
became worried thinking that if they knew my status, they might dismiss me from my job.  
Then I stopped taking the pills. (27 years, female, patient, cohabiting, 018)  
 Category IV: Responsibility for Raising Children 
Patients’ commitment to raise and educate their children facilitated medication taking. 
Patients with HIV were at the peak of their reproductive lives; 14 out of 24 (mean age 
36) had dependent children. They fear passing away with AIDS, leaving their children as 
orphans. Of 14 patients who were living with their children, 9 were found to be 
adherent by their ART nurses.   
… I have a boy born free of the virus.  As long as I am alive, I wish to see him achieving 
better opportunities. If I am not taking the medication properly or abandoned it 
altogether, I am ruining his chance. (35 years, male, patient, self-employed, 002) 
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Patients usually say that if they are not alive, it is difficult to imagine the survival of their 
children. They told me that the medicine kept them healthy to work and help their children 
to achieve a better future. (35 years, male, nurse, FG5)    
Category V: Reminders 
Patients frequently mentioned that setting alarms on watches or mobile phones helped 
them to remember to take their pills. Seven respondents said they set alarms on their 
mobile phones or watches.  Providers also stressed the benefit of reminders in avoiding 
pill missing due to hectic daily activity.  
To take my pills on time, I set a reminder on my mobile phone…it reminds me of the time of 
my medication even when I forget it. (41 years, male, patient, casual worker, 016) 
Especially use of mobile phones or watch alarm tones is more sustainable for not 
forgetting taking pills. (27 years, female, case manager, FG6)  
Although electronic reminder tools have the aforementioned advantages, some patients 
did not have their own mobile phone or watch, and some others were too illiterate to 
use these reminder tools. Eight respondents had no formal education and were not able 
to write and read. These patients used other alternative reminders such as the position 
of the sun, length of shadows, entrance and exit time of domestic animals and students, 
and bells from a church or mosque or factories to take their pills on time. Although such 
kinds of devices were helpful as pill reminders, they were limited in their ability to 
indicate the exact time.  
I take pills whenever I hear Allah Akbar. (26 years, male, patient, casual worker, 008)  
I have an old lady customer who is too illiterate to read a watch and who has no family or 
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relatives living with her…she usually takes her pills looking at students going to school in 
the morning. (33 years, male, nurse, FG5) 
Category VI: Religious Rituals  
Religious rituals like fasting and holy water were found to influence medication taking. 
Both Ethiopian Orthodox Christian followers and Muslims have several fasting days and 
seasons within a year.  
Sub-category I: Fasting  
During fasting seasons, some patients did not take their medications properly.  
I take the morning dose at midday during fasting since I have to wait without any meal 
until midday. (38 years, female, patient, secretary, 023) 
(Orthodox Christian) patients have a strong attitude towards fasting and become late in 
taking pills on Friday and Wednesday or in any fasting season. Patients take the morning 
dose at 12 am. (52 years, male, case manager, FG3) 
During Ramadan, I only take the evening dose. It is impossible to take the morning dose as 
we eat during the night-time. (38 years, male, patient, driver, 024) 
During Ramadan some Muslims do not take the daytime dose. They only take the evening 
dose while taking their food. They usually come and consult us on what to do. (40 years, 
female, nurse, FG2) 
Sub-category II: Being Baptized with Holy Water  
Going to monasteries to be baptized with holy water was the most frequently 
mentioned reason for patients being lost to follow-up. This was reported by five of the 
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11 patients lost to follow-up; all of them were females. Some Orthodox priests preached 
that patients should take holy water, pray to God, and stop taking their pills to be cured 
of their ‘curse’. 
I stopped taking my medication while I started being baptized with holy water (in a 
monastery). Priests there told us only to be baptized by the holy water and stop taking 
antiretroviral pills; I believed in Jesus and took only the holy water to be cured. (20 years, 
female, patient, waitress, 006) 
Patients preferred complete cure from HIV/AIDS with the holy water treatment rather 
than taking pills throughout their life. Interviewees and focus group members reported 
discontinuation of ART treatment in those being baptized with holy water.  
I have friends who were living with HIV; they told me that they get cured after attending 
holy water treatment for three months in a monastery. They told me to go and get the 
treatment; in addition I have been informed to stop the pills citing that I do not have to 
believe in the two things simultaneously to be cured. I left my pills at home and went there 
for two months. (24 years, female, patient, waitress, 022)  
During the time when I was tracking lost patients, members of a lost patient’s family told 
me that she is cured from her disease after she had been baptized from a monastery holy 
water. They tried to convince me to go and check her health status.  Still now she has not 
come back to the clinic. (31 years, female, case manager, FG2)    
Some of the patients were lost to follow-up after they were baptized by the holy water; 
they told us that they are cured from HIV/AIDS because of the holy water. (36 years, male, 
nurse, FG5) 
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6.5.2.2. Theme II: Healthcare-Related Factors 
Healthcare-related factors, such as patient education and counselling facilitated 
medication adherence, while busyness of healthcare providers, poor laboratory service, 
and poor medical record handling impaired adherence and retention.  
Category I: Counselling and Education  
Education and counselling of patients in the ART clinics motivated them to take their 
pills. Case managers and ART nurses provided education, which focused on the 
importance of perfect adherence, strategies to improve adherence, consequences of 
non-adherence, possible side effects of the medications, and the duration of treatment 
required.  
Every morning in the waiting room nurses and case managers teach us the consequences 
of not taking pills properly and the benefits of disclosure to family and the community. 
That helps me a lot to adhere to the treatment and improves my health condition. (36 
years, female, patient, self-employed, 014) 
If the healthcare provider who initiated ART gives comprehensive education, including 
how long the medications will be taken, the possible side effects of the medications, the 
importance of the treatment, whether it cures or not, and checks patients’ understanding 
at the end, it will help patients to continue their treatment without interruption. (28 years, 
female, nurse, FG5)  
Category II: Fatigue of Healthcare Providers  
In contrast, healthcare providers were fatigued with a high load of patients; this 
impaired the quality of the service delivered. Sometimes, it was felt that ART nurses did 
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not have empathy and rushed when writing prescriptions, without addressing patients’ 
concerns about their treatment. This impaired the ART nurse-patient relationship and 
patients did not enjoy coming to the clinics.  
They abuse you, they do not accept you in good terms, and I feel bad about these (things). 
Even, I feel my illness more when I come to the clinic and see their faces. I feel as if I went 
to a police station and was interrogated as a criminal. (38 years, female, patient, 
secretary, 023) 
…The hospital is crowded … it has many patients… professionals are fatigued with it. (52 
years, male, case manager, FG3) 
Category III: Poor Laboratory Service 
The ART clinics have large numbers of patients; there are queues to receive services. 
Patients were instructed to come to ART clinics early in the morning and line up to have 
their CD4 counts checked. Some of them were too busy to do so and unable to attend to 
their treatment properly.  
I came (to the ART clinic) early in the morning at 5 am to get a CD4 test. We were forced 
to struggle with the coldness and thieves at this time. This is the reason why I did not check 
my CD4 count regularly and attend my treatment properly. (38 years, female, patient, 
secretary, 023) 
The result of CD4 count tests are delayed up to one day after the test; this needs to be 
corrected. (28 years, female, case manager, FG6) 
Category IV: Poor Medical Record Handling 
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Several patients and healthcare providers mentioned that there have been serious 
problems in handling of patients’ medical records in the hospitals. Many patients 
experienced loss of their medical record and were forced to start a new medical record, 
losing all their previous data. Sometimes patients were forced to repeat CD4 count 
measures when the laboratory report was lost from the medical record and was 
therefore unavailable to inform medical decisions.  
My chart was lost from the chart room…the nurse told me to I needed a new chart but I 
was not voluntary to have a new one…I left the clinic citing the need for my previous 
documents for prescribing of my medications. (35 years, male, patient, self-employed, 002) 
There is problem of chart loss. Sometimes you find the empty cover of the chart while all 
the documents are lost. Patients were forced to repeat CD4 tests as a result. (36 years, 
female, case manager, FG2) 
6.5.2.3. Theme III: Medication-Related Factors  
Improvements of health on ART and medication side effects were the two consistent 
and contrasting themes related to medication. Improvement of health on ART facilitated 
adherence to HIV medication, while medication side effects was among the reasons for 
patients to be non-adherent or lost to follow-up.  
Category I: Improved Health on ART 
Most patients had been confirmed as HIV-positive after suffering a long-term sickness. 
They had seen the devastating effect of HIV on their bodies and had vivid illnesses and 
stories. A significant improvement of health witnessed soon after initiating ART 
heightened trust in the medications.  
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Both patients and providers highlighted being healthy, improved appetite, increased 
weight and CD4 count, and prolonged lives as positive treatment outcomes. Patients 
were no longer bedridden, had strength, resumed work, and increased their incomes. 
These improvements inspired them to continue taking their medicines.  
 I have decided to be more committed towards the treatment because I have seen the 
benefits of antiretrovirals. My appetite has improved, I was bedridden, but now I am 
healthy and I usually find myself at the field for work…. I achieved all this because of the 
pills. Hence, I should not stop taking the pills. (35 years, male, patient, farmer, 016)  
… Improvement of health after treatment of OIs, being able to live longer and progressive 
increments of CD4 counts were the major factors strengthening medication taking. (24 
years, male, nurse, FG5) 
Category II: Adverse Effects  
Patients who experienced unanticipated and/or intolerable side effects, like nightmares 
and psychosis, missed doses or discontinued therapy altogether. This was particularly 
likely among patients who had started ART when asymptomatic as they considered the 
medications had worsened their health.  
I was not conscious (after taking the medications), I was mad, as neighbours told me. I 
went to a neighbour’s house and shouted, calling on a certain woman, blaming her for 
being evil eye and making me sick. After that I stopped taking the pills. (26 years, female, 
patient, casual worker, 019) 
When I phoned a lost patient who was on TDF/3TC/EFV, for tracking, he told me that he 
could not come back unless the regimen changed. That was because he had developed 
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nightmares due to the efavirenz. (33 years, male, case manager, FG2)   
At the beginning of my treatment, I experienced vomiting. As the result, I missed some 
doses, until I adapted to the medication. (30 years, female, patient, waitress, 009) 
6.6. Discussion   
We sought to understand the barriers and facilitators that influence adherence in 
patients taking ART in the Amhara region of Ethiopia. We identified economic 
constraints as the greatest barrier, with fear of stigma and discrimination, fasting and 
holy water, poor healthcare services, and medication side effects also interfering. 
Meanwhile, disclosure of HIV status, social support, use of reminders, life-long projects, 
counselling and education, and improved health on ART facilitated medication 
adherence and retention in HIV care. Most of these factors were consistent with the 
findings reported in other regions of Ethiopia [180, 181, 291] and elsewhere in 
resource-limited settings [192, 193, 295]. However, some of the findings such as 
migration [296-300], holy water, fasting [295], and traditional time reminders have 
been rarely reported or not reported at all in other settings. These differences may be 
attributed to the socio-economic and socio-cultural differences of our study sample. The 
major findings that had significant impact on adherence including economic constraints, 
stigma and discrimination, and disclosure of HIV status and the new or the rarely 
reported findings highlighted above are discussed below.         
The two major socio-economic constraints that negatively affected adherence and 
retention in HIV care in our study were a lack of work, resulting in the need for 
migration to find a job, and food insecurity. These factors have also been documented in 
other studies [288, 295-297, 299-302]. Patients were lost to follow-up when they 
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migrated to other places either inside or outside Ethiopia to find a job. Migration of 
Ethiopian youths in large numbers from rural to urban areas of the country to find 
work, as well as out of the country to the Middle East and sub-Saharan African 
countries, has been reported by other authors [303, 304]. Patients also missed pills and 
stopped collecting repeat prescriptions from clinics when they could not afford to buy 
food, or when NGOs stopped supplying food rations. The negative impact of food 
insecurity on adherence has also been recognized in other studies conducted in sub-
Saharan Africa [288, 301, 302]. Lack of job opportunities and food insecurity, while not 
exceptional to patients with HIV/AIDS, were exacerbated by the co-existence of other 
HIV-associated challenges such as stigma and discrimination, reduced physical activity, 
medication schedules, and indirect treatment costs. Proactive strategies to improve 
access to jobs and food security for patients taking ART are required in Ethiopia. Both 
governmental and non-governmental organizations need to work in coordination to 
address the multilayered disadvantages in patients receiving ART.    
Socio-cultural factors, such as stigma and discrimination and religious rituals, also had 
undesirable effects on medication adherence and remaining in care in this sample. 
Stigmatization and discrimination are complex socio-cultural phenomena that arise 
from the perception that a person with HIV/AIDS has unwanted qualities, thus reducing 
him/her in the eye of society [305]. Perceived stigma (felt stigma) and discrimination 
and lack of privacy to take and collect medication hindered adherence to ART in this 
study; these factors were also identified in other sub-Saharan and Far-East Asian 
studies [147, 170, 295, 306-308]. As reported by other authors [300], patients in this 
study had concerns about being stigmatized and losing their jobs if their HIV status was 
discovered when they took pills in front of work colleagues or asked permission from 
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their employers to collect medications at appointment dates. Seeking treatment at 
health facilities far away from home to hide their HIV status from family and colleagues 
is consistent with findings of other qualitative studies [295, 309].  
A multi-faceted intervention, including information provision, skill building, counselling 
and facilitating interaction between people with HIV/AIDS and the community, has the 
potential to reduce stigma and improve ART adherence and retention in care [310-312]. 
A systematic review by Stangl et al. [310] reported that there was a lack of effective 
stigma reduction strategies that could be implemented on a large scale. Tackling stigma 
and discrimination at multiple levels might also improve patients' abilities to adhere to 
ART treatment and continue presenting for medical care in Ethiopia. 
Religious beliefs are complex cultural concepts and influenced patients’ treatment with 
antiretrovirals in our sample of study; this has been reported elsewhere [295, 313, 314]. 
The Ethiopian Orthodox Church does not allow eating until midday every Wednesday 
and Friday, as well as in fasting seasons such as Flseta and Worha-Tsom.  Similarly, 
Muslims do not eat during the daytime in Ramadan. Patients miss or delay medications 
to fulfill these religious obligations. Going to monasteries to be baptized with holy water 
was found to be the most important reason for patients being lost to follow-up in this 
study. Another study in Ethiopia has also found seeking traditional treatment and/or 
holy water treatment to be the most important reason for patients being lost to follow-
up care [315]. Stakeholders, governmental and non-governmental, should work with 
religious authorities to reduce the negative impact of fasting and holy water on 
medication-taking.  
Disclosure of HIV status, social support, and use of reminders  were identified as 
important facilitators of adherence in this study; other studies have reported similar 
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findings [119, 155, 156, 295, 316-319]. Case managers and ART nurses encouraged 
patients to disclose their HIV status to family members or close friends who can provide 
them social support, reminders about pills, financial assistance, and emotional backing 
to facilitate medication taking in our study and elsewhere [179, 192, 287, 320]. Case 
managers at the clinics are also working to deliver emotional support and resolve 
patients’ problems based on their experiences living with HIV. Intervention studies 
reported that integration of dialogue and thinking about what needs to be done prior to 
disclosure, role-playing, and behavioural exercise were more effective than separate 
interventions in promoting disclosure [321, 322]. There appears to be a role for these 
types of interventions to enhance disclosure of HIV status and therefore aid in the 
achievement of optimal adherence and retention in care in Ethiopian patients taking 
ART as well.  
One facilitator of medication adherence was the use of electronic devices, such as 
mobile phones and alarms. These have the advantage of reminding patients of their 
medication times without the need for disclosure of their HIV status to others. Access to 
mobile phones is increasing in Ethiopia [323] and setting alarm tones on mobile phones 
helped patients to remember to take pills. Randomized controlled trials in Kenya 
reported a mobile phone short message service improved adherence to ART treatment 
and retention in medical care [155, 156]. Healthcare providers need to use the 
opportunity of increasing access to mobile phones in the local area [323] for improving 
patients’ adherence to HIV medication. Illiterate patients used the position of the sun, 
entrance and exit time of students, and the bell or sound of prayer time as their 
reminder to take pills. This finding is unique; no other studies have reported the use of 
the aforementioned traditional ways of time measuring for taking pills. Given many 
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Ethiopian HIV-positive patients are illiterate [324] and depend on traditional ways of 
time counting, which do not measure point to point medication time and influenced by 
many factors, the healthcare providers need to train patients how to use the simple 
electronic reminder devices to improve adherence. 
6.7. Strengths and Limitations 
One of the primary strengths of this study was the use of multiple data sources 
including focus group discussions and semi-structured interviews, involving patients on 
ART, ART nurses, and case managers across two sites. Almost all participants accepted 
our offer and were involved in the study; the non-response rate was very low. This may 
have been due to scarcity of this kind of research in our region of Ethiopia, and thus this 
research gave an opportunity for participants to share their experiences of ART. Both 
patients, who were adherent and non-adherent, including those who had been lost to 
follow-up from ART clinics, were included in this study.  
The study has some limitations. People who were picking up medications for someone 
else were not included in this study. Moreover, patients who were bedridden or with 
psychiatric or other problems who were not able to attend ART clinics at the times of 
data collection were not interviewed.  
6.8. Conclusion 
Scale-up of treatment and care for patients with HIV/AIDS in sub-Saharan Africa has 
been a decisive clinical achievement. The full benefit of the scale-up cannot be realized 
without achieving long-term optimal adherence and retention in care. In this study we 
found that economic constraints, perceived stigma and discrimination, fasting, holy 
water, and poor healthcare services hamper adherence to ART and retention in care. 
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Conversely, disclosure of HIV status, social support, use of reminder aids, having life-
long projects, and patient education and counselling facilitated adherence and retention 
in care. International studies have demonstrated that interventions directed at many of 
these factors have encouraged patients to achieve optimal adherence and remain in 
care. Interventions integrating enhanced treatment access with improved job and food 
security, supporting healthcare providers, development of social policies, and 
cooperation between various agencies are required to facilitate optimal adherence to 
ART, retention in care, and improved patient outcomes.   
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CHAPTER SEVEN  
7. ADHERENCE TO ANTIRETROVIRAL THERAPY AND VIROLOGIC FAILURE: A 
META-ANALYSIS 
7.1. Abstract  
The often cited need to achieve 95% (nearly perfect) adherence to antiretroviral 
therapy (ART) for successful virologic outcomes in HIV may present a barrier to 
initiation of therapy in the early stages of HIV. This meta-analysis synthesised 43 
studies (27,905 participants) performed across more than 26 countries, to determine 
the relationship between cut-off point for optimal adherence to ART and virologic 
outcomes. Meta-analysis was performed using a random-effect model to calculate 
pooled odds ratios with corresponding 95% confidence intervals. The mean rate of 
patients reporting optimal adherence was 63.4%. Compared with suboptimal 
adherence, optimal adherence was associated with a lower risk of virologic failure 
(0.34; 95% CI: 0.26-0.44). There were no significant differences in the pooled odds 
ratios among different optimal adherence thresholds (98-100%, 95%, 80-90%). 
Study design (randomised controlled trial versus observational study) (regression 
coefficient 0.74, 95% CI: 0.04 - 1.43, p< 0.05) and study region (developing versus 
developed countries; regression coefficient 0.56, 95% CI: 0.01-1.12, p<0.05) remained 
as independent predictors of between-study heterogeneity, with more patients with 
optimal adherence from developing countries or randomised controlled trials 
experiencing virologic failure. The threshold for optimal adherence to achieve better 
virologic outcomes appears to be wider than the commonly used cut-off point (95% 
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adherence). The cut-off point for optimal adherence could be redefined to a slightly 
lower level to encourage the prescribing of ART at an early stage of HIV infection.   
7.2. Introduction  
HIV/AIDS has been transformed into a manageable chronic disease with the advent of 
combination antiretroviral therapy (ART) initiated as the standard of care [325]. Three 
classes of HIV medications have been widely used in combination - 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse 
transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) [325]. Despite the 
availability of effective treatment options, suboptimal adherence to treatment can result 
in insufficient viral suppression and promote the emergence of drug-resistant viral 
strains, resulting in regimen failure, progression to AIDS, and death [220, 221, 326]. 
Paterson et al. [89] suggested that at least 95% adherence to unboosted PIs was 
required for virologic suppression. This 95% adherence cut-off point, based on what is 
now obsolete therapy, has been widely used as the level of optimal adherence needed to 
be met by patients taking newer agents and their combinations. The concern that 
patients may not achieve a near perfect adherence presents a barrier for initiation of 
therapy in the early stages of HIV [327].   
This meta-analysis integrated finding from observational studies on ART adherence 
with two objectives: (a) to critically evaluate the association between optimal 
adherence to ART and virologic outcomes, and (b) to use meta-regression to determine 
methodological, regimen, and population factors that could moderate the relationship 
between adherence and virologic outcomes. 
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7.3. Methods         
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) Statement in conducting this meta-analysis [328]. Studies eligible for 
inclusion were randomised controlled trials, retrospective analyses of data from trials, 
and cohort studies measuring the relationship between medication adherence to ART 
and virologic failure. 
7.3.1. Search Strategy  
WB carried out systematic literature searches of the electronic databases MEDLINE via 
PubMed, Cochrane Clinical Trials, and EMBASE from their inception date to 17 April 
2015. This search used combinations of the following key words: medication adherence, 
patient compliance, antiretroviral therapy, antiretroviral agent, antiretroviral 
treatment, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, 
virologic failure, and viral load. The reference lists of all articles included in this meta-
analysis were also searched. Review articles, editorials, commentaries, government 
reports, and guidelines were excluded from this review. Titles and abstracts of 
potentially relevant articles were screened independently by WB and YM. Full articles of 
potentially appropriate citations were screened for inclusion in this review if they 
fulfilled the following criteria: original research, participants aged 16 years or older, 
having a clear definition of medication adherence measurement and clear cut-off points 
for optimal and suboptimal adherence, and virologic failure stratified by optimal and 
suboptimal medication adherence groups. Ethical approval was not required as this 
study was based on published data and had no direct access to patient information.  
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7.3.2. Data collection and outcome measures 
WB extracted data using standardised forms, with recording of authors, year of 
publication, country of study, study type, regimen, method of adherence measurement, 
cut-off points for good adherence and virologic failure. The data were verified by a 
second reviewer (YM). Disagreements between reviewers were resolved through 
discussion until a consensus was reached. Study authors’ grouping of patients into 
optimal and suboptimal adherence using the most objective measure was used. When a 
study reported more than one adherence measurement, the most reliable adherence 
measurement data was used, with reliability defined in following order: Medication 
event monitoring system (MEMS) > pill count > pharmacy refill > self-reported 
adherence in the past week > self-reported adherence in the past month. When the 
number of virologic failures within each adherence group was not reported, we 
calculated virologic failure from the information provided in the paper or contacted the 
corresponding author. Studies were excluded when it was not possible to obtain 
virologic failure data in each adherence group. The United Nations Human Development 
Index (HDI) ranking was used to categorise studies into low and high human 
development groups [329].    
7.4. Statistical analysis 
The data were analysed using Review Manager (RevMan) version 5.3 (Cochrane 
Collaboration, The Nordic Cochrane Centre, Copenhagen, 2014) and Comprehensive 
Meta-Analysis (CMA) version 3.3.070 (Biostat, Englewood, NJ, USA, 2014). Each class of 
antiretroviral was considered in a separate analysis of the association between 
adherence and virologic failure in randomised clinical trials. Results are presented 
based on nine categories, including study region, antiretroviral regimen, treatment 
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experience, virologic failure cut-off points, adherence cut-off points, adherence 
measurement, study design, observation period, and year of publication. Adherence 
pooled odds ratios and 95% confidence intervals were calculated using a random effect 
model (DerSimonian and Lard) [330] that accommodated the random variation within 
studies and between-studies [331]. 
 Heterogeneity between-studies were examined using the Q and I2 statistics [330, 332]. 
The odds ratio was plotted against the inverse of standard error to identify the risk of 
publication bias by visually assessing the symmetry of funnel plots. Statistical 
significance was confirmed using Egger’s test [333], with a p value less than 0.05 
considered suggestive of publication bias. A meta-regression was performed to examine 
major moderators of the between-studies heterogeneity. Results with p-values less than 
0.1 from univariate analyses were included in the multivariate meta-regression model.  
7.5. Results 
Overall, 1,796 studies were identified, of which 1,449 were excluded after review of the 
title and abstract Figure 7. The full text of the remaining 347 citations was screened, and 
43 studies with 27,905 participants met the inclusion criteria. The included studies had 
wide a variation in sample sizes (range=34-3,607, mean=649, SD=805) and a slight 
majority of participants were male (57%). Twenty-five studies were prospective studies 
[89, 157, 218, 235, 244, 334-354] that reported virologic failure according to adherence 
group. The remaining studies were randomised controlled trials (11) [187, 355-364] 
and retrospective studies (7) [234, 365-370]. Characteristics of the included studies are 
shown in Table 14. 
With respect to location, 14 studies were conducted in sub-Saharan Africa; 9 in the US; 6 
in Canada; 5 in Europe; 5 in Asia; 1 in Australia; and 3 studies in multiple countries. 
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Twenty-two (49%) studies included only treatment-naïve patients and the remaining 
21 studies included both treatment-naïve and/or treatment-experienced patients. All 
studies reported cut-off points for optimal adherence and virologic failure. Thirty 
studies (70%) defined optimal adherence as 95%, with the remainder using 100%, 
98%, 90%, 85% and 80% as the cut-off points. Optimal adherence rates varied greatly 
across studies, partially due to the use of these different cut-off points and also different 
methods of measurement to assess adherence. The mean rate of achieving optimal 
adherence in adults was 63.4% (standard deviation (SD)=23.7, range 5% to 97%, n=43). 
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Figure 7.  Study selection used in the meta-analysis 
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Table 14.  Characteristics of included studies in meta-analysis of adherence to antiretroviral therapy and virologic failure. 
 
Study Country Study type Definition of 
virologic failure 
(copies/mL) 
Adherence 
measures 
Cut-off point for 
good adherence 
% 
Observation period 
Pasternak et al. 
2012 [355]  
Netherlands  Randomised 
controlled trial  
≥50  MEMS* 100 9 months 
Okonjio et al. 2012 
[356] 
Kenya Randomised 
controlled trial  
≥400 Pill count ≥95 24 weeks 
Murphy et al. 2012 
[365] 
South Africa  Retrospective study  ≥50 Pharmacy refill >90 24 months 
Nolan et al. 2011 
[366] 
Canada Retrospective study ≥500 Pharmacy refill ≥95 median 51 months 
El-Khatib et al. 
2011b [367] 
South Africa  Retrospective study >50 Pharmacy refill ≥95 median 44 months 
Messou et al. 2011 
[334] 
Côte d’Ivoire Prospective study ≥300 Pharmacy refill ≥95 12 months  
Lima et al. 2010 
[368] 
Canada Retrospective study >400 Pharmacy refill ≥95 median 2 years 
Ford et al. 2010 
[157] 
South Africa  Prospective study >5000 Self-report ≥95 5 years 
Nellen et al. 2009 
[335]  
Netherlands  Prospective study >400 Pharmacy refill ≥85 2  years 
San et al. 2008 [336] Mozambique Prospective study ≥1000 Pill count >95 1 year 
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Study Country Study type Definition of 
virologic failure 
(copies/mL) 
Adherence 
measures 
Cut-off point for 
good adherence 
% 
Observation period 
Nachega et al. 2007 
[218] 
South Africa  Prospective study >400 Pharmacy refill 100 median 2.2 years 
Gross et al. 2006 
[338] 
Canada Prospective study >1000 Pharmacy refill >95 median 29 months 
Moore et al. 2005 
[337] 
Canada Prospective study ≥500 Pharmacy refill >95 median 44.7 months 
Kitahata et al. 2004 
[369] 
USA Retrospective study >500 Pharmacy refill >90 median 89 weeks 
Cahn et al. 2004 
[357] 
Argentina, Brazil, 
Mexico, Italy, 
Thailand, Canada 
Randomised 
controlled trial  
≥400 Self-report ≥95 48 weeks 
Arnsten et al. 2001 
[244] 
USA Prospective study >500 MEMS ≥90 5.1 months 
McNabb et al. 
2001[339] 
USA Prospective study ≥400 MEMS >95 3 months 
Parienti et al. 2010 
[340] 
USA Prospective study  ≥50 (400) MEMS >95 2 years 
Bangsberg et al. 
2000 [341] 
USA Prospective study  ≥400  MEMS ≥98 median 9.4 weeks 
Paterson et al. 2000 
[89] 
USA Prospective study  ≥400 MEMS ≥95 median 6 months 
Tuldra et al. 2000 Spain  Randomised >400 Self-report ≥95 48 weeks 
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Study Country Study type Definition of 
virologic failure 
(copies/mL) 
Adherence 
measures 
Cut-off point for 
good adherence 
% 
Observation period 
[364] controlled trial  
Meresse et al. 2013 
[358] 
Cameroon Randomised 
controlled trial  
≥40 Self-report ≥80 24 months 
Abah et al. 2014 
[370] 
Nigeria  Retrospective study >1000 Pharmacy refill ≥95 median 12 months  
Neogi et al. 2013 
[342] 
India  Prospective study  >400 Self-report 100 2 years 
Li et al 2012. [343] USA  Prospective study ≥200 Self-report and 
Pill count  
≥95 32 months  
McMahon et al. 
2013 [234] 
India  Retrospective  study ≥200 Pharmacy refill  >95 12 months  
Ekstrand et al. 2011 
[344]  
India  Prospective study  >1000 Self-report  ≥95 2 years 
Lower-Beer et al. 
2000 [345] 
Canada  Prospective study  >500 Pharmacy refill ≥95 median 19 months  
Carr et al. 2000 
[187] 
Australia Randomised 
controlled trial  
≥50 Self-report  100 52 months 
Cohen et al. 2013 
[359] 
21 countries Randomised 
controlled trial  
≥50 Self-report  >95 96 weeks 
Haubrich et al.  
1999 [360] 
USA Randomised 
controlled trial  
<500 Self-report  ≥95 6 months 
Muyingo et al. 2008 Uganda and Randomised >50 (400)  Pharmacy refill 100 48 weeks 
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Study Country Study type Definition of 
virologic failure 
(copies/mL) 
Adherence 
measures 
Cut-off point for 
good adherence 
% 
Observation period 
[361] Zimbabwe controlled trial  
Anude et al. 2013 
[346]  
Nigeria  Prospective study  ≥400 Pharmacy refill ≥95 12 months  
Nelson et al. 2010 
[362] 
26 countries Randomised 
controlled trial  
≥50 Self-report  >95 96 weeks  
Biswas et al. 2014 
[347] 
USA Prospective study ≥40 Self-report  >95 3 years 
Ti et al. 2014 [349] Canada Prospective study  ≥500 Pharmacy refill ≥95 median 32 months  
El-Khatib et al. 
2011b [348] 
South Africa  Prospective study  ≥400 Pill count  ≥95 24 weeks  
Glass et al.  2006 
[350] 
Switzerland  Prospective study  ≥50 (400) Self-report ≥95 12 months  
Jordan et al. 2009 
[351] 
Vietnam  Prospective study ≥1000 Self-report ≥95 16.65 months  
Goldman et al. 2008 
[352] 
Zambia  Prospective study ≥400 Pharmacy refill ≥95 744 days 
Court et al. 2014 
[353] 
South Africa  Prospective study  >1000 copies/mL Pharmacy refill  90% 27 months  
Shet et al. 2014 
[363]  
India  Randomised 
controlled trial  
>400 copies/mL Pill count  95% 96 weeks  
Carrieri et al. 2003 
[354]  
France Prospective study  200, 400, 500 
copies/mL 
Self-report  100% 36 months  
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7.5.1. Meta-analysis and Meta-regression 
Of a total 27,905 participants, 22,740 participants had a viral load and adherence 
measurement; 7,056 (31%) had virologic failure. Overall, 3,464 of 15,067 participants 
with optimal adherence to ART (23%), and 3,592 of 7,673 participants with suboptimal 
adherence (47%) had virologic failure (Figure 8). The pooled odds ratio for virologic 
failure for optimal adherence compared to suboptimal adherence was 0.34 (95% CI: 
0.26-0.44). A high degree of heterogeneity was found: Q statistic P<0.001 and I2 =90%. 
The funnel plot did not show asymmetry (Figure 9), and the result of Egger’s test was 
not statistically significant (p=0.68). We conducted subgroup analyses to recalculate the 
pooled odds ratio according to study design, HDI rank, regimen, treatment experience, 
viral load cut-off points, adherence measurement, and adherence cut-off points (Table 
15).  
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Figure 10. Association between adherence to antiretroviral therapy and virologic 
failure. 
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Figure 11. Funnel plot for the association between adherence to antiretroviral 
therapy and virologic failure (p=0.68 at Egger’s test). 
 
The results of univariate meta-regression analyses for different moderators are shown 
in Table 16.  Based on virologic failure cut-off points, studies were classified into three 
sets including: 100 copies/mL, 11 studies (N=5,646); between 100 copies/mL and 400 
copies/mL, 17 studies (N=9,351); and between 500 copies/mL and 1000 copies/mL, 14 
studies (N=7,383). The pooled odds ratio for virologic failure for optimal adherence 
compared to suboptimal adherence for the studies with the lowest virologic failure cut-
off was higher (0.55; 95% CI: 0.41-0.74, I2=56%) than for the studies with an 
intermediate virologic failure cut-off (0.37; 95% CI: 0.26-0.54, I2=88%). The group using 
a virologic failure cut-off greater than 500 copies/mL had the lowest pooled odds ratio 
for virologic failure (0.25; 95% CI: 0.16-0.41, I2=92%). Studies with the lowest virologic 
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failure cut-off reported a significantly different pooled odds ratio compared with studies 
with a virologic failure cut-off greater than 500 copies/mL (regression coefficient -0.75; 
95% CI: -1.39 - -0.12, p=0.02). 
According to participants’ treatment experience, studies were grouped into three sets: 
treatment-naïve patients only, 22 studies (N=17,010); treatment-experienced patients 
only, 12 studies (N=4,009); and both treatment-naïve and experienced patients, 9 
studies (N=1,721). The pooled odds ratio for optimal adherence compared to 
suboptimal adherence for virologic failure for treatment-experienced patients was the 
highest; however, no statistically significant difference in pooled odds ratio was found 
between the three groups.      
The relationship between adherence and virologic outcomes varied with type of 
adherence measurement. The pooled odds ratio for the self-report adherence measure 
(0.45; 95% CI: 0.37-0.55, I2=31%) was higher than the pooled odds ratio for the 
pharmacy refill (0.29; 95% CI: 0.20-0.41, I2=94%). The group using MEMS adherence 
measure had the lowest pooled odd ratio (0.15; 95% CI: 0.06-0.37, I2=35%) for optimal 
adherence compared to suboptimal adherence for virologic failure. There was a trend 
towards significant difference across the odds of virologic failure between self-report 
and MEMS (regression coefficient -1.00; 95% CI: -2.05, 0.06, p=0.06), but not between 
self-report and pharmacy refill (regression coefficient -0.22; 95% CI: -0.78, 0.34, 
p=0.45).  
The pooled odds ratios were also estimated by grouping studies using cut-off points for 
optimal adherence - studies with a cut-off point between 98% and 100%, 7 studies 
(N=3,940); studies with a cut-off point of ≥95%, 30 studies (N=17,779); and studies 
with a cut-off point of 80-90%, 6 studies (N=1,021). The pooled odds ratios for virologic 
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failure for optimal adherence compared to suboptimal adherence for each cut-off point 
were similar, with no statistically significant differences. 
The pooled odds ratio for optimal adherence compared to suboptimal adherence for 
observational studies was significantly greater than randomised controlled studies 
(regression coefficient, 0.66; 95% CI: 0.10, 1.21, p=0.02).  Studies were aggregated into 
three subgroups according to HIV-medication regimens: NNRTI-based, boosted PI-
based, and unboosted PI-based. The pooled odds ratio for virologic failure for optimal 
adherence compared to suboptimal adherence for patients taking NNRTI-containing 
regimens was the highest, but the differences in pooled odds ratios between the 
regimens were not statistically significant. 
Studies were subgrouped into two groups based on the HDI of the country in which the 
study was performed: very high HDI, 21 studies (N=10,466); low HDI, 19 studies 
(N=9,945). The pooled odds ratio for optimal adherence compared to suboptimal 
adherence for countries with low HDI (0.50; 95% CI: 0.35-0.72) was significantly higher 
than countries with very high HDI (0.23; 95% CI: 0.15-0.33).     
A multivariate meta-regression model was built-in to examine the specific moderators 
of the between-study heterogeneity, including the following: study region, threshold 
used to define virologic failure, adherence measurement, study design and year of 
publication. Study design (observational study versus randomised controlled trials; 
regression coefficient 0.74, 95% CI: 0.04 - 1.43, p<0.05) and study region (developed 
versus developing countries; regression coefficient 0.56, 95% CI: 0.01-1.12, p<0.05) 
remained as independent predictors of between-study heterogeneity.  
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Table 15. Subgroup analysis adherence to antiretroviral therapy and virologic 
failure. 
 
Analysis group  No of 
studies  
Pooled odds ratio 
(95% CI) 
Tests for heterogeneity  
P value (Q 
statistic) 
I2 (%) 
Study design:      
Randomised controlled trial  11 0.55 (0.33-0.92) <0.001 85 
Observational study  32 0.29 (0.22-0.38) <0.001 90 
HDI rank:      
High HDI  21  0.23 (0.15-0.33) <0.001 91 
Low HDI  19 0.50 (0.35-0.72) <0.001 87 
Regimen:      
NNRTI-based 17 0.54 (0.38-0.77) <0.001 88 
Boosted PI-based 4 0.31 (0.14-0.71) 0.06 59 
Unboosted PI-based 5 0.25 (0.13-0.47) 0.11 47 
Treatment experience:      
Naïve  22 0.33 (0.23-0.47) <0.001 94 
Experienced  12 0.52 (0.41-0.66) 0.36 9 
Naïve and experienced  9 0.28 (0.17-0.46) 0.001 69 
 
Threshold used to define 
virological failure: 
    
100 copies/mL 11 0.55 (0.41-0.74) 0.01 56 
100-400 copies/mL 17 0.37 (0.26-0.54) <0.001 88 
500 copies/mL 14 0.25 (0.16-0.41) <0.001 92 
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Analysis group  No of 
studies  
Pooled odds ratio 
(95% CI) 
Tests for heterogeneity  
P value (Q 
statistic) 
I2 (%) 
Threshold used to define 
optimal adherence group: 
    
≥98-100% 7 0.54 (0.29-1.00) <0.001 85 
≥95% 30 0.34 (0.24-0.47) <0.001 92 
80-90% 6 0.34 (0.23-0.51) 0.57 0 
Measurement:      
Self-report 14 0.45 (0.37-0.55) 0.13 31 
Pharmacy refill 18 0.29 (0.20-0.41) <0.001 94 
MEMS 6 0.15 (0.06-0.37) 0.18 35 
Pill count  4 0.80 (0.21-3.02) <0.001 93 
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Table 16. Meta-regression analysis of moderators for the association between 
antiretroviral adherence and virologic failure.   
 
Moderator  
 
Category 1  Category 2 Regression 
coefficient 
(95%CI) 
P-value  
 
I2 inconsistency  
Q statistic  
      
Region  Developing 
countries   
Developed 
countries   
0.79 (0.25, 1.32) 0.004 89.2% 
352.4 (38 df), p<0.001 
 Regimen NNRTIs Boosted PIs 0.58 (-0.42, 1.59) 0.257 88.8% 
349.11 (39 df), p<0.001 
 
Treatment 
experience  
Experienced  Naïve 0.38 (-0.27, 1.04) 0.250 90.1%  
404.22 (40 df), p<0.001 
Threshold used 
to define 
virologic failure 
100-400 
copies/mL 
≤100 
copies/mL 
-0.30 (-0.92, 0.33) 0.353 87.5% 
312.53 (39 df), p<0.001 
 500 
copies/mL 
≤100 
copies/mL 
-0.75 (-1.39, -0.12) 0.020  
Threshold used 
to define optimal 
adherence group 
≥80-90% ≥98-100% -0.56 (-1.62, -0.51) 0.304 90.7%  
430.21 (40 df ), p<0.001 
 ≥95% ≥98-100% -0.54 (-1.31, 0.23) 0.171  
Measurement  Pharmacy refill  Self-report  -0.22 (-0.78, 0.34) 0.446 90.2% 
398.75 (df 39), p<0.001 
 MEMS  Self-report  -1.00 (-2.05, 0.06) 0.064  
 Pill count  Self-report  0.17 (-0.89, 1.24) 0.749  
Study design  RCT Observational 
study  
0.66 (0.10, 1.21) 0.020 88.7% 
364.17 (41 df ), p<0.001 
Observation 
period  
<=1 year >1 year 0.15 (-0.38, 0.69) 0.574 90.1%  
413.84 (31 df), p<0.001 
Year of 
publication  
≥2005 <2005 0.67 (0.07, 1.28) 0.028 89.6%  
394.36 (41 df), p<0.001 
Multivariate 
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Moderator  
 
Category 1  Category 2 Regression 
coefficient 
(95%CI) 
P-value  
 
I2 inconsistency  
Q statistic  
      
Region  Developing 
countries  
Developed  0.56 (0.01, 1.12) 0.048 82.6% 
172.5 (30 df), p<0.001 
Threshold used 
to define 
virologic failure 
500 
copies/mL 
≤100 
copies/mL 
-0.46 (-1.23, 0.30) 0.238  
Measurement MEMS Self-report -0.50 (-1.58, 0.58)  0.366  
Study design  RCT Observational 
study  
0.74 (0.04, 1.43) 0.038  
Year of 
publication 
≥2005 <2005 0.43 (-0.37, 1.23) 0.291  
 
7.6. Discussion 
This meta-analysis of 43 studies, involving 27,905 participants, addresses a gap in the 
current HIV treatment adherence literature with a quantitative evaluation of the 
association between level of adherence and virologic outcomes among adults taking 
ART. This study revealed that adherence levels as low as 80-90% may be adequate for 
viral suppression in patients taking newer antiretroviral drugs. Our data also showed 
that pooled odds ratios for virologic failure for optimal adherence compared to 
suboptimal adherence were similar between NNRTI-based and boosted PI-based 
regimens. The effectiveness of newer antiretroviral agents at the lower level of 
adherence may encourage the prescribing of ART at an early stage of HIV infection.  
The findings indicated that the mean proportion of patients who were reported to 
demonstrate optimal adherence worldwide was 63.4%, which is similar to a meta-
analysis of 84 studies that reported 62% of patients take 90% of their prescribed ART 
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[47]. The results of this study demonstrate that adherence is robustly associated with 
virologic outcomes across the various types of adherence measure, ART regimen, study 
population, and reporting. The odds of virologic failure were almost three times higher 
for participants with suboptimal adherence compared with those with optimal 
adherence. This confirms that achieving long-term optimal adherence is indeed the 
Achilles’ heel of successful virologic outcomes [371]. The need for clinicians to exert 
concerted efforts to maintain continuing optimal adherence to antiretroviral therapy is 
indisputable.  
Classifying patients according to various optimal adherence thresholds (98-100%, 
95%, and 80-90%) did not result in statistically significant differences in the odds of 
virologic failure. This finding is consistent with a meta-analysis of 37 studies in children 
that reported no significant group differences in virologic outcomes between different 
thresholds of good adherence [372]. This suggests that patients who achieved “perfect” 
(100%) or “near perfect” (95%) adherence did not necessarily have better virologic 
outcomes than patients who had achieved “good enough” (80-90%) adherence. This 
finding has clinical importance and is in line with previous studies [373, 374] that 
indicated that, while the need to maintain high levels of adherence to achieve long-term 
virologic suppression is clear, the level of adherence behaviour capable of sustaining 
viral suppression is broader than previously thought.  
Considerable variation in the relationship between adherence and virologic outcomes 
was found based on the type of adherence measurement used in the studies we 
reviewed. For studies using self-reported adherence, the odds of virologic failure in 
participants with optimal adherence was about half that of participants with suboptimal 
adherence. The odds of virologic failure for optimal adherence were about one-third 
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and one-seventh that of the participants with suboptimal adherence using pharmacy 
refill and MEMS, respectively. Our meta-analysis undermines the validity of using self-
reported adherence to distinguish virologic outcomes. A high proportion of patients 
with optimal self-reported adherence experienced virologic failure. Self-reported 
adherence is potentially confounded by social desirability and recall bias, which leads 
patients to over-estimate their actual adherence; [96] this method is inferior to MEMS 
in its ability to explain virologic outcomes.  
Despite the findings [217, 218] of previous studies suggesting the need for different 
levels of optimal adherence between antiretroviral regimens for achieving similar 
virologic outcomes, classifying patients based on regimen did not result in statistically 
significant differences in the odds of virologic outcomes in this meta-analysis. 
Pooled odds ratio for optimal adherence compared to suboptimal adherence for 
virologic failure for studies with virologic failure cut-offs <100 copies/mL were 
significantly higher than studies with virologic failure cut-offs between 500 copies/mL 
and 1000 copies/mL. The rate of virologic failure detected in patients with good 
adherence increased when studies defined a virologic failure at a low level of HIV-1 
ribonucleic acid (RNA). The relationship between adherence and viral load improved 
when the level of detection of HIV-1 RNA increased. The tighter the definition of 
virologic failure the more likely it is to unmask suboptimal adherence. 
The odds of virologic failure for optimal adherence were about half and one-third that of 
the patients with suboptimal adherence in countries with a low HDI and high HDI, 
respectively. More patients with optimal adherence experienced virologic failure in 
countries with low HDI than in countries with high HDI. This review indicates that 
patients with equal or better levels of optimal adherence in developing countries 
 156 
 
compared to developed countries [113] does not necessarily translate into better 
virologic outcomes. This might be associated with the increase in pre-treatment 
antiretroviral drug resistance [375]  and unavailability of baseline HIV drug resistance 
testing before initiation of ART [33] in resource-limited settings that have a potential to 
contribute to the increasing rates of virologic failure in optimally adherent patients. We 
support moves toward the use viral load monitoring at the point of care in resource-
limited settings [376] to improve treatment outcomes. 
Study design (observational study versus randomised controlled trials) was an 
independent predictor of between-study heterogeneity. More patients with optimal 
adherence experienced virologic failure in randomised controlled trials than in 
observational studies. Differences in estimated magnitude of treatment effect are very 
common between randomised controlled trials and observational studies [377]. This 
difference in virologic outcomes between study designs might be related with selection 
bias in observational studies [378] and higher  quality and rigour of randomised 
controlled trials.  
This meta-analysis shares the limitations intrinsic to meta-analysis in general and with 
studies of adherence in particular. We only included studies published in English, so we 
may have missed studies that were relevant to our research question during the 
literature search. When the included studies were stratified and analysed based on 
regimen, virologic failure cut-off, adherence cut-off and type of adherence 
measurement, heterogeneity between-studies remained high for most of the subgroups. 
Because of this high degree of heterogeneity, which was not entirely described either by 
subgroup analysis or by meta-regression, our pooled results need to be viewed with 
caution.  
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7.7. Conclusion 
Irrespective of the cut-off point for optimal adherence, our findings support the tenet 
that optimal adherence to ART is associated with positive clinical outcomes. The 
threshold for optimal adherence to achieve better virologic outcomes appears to be 
wider than the commonly used cut-off point (95% adherence). Though patients taking 
ART should be instructed to attain 95% adherence, apprehensions of slightly lower 
adherence should not deter prescribing ART regimens at an early stage of HIV infection.   
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CHAPTER EIGHT 
8. GENERAL DISCUSSION AND CONCLUSION  
This body of work represents a significant step forward for Ethiopian research into 
HIV/AIDS and ART. Adherence to ART is a complex issue and understanding of its 
barriers and facilitators requires a comprehensive and holistic approach. We used a 
one-year prospective study and qualitative study to assess the association between 
adherence and a broad range of factors in adult HIV/AIDS patients. Adherence was 
measured using multiple adherence measures, which were evaluated with surrogate 
endpoints. A meta-analysis was performed to critically assess the association between 
optimal adherence to ART and virologic outcomes. ADRs associated with ART pose a 
unique challenge in the treatment of HIV/AIDS. We have assessed ADRs and their 
impact on treatment outcomes. We believe findings from this study have a number of 
implications for future research, clinical practice, and policy.  
In this study, we found data in support of the following practical and methodological 
concerns. As there is no ‘gold standard’ measure of adherence [91], we not only used 
multiple measures of adherence but also validated these tests with a surrogate marker. 
A significant CD4 increase in adherent patients compared to non-adherent patients was 
found using the ACTG self-reported adherence measure. In this study, self-reported 
adherence differentiated meaningful patterns of adherence behaviour over other 
methods clinically, which is similar to the conclusion of a meta-analysis reported by 
Nieuwkerk et al. [379]. This finding supports the use of self-report of adherence in 
research and clinical practice in resource-limited settings.  
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Optimal adherence in this study was defined as achieving 95% or more of self-reported 
dose and time adherence. The meta-analysis data highlighted classifying patients 
according to various optimal adherence thresholds (90-100%, 95%, and 80-90%) did 
not result in statistically significant differences in the odds of virologic failure.  
Viswanathan et al. [374] found that odds of virologic suppression did not differ for 
85%-89% adherence compared to those with 95% adherence in patients taking NNRT-
containing regimens. While all patients taking ART should be trained to achieve 95% 
adherence, apprehension about slightly lower adherence should not hamper 
prescribing ART at an early stage.  
Adherence to ART is a dynamic behaviour. The prospective nature of this study allowed 
assessment of changing adherence levels over time. The proportion of non-adherent 
patient increased over the study period, as reported elsewhere [231, 380]. Based on 
ACTG self-reported adherence that combined dose and time adherence, 23.4% of 
patients were non-adherent at 12 months, which is similar to the combined dose and 
time adherence reported by Amberbir et al. [151] at 3 months, in Jimma, Ethiopia. A 
meta-analysis by Ortego et al. [47] reported that 33% of HIV/AIDS patients in sub-
Saharan Africa studies were non-adherent, which is greater than the rate determined in 
this study. The difference in the rate of non-adherence among studies may be due to 
dissimilarity in study design and setting. In this study, the increase in non-adherent 
patients over the study period varied using different adherence measures; VAS better 
identified non-adherent patients. Researchers in resource-limited settings may choose 
VAS over other measures for this advantage.  
We used a simultaneous methodological triangulation approach to gain a 
comprehensive understanding of the problem of ART adherence. Data were obtained 
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from the various sources (i.e. patients taking ART, case managers, and nurses) and 
different techniques of data collection (i.e. semi-structured interviews, focus group 
discussion, clinical records, and a follow-up survey) were applied. This methodological 
triangulation has resulted in more valid and reliable findings. This study has confirmed 
the importance of mixed methods and encourages researchers to use this approach to 
examine multifaceted issues.  
Cultural suitability was cautiously considered in the design and execution of the 
prospective study and exploratory qualitative study. Forward and backward translation 
and pretesting was carried out to ensure the validity and reliability of questionnaires. 
Only emerging concepts and categories obtained from analyses of the interviews and 
focus groups using Amharic were subsequently translated into English. Undertaking a 
translation after completing the data analyses in the original language decreased cost, 
preserved meaning, and improved the validity of the data [381].The authors suggest 
that translation after completing the data analysis in the original language improved the 
quality of findings.  
The qualitative data highlighted socio-economic constraints, such as unemployment and 
food insecurity, as barriers to adherence and retention in HIV care. HIV treatment 
knowledge score and attaining secondary education or above were significantly 
associated with adherence in the bivariate analysis. The impacts of socio-economic 
constraints were also indirectly supported by our prospective study, in which a lower 
body mass index (BMI) at baseline was independently associated with non-adherence. 
Besides, being unemployed was an independent predictor of experiencing severe ADRs, 
which were more likely in non-adherent patients. As financial insecurity is a major 
problem in resource-limited settings, including Ethiopia [382], improving food security 
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and job opportunities in patients taking ART may improve adherence to ART and 
treatment outcomes. Further studies are needed to evaluate the effect of such 
interventions on adherence to ART among economically disadvantaged adults who are 
initiated on ART in Ethiopia. 
In the qualitative study, psychosocial factors such as stigma and discrimination and 
religious rituals (e.g. being baptised with holy water, fasting) were found as important 
barriers to adherence. Significant associations were reported between adherence and 
psychological variables such as stigma and discrimination, depression, and belief about 
medicines in the univariate analysis, but these associations did not persist in the 
multivariate analysis. A systematic review by Sweeney et al. [383] confirmed that 
stigma was negatively associated with adherence to HIV-medication. Tackling stigma 
and discrimination might also improve patients’ abilities to adhere to ART and continue 
attending HIV care in Ethiopia.  
Social support and use of reminders were identified as important facilitators of 
adherence in the qualitative study. In the prospective study, the use of electronic 
reminder devices was independently associated with medication adherence. The use of 
mobile phone text messaging to improve adherence was also confirmed in randomised 
clinical trials [155, 156] carried out in resource-limited settings. Given that the majority 
of patients in this study possessed a mobile phone, and were able to send and receive 
text messages, more rigorous randomised controlled trials are warranted using mobile 
phones to improve patients’ adherence to ART. 
Antiretrovirals are the most commonly reported class of pharmacological agents 
implicated in ADRs in Africa based on the WHO global Individual Case Safety (ICSR) 
database [384]. ADRs reporting into ICSR database from Ethiopia is extremely low 
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compared to other African countries such as South Africa and Morocco [384]. This study 
evaluated the burden of ADRs of antiretrovirals and their impact on treatment 
outcomes. In our follow-up study, we found that more than one-third of patients who 
were initiated on ART experienced severe ADRs. Shet et al. [263] reported that 26.5% of 
patients who were initiated on ART experienced at least one severe reaction over a two-
year study period. The high incidence of severe ADRs in this study might be related to 
rigorous prospective data collection, which helped to detect ADRs that might be 
unreported in other studies. The majority of severe ADRs were reported within the first 
three months. Patients who experienced severe ADRs were significantly less likely to be 
adherent, as described elsewhere [6, 7]. Dose omission or treatment discontinuations in 
order to avoid intolerable side effects were detected in our qualitative study. A high 
distress score as the result of HIV symptoms and ADRs was independently related to 
non-adherence. To our knowledge, this is the first study to demonstrate the negative 
impact of distress due to antiretroviral drug ADRs on adherence. Distress causes 
undesirable health behaviour [239] that may impair patients from attaining optimal 
adherence to ART.  
The most important class of severe ADRs were gastrointestinal complaints, followed by 
cutaneous reactions and haematological abnormalities, similar to the reactions reported 
in the ICSR database [384]. A systematic review and meta-analysis by Al-Dakkak et al. 
[385] reported that patients who experienced ART ADRs were less likely to be adherent. 
Almost half of the severe ADRs related to ART were found to be preventable, 
highlighting the importance of improving ADR monitoring practices to improve ART 
adherence and retention in HIV care. Strategies for monitoring ADRs associated with 
ART are diverse [62]. Future research needs to focus on rationalising ART ADR 
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monitoring [385]. Policymakers need to consider balancing the risks of severe ADRs 
associated with the continuing use of older antiretroviral drugs such as zidovudine over 
the cost of newer antiretroviral agents with a better ADR profile.  
Scale-up of treatment and care for patients with HIV/AIDS in Ethiopia has been a 
significant clinical success. The full advantage of the scale-up cannot be recognised 
without attaining long-term optimal adherence and retention in care. This study has 
identified several factors that influence long-term adherence to ART and contributed in 
the arena of HIV/AIDS treatment and care in Ethiopia in a number of ways. 
Implementation of measures to consistently monitor ADRs, improving job and food 
security, and promoting the use of reminder devices may improve adherence and 
treatment outcomes in Ethiopian patients initiated on ART. 
Recommendations and Future Directions  
 Several issues for future research arose from this work. A number of factors (such 
as disclosure of HIV status, stigma and discrimination, depression, and social 
support) that are reported as strong predictors elsewhere [224], as well as some 
other factors identified in our qualitative study, were not identified as independent 
significant predictors of measured adherence in the prospective study. Adherence 
is a multifaceted issue; no study can evaluate all variables potentially related to 
ART.  Future research aimed to examine these and some other factors (e.g. partner 
violence) using a larger sample size and a longer follow-up is required.    
 This work has identified important factors including food security, ADRs, and use 
of reminder devices that influence long-term adherence and retention in HIV care 
using a mixed methods approach in the Ethiopian setting. However, the impact of 
these factors on treatment outcomes might be subjected to potential bias. Thus, it 
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would be worthwhile to evaluate the influence of these factors using randomised 
controlled trials to obtain sound evidence before implementing these findings in 
clinical practice.  
 Clinical monitoring with biannual CD4 counts is used to routinely monitor 
treatment response for patients taking ART in Ethiopia. Self-reported adherence 
predicted CD4 changes in patients initiated on ART in this study. The changes in 
CD4 count tend to occur later and are, consequently, less visible than the changes 
in HIV viral load [247]. Adherence values have greater accuracy in detecting 
virologic changes [386].  Future studies need to validate adherence measures with 
virologic outcomes in the Ethiopian setting. 
 Self-reported adherence measures have several advantages and are widely applied 
in research and clinical settings [93]. In this study, self-reported adherence 
measures (ACTG self-report and VAS) better identified non-adherent patients and 
predicted clinical outcomes. Future studies in resource-limited settings may 
choose VAS and ACTG self-reported adherence measures for these advantages.     
 One-third of patients initiated on ART experienced severe ADRs within a one-year 
period and these events were related to worse treatment outcomes. Severe 
laboratory ADRs were underreported in our study as a result of inadequate 
number of laboratory testing being performed to monitor ADRs in these resource-
limited hospitals. Future studies should focus on performing a broad range 
laboratory tests to examine the full impact of ADRs on treatment outcomes. 
Besides, future studies may address interventions to improve the detection of 
ADRs in patients initiated ART.  
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